

Viruses with Modified Capsid Proteins

Field of the Invention

This invention relates to preparations comprising adenoviral vectors with modified capsid proteins. These modified capsid proteins enable customisable decoration of the adenoviral vector to be performed, enabling diverse applications from personalised cancer vaccines to targeted gene therapy vectors, and mixtures of the same.

In particular, the adenoviral vectors with modified capsid proteins may be modified in the hexon and/or pIX capsid proteins.

Furthermore, the adenoviral vectors of the present invention are less susceptible to clearance by neutralising antibodies than the vectors of the prior art. Advantageously, therefore, these modified adenoviral vectors may evade the host immune response.

A preferred aspect of the invention is to use adenoviral vectors with modified capsid proteins in the preparation of vaccines. These vaccines may be prophylactic or therapeutic. In this aspect of the invention, the modified capsid proteins enable modular covalent display of antigens, thereby inducing immune responses to said antigens, and compositions comprising the same. In particular it relates to an adenoviral vector with modified capsid proteins that permits the quick assembly of personalised vaccine therapies, in order to fight disease. The inventors have shown that the display of antigens using adenoviral vectors increases the immune response to the antigen.

Other aspects of the invention include the use of the adenoviral vectors with modified capsid proteins in the preparation of oncolytic viruses, gene therapy vectors and/or retargeting of adenoviral tropism.

Yet further aspects of the invention allow the combination of different types of modification to enable several therapeutic applications simultaneously, such as an oncolytic virus expressing cancer antigens.

Background of the Invention

Adenoviruses (Ads) have an icosahedral protein capsid that surrounds the linear duplex genome. No lipid envelope is present. The capsid includes the structural proteins hexon, fiber, penton, IIIa, VIII and IX. It is thought that the fiber capsid protein aids attachment to the host cell, via the knob domain. Ads rely upon host infection in order to be able to replicate using the host

cell's replication machinery. There are at least 57 serotypes of human adenovirus, Ads1-57 that may be grouped into seven "species" A-G. Similarly, animal Ads exist, such as canine and equine Ads, also classifiable into various serotypes and "species". Serotypes are generally defined by the ability of antisera to neutralise the infection of cells *in vitro*. These viruses are well studied and understood, they can be grown in high titres, they can infect both dividing and non-dividing cells and can be maintained in host cells as an episome. These characteristics make them a good therapeutic choice, since nearly all trials have shown they are safe and well-tolerated.

The icosahedral capsid is made up of several proteins. Hexon is the major protein forming the 20 triangular faces of the viral capsid. The hexon proteins form trimers, and each trimer interacts with six other trimers. The 12 vertices are formed by the penton capsomere, these are a complex of 3 fiber proteins and five penton proteins. A long fiber extends from each vertex, composed of three identical chains that form a knob at the end. The capsid also includes minor proteins, notably amongst them pIIIa, pVI, pVIII and pIX. These minor capsid proteins may be located on the inner or outer surface of the capsid and may have additional functions beyond structural ones. Exemplarily, pVI may facilitate nuclear import of hexon proteins and pIX may be involved with DNA packaging into the capsid and transcriptional activation.

Ads are commonly used for gene therapy, in particular as gene delivery vectors, due to their capacity for inclusion of additional genetic sequences. Over 2,000 gene therapy trials have been conducted using Ads. Adenoviral vectors allow for the transmission of the transgene they carry into the host nucleus but do not integrate viral DNA into the host chromosome. The insert size for Ads when used as gene therapy vectors is large, with a capacity of 8-36 kb possible.

Oncolytic adenoviruses are being explored for use in cancer, most notably for the treatment of head and neck cancer. Oncolytic viruses preferentially infect and kill cancer cells, the process of oncolysis releasing new infective adenoviral virions and also recruiting the host immune system to raise an anti-cancer response. Various means have been used to ensure the targeting of the oncolytic adenovirus to the cancer cell, including the use of adapter molecules such as fusion proteins including an antibody to a capsid protein, directly modifying the viral capsid proteins or using transcriptional targeting.

Additionally, Ads have emerged as a promising vaccine delivery vehicle due to their ability to induce both innate and adaptive immune responses; having the capacity to induce potent antigen-specific B and T cell immune responses. Adenoviral vectors are highly immunogenic and are efficient

in delivering antigens. However, this potential has yet to be fully realised. Several adenoviral vector based vaccine candidates were developed and pursued further in clinical trials, however, these were not successful. Adenovirus of the human serotype 5 (AdHu5) based vaccine, developed against HIV-1 by Merck, induced CD8⁺ T cell responses but failed to prevent HIV infections.

5 A major obstacle to the success of adenoviral based vectors in human and animal therapy is the neutralisation by virus-specific antibodies. Natural infection by adenovirus is high in human and animal populations, and therefore the adaptive immune system may recognise and respond to the presence of adenoviral vectors by the secretion of neutralising antibody (NAB). Similarly, the innate immune system may also be responsible for assisting the response to adenoviral vectors. It is
10 estimated that 50% to 90% of the adult population has pre-existing immunity to AdHu5 for example. Such a response can clear the therapeutic adenoviral vectors before the desired effect is seen. Solving this issue would enable adenoviral therapeutic vectors to be more routinely used.

 Various approaches have been taken to evade the host immune response in the use of adenoviral vectors. One approach was to swap the hypervariable regions (HVR) of AdHu5 with
15 hypervariable regions from another adenoviral serotype, in order to produce a “chimera”. This may allow the chimera to avoid AdHu5 neutralising antibodies, but will only be effective in the absence of neutralising antibodies against the alternative serotype. An improved means of evading the immune response is desirable.

 Ads have been used as vaccines, mainly as DNA vaccine delivery vectors by including within
20 the adenoviral genome the genetic sequence for an antigen that is expressed within the host cell. Alternative ways of using Ads as vaccine compositions include the use of the adenovirus particle itself to display antigens. This approach has had varying degrees of success, depending on the nature of the decoration, such as the use of genetic fusions, use of modified antibodies to bind to capsid proteins and click chemistry. Incorporating immunogenic peptides into the capsid offers
25 potential advantages, such as the ability to induce a strong humoral response, similar to the response generated by native capsid proteins.

 One approach is to modify the adenoviral capsid proteins to include an immunogenic peptide for display on the virus surface. A major obstacle to the “antigen capsid-incorporation” strategy is the limitation this places on the size of insertion, since it must not disrupt the natural
30 folding of the capsid protein, nor affect the interaction which holds the capsid proteins together. Further, one disadvantage of directly encoding the antigen within the capsid protein is the amount

of time and work that is required to optimise the vaccine for each individual antigen. It would be desirable to formulate an adenovirus vector with a modified capsid protein that was ready for the attachment of any desired antigen, without the need for optimisation of the insertion within a capsid protein. Such a "primed" adenoviral vaccine composition would be of particular use when it comes to the preparation of personalised vaccines, where a vaccine is prepared in a bespoke manner for just one individual. The latter may be the case for personalised cancer vaccines or to raise an immune response to a particular drug-resistant microbiological infection and the like.

Indeed, given the current challenges with exploiting adenovirus as a therapeutic delivery vehicle due to the neutralisation of the virus, and an inability to include a sequence of longer than 100 amino acids into some of the capsid proteins including the most abundant capsid protein, hexon, there remains a pressing need to develop an approach which would allow for the utilisation of the clear benefits of an adenovirus vector, allow for a personalisation of the therapeutic and also reduce the immune clearance of the vector. It would be desirable to prepare a "primed" adenoviral vector, which has a modified capsid protein that is ready to accept decoration by an entity, such as an antigen, immunogenic peptide, protein, glycoprotein, antibody, targeting molecule, cell surface marker, protein, peptide, glycoprotein, lipoprotein and the like. The production of a "primed" adenovirus may permit the preparation of personalised therapeutics without laborious trial and error, since the modification of the capsid protein has already been completed and this reduces the restriction on the decoration of the viral capsid that may be achieved.

Adenoviral capsid proteins have been previously modified; most commonly the work is to alter the natural tropism of the viral vector, rather than to overcome the neutralisation of the virus-based vector. Altering the tropism, the particular cells and/or tissues of a host that support growth of the virus, is undertaken such that the viral vector may be targeted to a particular cell type for a particular indication. For example, a gene therapy adenoviral vector may wish to be directed only to retinal cells, and the tropism may be altered accordingly. For vaccine applications in particular, the natural tropism of the virus may be less important, since it is the aim of the viral vaccine vector to induce an immune response to the antigen it is displaying, rather than to infect any particular cell type.

The present invention concerns incorporating modifications, such as peptide insertions, into the adenoviral capsid proteins in order to prepare a vector ready for addition of decoration. These insertions allow for modular assembly and display of a foreign entity on the surface of the adenovirus that are not limited in size. It also allows for the preparation of bespoke therapies, such

as vaccines, for example personalised cancer vaccines or oncolytic viruses, with the minimal amount of preparation. The viral vector described here is a flexible platform, allowing the preparation of a multitude of different therapeutics using the same vector. This is a novel technology that has been demonstrated for the first time, using modular covalently-bonded display of multiple peptide and protein partners on the surface of the virus. Adenoviral vectors have not been successfully modified previously using the technology proposed by the current inventors.

The present invention provides a significant improvement over the art. The present inventors have shown that the technology enables the attachment of entities to the capsid proteins through the protein partner pairs that effectively shield the adenovirus from the effect of neutralising antibodies. This improvement is demonstrated here with the attachment of antigens, but in practice any entity could be attached in order to have this shielding or blocking effect. Notably, the inventors are particularly pleased to note that despite the large size of some of the entities added using the technology, the infectivity of the adenovirus is retained. Therefore, the present technology could be used to improve current gene therapy vectors or oncolytic adenovirus vectors by simply modifying a capsid protein and adding a shielding entity.

In relation to vaccine preparations, the present invention enables immune responses to be generated against displayed antigens. Advantageously, for the first time, the inventors demonstrate that the surface of the virus can be decorated with larger antigenic proteins that have an advantageous effect of blocking the neutralisation of the virus by potent neutralising monoclonal antibody. Thus, not only can the viral vaccine vector be used for a variety of antigen types, should the antigen be sufficiently large, the displayed antigens may also protect the viral vaccine vector from neutralisation by host antibody. This would ensure that the viral vaccine vector can persist for longer to induce an immune response, and could also enable the same vector to be used for multiple immunizations without reduction in efficacy associated with vector neutralisation.

Use of peptide binding pairs, such as SpyCatcher and SpyTag (WO2011/098772), based upon attachment proteins from a bacterium, has been established as a technology to irreversibly conjugate recombinant proteins and the like. Bio-conjugation between entities that would be impossible to achieve through genetic fusion between proteins can work using peptide binding pairs. Various Catcher and Tag pairs are now available, some based upon modifications of SpyCatcher and SpyTag and others based upon similar chemistry from alternative bacterial proteins.

In relation to adenovirus, the present inventors found that the inclusion of the peptide pairs within the adenoviral capsid proteins were not as routine or straightforward as postulated, particularly in relation to the provision of an attachment means for antigens. Indeed, work by the inventors has shown that the most commonly utilised peptide pair, in this case insertion of SpyTag
5 into the hexon capsid protein did not allow for the formation of a functional adenoviral vector (a vector allowing for effective coupling of SpyCatcher and capable of infecting cells). Indeed, the data showing that SpyTag was poorly reactive after insertion is included in the Examples, together with data on the lack of infectivity of the modified adenovirus. Thus, significant work has been expended in developing a system that works in relation to a modified adenoviral vector that is ready to accept
10 peptide pairing and attachment of an entity to the modified capsid protein via the peptide partner inserted into the capsid protein.

Summary of the Invention

In accordance with a first aspect of the invention, there is provided an adenoviral vector for preparation of a prophylactic or therapeutic adenoviral composition, comprising at least one
15 modification in the capsid protein, wherein said modification comprises the inclusion of a first peptide partner in a capsid protein, wherein said first peptide is capable of forming a covalent bond with a second peptide partner, which can be attached to an entity.

The modification may be a fusion with the first peptide partner or an insertion of the first
20 peptide partner into the capsid protein.

The capsid protein may be any capsid protein, but is preferably a hexon protein or a pIX protein.

The first peptide partner and the second peptide partner form a peptide partner pair, which
25 may be covalently linked by an isopeptide or ester bond, preferably an isopeptide bond.

In one aspect, the first peptide partner is the "tag" partner, which may be covalently linked by an isopeptide or ester bond to a second peptide partner which is a "catcher". In this aspect, the capsid protein is preferably a hexon protein. Thus, the first peptide partner or "tag" which modifies
30 the hexon is preferably a DogTag, Isopeptag, Isopeptag-N, SdyTag, PsCsTag or Jo. It is preferred that the first peptide partner or tag is not SpyTag. In this embodiment, SpyTag is unmodified during its insertion into the hexon protein.

In an alternative aspect, the first peptide partner is the “catcher” partner, which may be covalently linked by an isopeptide or ester bond to a second peptide partner which is a “tag”. In this aspect, the capsid protein is preferably a hexon protein. Thus, the first peptide partner or
5 “catcher” which modifies the hexon may be a DogCatcher, SpyCatcher, SnoopCatcher, Pilin-C, Pilin-N, SdyCatcher, PsCsCatcher or In.

In one aspect, the first peptide partner is the “catcher” partner, which may be covalently linked by an isopeptide or ester bond to a second peptide partner which is a “tag”. In this aspect,
10 the capsid protein is preferably a pIX protein. Thus, the first peptide partner or “catcher” which modifies the pIX is preferably a SpyCatcher, DogCatcher, SnoopCatcher, Pilin-C, Pilin-N, SdyCatcher, PsCsCatcher or In.

In an alternative aspect, the first peptide partner is the “tag” partner, which may be covalently linked by an isopeptide or ester bond to a second peptide partner which is a “catcher”. In
15 this aspect, the capsid protein is preferably a pIX protein. Thus, the first peptide partner or “tag” which modifies the pIX protein is preferably a SpyTag, SnoopTagJr, DogTag, Isopeptag, Isopeptag-N, SdyTag, PsCsTag or Jo.

20 In one aspect, the first peptide partner may be inserted into a hexon protein, and optionally the insertion into the hexon protein may be up to 200, up to 150 or up to 100 amino acids in length. The insertion into the hexon protein may be at any appropriate point, optionally in any one or more of the hypervariable HVR loops. The first peptide partner inserted into the hexon protein may be a DogTag. DogTag is capable of forming a spontaneous covalent bond with DogCatcher, or a covalent
25 bond with SnoopTagJr or SnoopTag in a reaction requiring a catalyst, SnoopLigase. DogCatcher or SnoopTagJr or SnoopTag may therefore be the second peptide partner. DogTag or SnoopTagJr may therefore be the second peptide partner. The second peptide partner is linked or attached to an entity such as an antigen. It is surprising to the inventors that DogTag was able to be inserted into the hexon capsid protein to form a functional adenovirus vector for capsid display of protein
30 partners after the failure of the SpyTag insertion, as described above. As the Examples show, the insertion of DogTag into the hexon and pairing with SnoopTagJr or DogCatcher enables the modified adenovirus to retain its infective ability in the cells tested after coupling. A wide range of SnoopTagJr and DogCatcher fusion proteins, some over 50 kDa in size, have been coupled efficiently

and displayed on adenovirus with no reduction in viral infectivity. The retention of infectivity is important if the therapeutic use of the adenoviral vector requires cell entry, for example for gene therapy or as an oncolytic virus.

5 Other first peptide partners that may be included within the hexon protein that are less than 100 amino acids in length include:

Isopeptag which pairs with Pilin-C

Isopeptag-N which pairs with Pilin-N

SdyTag which pairs with SdyCatcher

10 PsCsTag which pairs with PsCsCatcher

Jo which pairs with In, or

RrgATag/RrgATag2/DogTag which pair with RrgACatcher (also denoted here as “DogCatcher”).

15 It is preferred that of the possible peptide partners that are included within the hexon protein, the inclusion is not an insertion of SpyTag. In this embodiment, SpyTag was inserted within various HVRs of hexon and found to reduce infectivity to an unsatisfactory level once paired with SpyCatcher. Thus, viral fitness was impaired.

20 In another aspect, the first peptide partner may be fused to the pIX capsid protein, optionally at the N- or C- terminal end, preferably at the C-terminal end. The first peptide partner fused to the pIX capsid protein may be a SpyCatcher, SnoopCatcher or DogCatcher. SpyCatcher is capable of forming a covalent bond with SpyTag, which herein forms the second peptide partner, and can therefore be attached to an antigen. SnoopCatcher is capable of forming a covalent bond
25 with either SnoopTag or SnoopTagJr, and DogCatcher is capable of forming a covalent bond with DogTag, and may be used as a binding pair in either orientation as first or second peptide partner. The first peptide partner may also be a DogTag, SpyTag, SnoopTagJr or SnoopTag, wherein the matching second peptide partner is DogCatcher, SnoopTagJr, SnoopTag, SpyCatcher, DogTag, or SnoopCatcher. Other peptide partner pairs that may be suitable for fusion with pIX in either
30 orientation are: RrgATag/RrgATag2/DogTag and RrgACatcher, Isopeptag/Pilin-C, Isopeptag-N/Pilin-N, SdyTag/SdyCatcher, PsCsTag/PsCsCatcher and Jo/In.

The insertion of SpyCatcher into pIX has been demonstrated to permit the coupling of SpyTag conjugated entities, including the HCMV pentamer, whilst retaining infectivity.

Particularly preferred may be the insertion of SnoopCatcher or DogCatcher into pIX, since these have both been demonstrated herein to have good adenoviral viability. These insertions are furthermore genetically stable for greater than 3 passages.

5

As used herein for any aspect of the invention, the first peptide partner is part of a pair of peptides that are capable of forming a covalent bond, such as an isopeptide bond or ester bond under the appropriate conditions. These are also known as protein tag and catcher pairs or protein tag and binding partner pairs. The first peptide partner may be a first peptide tag or may be a first peptide catcher. Each partner pair may comprise a tag and a catcher. The covalent bond that is formed may spontaneously react, or require the assistance of a third entity such as a ligase. Further information on suitable peptide pairs is included below.

Said adenoviral vector may be used in the preparation of a vaccine. The vaccine may be prophylactic or therapeutic. The invention therefore extends to a method of preparing a vaccine, comprising the use of an adenoviral vector as described herein. The method comprises the attachment of an antigen to the adenoviral vector via a second peptide partner. Said second peptide partner is attached to the antigen, preferably fused to said antigen, and is capable of forming a covalent bond with the first peptide partner present on the immunogenic adenoviral vector. The covalent bond, and therefore attachment, may occur spontaneously, or may require the use of a third entity to facilitate binding, such as a ligase. Thus, the antigen is attached to the adenovirus by means of the peptide partner pair, the first partner of which is included within a modified capsid protein.

In another aspect of the invention, there is provided a vaccine composition comprising an adenoviral vector including at least one modification in a capsid protein, wherein said modification comprises the inclusion of a first peptide partner, and said first peptide partner is covalently bonded to a second peptide partner attached to an antigen. Said adenoviral vector is as described extensively herein.

30

In another aspect of the invention, there is provided an immunogenic adenoviral vector comprising of at least one modification in the hexon capsid protein, wherein said modification comprises:

- a. a first peptide partner; and
- b. a second peptide partner attached to an antigen

wherein the first peptide partner and second peptide partner are coupled via a covalent bond.

5 In one embodiment of this aspect of the invention, the first peptide partner inserted into the hexon capsid protein is less than 200 amino acids in length, less than 150 amino acids in length, less than 100 amino acids in length, optionally wherein said first peptide partner is a DogTag. If DogTag is the first peptide partner, the second peptide partner may be DogCatcher or SnoopTagJr or SnoopTag. In order to assist the formation of a covalent bond between DogTag and SnoopTagJr or
10 SnoopTag, a ligase may be utilised.

The first peptide partner inserted into the hexon may also be any one of SnoopTag, SnoopTagJr, SnoopCatcher, DogCatcher, Isopeptag, Pilin-C, Isopeptag-N, Pilin-N, SdyTag, SdyCatcher, PsCsTag, PsCsCatcher, RrgATag/RrgATag2, RrgACatcher, Jo, or In.

15

It is preferred that SpyTag is not used as the first peptide partner in the hexon protein, with SpyCatcher as the second peptide partner.

20 In another aspect of the invention, there is provided an immunogenic adenoviral vector comprising of at least one modification in the pIX capsid protein, wherein said modification comprises:

- a. a first peptide partner; and
- b. a second peptide partner attached to an antigen

wherein the first peptide partner and second peptide partner are coupled via a covalent
25 bond.

According to one aspect, the first peptide partner may be a SpyCatcher protein. In this instance, the second peptide partner may be a SpyTag. The covalent bond that forms between these partner pairs is spontaneous and does not require assistance. SnoopCatcher or DogCatcher
30 could equally be utilised as the first peptide partner, with their partner pairs being SnoopTag/SnoopTagJr or DogTag respectively. SnoopTagJr/SnoopTag or SpyTag could equally be utilised as the first peptide partner, with their partner pairs being SnoopCatcher or SpyCatcher respectively.

Equally, any one of the following pairs could be utilised: Isopeptag which pairs with Pilin-C

Isopeptag-N which pairs with Pilin-N

SdyTag which pairs with SdyCatcher

5 PsCsTag which pairs with PsCsCatcher

Jo which pairs with In, or

RrgATag/RrgATag2/DogTag which pair with RrgACatcher (DogCatcher).

10 Any of the modifications to the adenoviral capsid proteins with a first peptide partner described herein permits the construction of an adenoviral vector, which is effectively an adenoviral vector which has been "primed" for the addition of an entity in order to manufacture a prophylactic or therapeutic composition, such as the addition of an antigen to manufacture a vaccine. Alternatively, the adenoviral vector is primed to receive the attachment of a shielding entity whose sole purpose is to block the recognition and binding of host antibodies to the adenovirus.

15

The entity can then be added by contacting the adenoviral vector with the second peptide partner attached to the entity, which is capable of forming a spontaneous or assisted covalent bond with the first peptide partner on the adenoviral vector. Any entity can also be added using this technology. Thus, targeting entities or moieties, such as antibodies or fragments thereof, cell
20 surface marker binding agents or partner pairs may be used. Alternatively, the entity may be a shielding entity. These may be a benign, unreactive or innocuous protein, polypeptide, peptide, glycopeptide, lipopeptide, polysaccharide or lipid whose sole function is to shield the adenovirus capsid from binding of host immune cells. In this context benign means an entity that has no additional function, such as an antigen for a vaccine or a targeting moiety. All the shielding entity
25 does is provide a physical shield to the capsid that does not allow the binding of host antibodies. Nevertheless, the inventors have shown that it is possible to retain infectivity with such attachments, which is a surprise. This effect was particularly seen with modifications to the hexon, the major component of the viral capsid.

30 The adenoviral vector may be decorated by attaching more than one entity. The adenoviral vector may have attached a multiplicity of entities. Each entity may have a distinct function, for example, an antigen and a targeting moiety. Multiple entities may be attached, each one to a separate second peptide partner. This enables the attachment of multiple entities to a single

adenoviral vector. The different entities may be for the same indication (for example different antigens for the same disease) or different indications (for example a combined vaccine composition for different diseases such as measles, mumps and rubella on a single adenoviral vector).

5 It is not generally an object of the invention in relation to vaccines to be altering the natural tropism of the adenovirus, since the present invention is seeking to raise antibodies or T cells to the presented antigen, rather than to retarget the vector to specific cell types. The fiber component is thought to be the major determinant of tropism. The inventors have seen for several Examples using a DogTag modification in the hexon protein that the modification to the capsid protein has
10 little or no effect on the capability of transducing a specific target cell. Indeed, in the Examples, there was no drop in infectivity in HEK293 cells when DogTag was inserted into the hexon and paired with DogCatcher on the antigen. However, in some instances, the inventors have shown that modifications can affect the ability of the virus to infect HEK293 cells, herein this was demonstrated with SpyTag when inserted into the hexon and paired with SpyCatcher on the antigen. A 100-fold
15 decrease in infectivity was seen for the SpyTag-inserted adenovirus. This is undesirable and unexpected. Indeed, given that this is the most commonly used peptide tag, and is frequently preferred for most applications, the inventors were of the opinion that adenovirus may be intransigent to the modification of the capsid protein using partner pairs. It was only through significant work that it was appreciated that this did not hold true for all partner pairs, and that
20 DogTag in particular was a workable modification of the hexon protein.

The modified adenoviral vectors described here have been carefully engineered such that they are readily produced with yields comparable to vectors with a wild-type capsid protein, e.g. wild-type hexon or wild-type pIX capsid proteins. Methods of producing adenovirus *in vitro* are well
25 known to those skilled in the art, along with methods of introducing recombinant genes into the adenovirus.

It is widely appreciated in the field that performing modifications and / or insertions to viral capsid proteins is difficult and often disruptive to viral function and replication. Modification must
30 not inhibit correct folding of the capsid protein or its incorporation within the capsid structure of the virion during assembly. For antigen display in particular, modifications must be performed such that the conformation and location of the displayed antigen enables recognition by the immune system, and in the case of infectious viral particles, does not impede the ability of the viral vector to infect

cells. Previous studies have demonstrated the complexity of these requirements. In the context of hexon HVR loops, Matthews *et al* showed that vector viability is dependent upon the size of insertion and which HVR loop is targeted. [Matthews QL, *et al* Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol J. 2008 Aug 21;5:98. doi: 10.1186]. The same study also demonstrated that immune recognition by displayed epitopes was also dependent on the nature and location of the inserted antigen. Other studies, such as in Gu *et al*, have revealed the importance of the nature and length of linker sequences to facilitate efficient epitope display. [Linlin Gu, *et al*, A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy, Virol J. 2014 Jun 16;11:112. doi: 10.1186]. In the present application, the present inventors again demonstrate this phenomenon, by showing that coupling of SpyCatcher to Ad5-HVR-SpyTag vectors is less efficient, and substantially impedes vector infectivity (Figure 2), while coupling of Ad5-HVR-DogTag to DogCatcher is highly efficient and does not impede vector infectivity (Figure 3). The superior efficiency and utility of DogTag:DogCatcher coupling compared to SpyTag:SpyCatcher coupling in the context of adenovirus hexon insertion was unexpected, since SpyTag:SpyCatcher coupling has been shown to be highly efficient in a wide variety of other contexts. Indeed, there are over 500 documented constructs using the SpyCatcher:SpyTag technology.

In the context of pIX modification, studies have demonstrated that the pIX protein can tolerate a variety of different extensions to the C-terminus. However, the viability, capsid stability, and efficiency of antigen display are highly dependent on the nature and length of the fusion [Igor P. Dmitriev, *et al*, Engineering of Adenovirus Vectors Containing Heterologous Peptide Sequences in the C Terminus of Capsid Protein IX. J Virol. 2002 Jul;76(14):6893-9] [Nadine C. Salisch, *et al*, Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform. PLoS One. 2017; 12(3): e0174728].

In some embodiments of any aspect of the invention at least one modification in the capsid protein of the virus is within a major capsid protein or within a minor capsid protein. All of the adenovirus proteins on the outer surface of the virion (hexon, fiber, protein IX and penton) are capable of being modified.

In one embodiment, the modification in the major capsid protein is in the hexon protein.

In other embodiments, the modification in the minor capsid protein is in the pIX protein.

For any aspect of the present invention, at least one modification is the insertion or fusion of a first peptide partner to the capsid protein. Preferably, at least one modification is the insertion or fusion of a first peptide partner to the capsid protein via genetic modification of the adenovirus genome. Suitably, the modification is the insertion of a first peptide partner in the hexon protein, preferably into one or more of the HVR loops of the hexon protein. Thus, the insertion may be made into the sequence of the hexon protein, rather than fusing the first peptide partner to the N- or C-terminus. Suitably, the modification is the fusion of a first peptide partner in the pIX protein. For the pIX fusion, the first peptide partner may be fused at any suitable location, optionally the C- or N-terminal ends, preferably the C-terminal end. Those skilled in the art of modifying an adenovirus would be aware of how to introduce genetic modifications in order to modify the viral coat proteins as discussed herein.

In some embodiments of any aspect of the invention a covalent bond is an isopeptide. This allows irreversible conjugation of the first peptide partner to the second peptide partner forming covalently stabilised multi-protein complexes. This isopeptide bond may be spontaneous, i.e. without assistance, or require assistance, i.e. from a ligase. Specific peptide partner pairs are well known in the art, and includes the non-exhaustive list: SpyTag/SpyCatcher and derivatives and modifications thereof, SnoopTag/SnoopCatcher, DogTag/DogCatcher, SnoopTagJr/SnoopCatcher, SnoopTagJr/Dog Tag, Isopeptag/Pilin-C, Isopeptag-N/Pilin-N, SdyTag/SdyCatcher, PsCsTag/PsCsCatcher, RrgATagor RrgATag2/RrgACatcher and/or Jo/In and modifications and variants of any of these partner pairs.

In one embodiment, a first peptide partner may be DogTag, or SpyCatcher. Alternatively, a first peptide partner may be SpyTag. The adenoviral capsid protein inserted with DogTag is assigned the term "Ad-DogTag". The adenoviral capsid protein inserted with SpyTag is assigned the term "Ad-SpyTag". The adenoviral capsid protein fused with SpyCatcher is assigned the term "Ad-SpyCatcher".

In other embodiments, a second peptide partner may be DogCatcher, SnoopTagJr, or SpyTag. In one example, a first peptide partner couples to a second peptide partner forming an isopeptide bond to make a peptide: peptide binding pair.

In relation to the data presented here, it is show that the insertion of DogTag into the hexon capsid protein performs well, and is capable of a good yield (Figure 12).

In relation to the data presented here, the insertion of the following first peptide partners
5 into pIX have been demonstrated as viable: SpyCatcher, SnoopCatcher, DogCatcher, SpyTag and SnoopTagJr. In Figure 12 it is demonstrated that SpyCatcher fusions into pIX may be genetically less stable under certain circumstances, whilst SnoopCatcher and DogCatcher inserted into the same capsid protein may be more genetically stable, and therefore preferable under certain circumstances. However, SpyCatcher fusions are operable, see Figure 11 where various entities are
10 attached, whilst the virus retains infectivity. In Figure 14 it is demonstrated that SnoopTagJr and SpyTag insertions into pIX do not adversely affect infectious yield, even when entities such as antigens are attached to these first peptide partners using the second peptide partner. It should be noted that the entire spike protein from Sars-CoV2 is over 500KDa and is therefore a large attachment which has been successfully attached. Thus, SpyCatcher, SnoopCatcher, DogCatcher,
15 SpyTag and SnoopTagJr may be inserted into pIX as the first peptide partner, most preferably SnoopCatcher, DogCatcher, SpyTag and SnoopTagJr may be inserted into pIX as the first peptide partner.

Examples of the peptide:peptide binding pair described herein includes but are not limited
20 to SpyTag and SpyCatcher, DogTag and DogCatcher, SnoopTag/SnoopTagJr and SnoopCatcher; RrgATag/RrgATag2/DogTag and RrgACatcher, IsopepTag/ IsopepTag-N and Pilin-C or Pilin-N, PsCsTag and PsCsCatcher; SnoopTagJr/SnoopTag and DogTag (mediated by SnoopLigase), and variants, derivatives and modifications of all these systems. Suitable peptide tag/binding partner pairs are described in detail in WO2011/09877, WO2016/193746, WO2018/18951 and WO2018/197854,
25 herein incorporated by reference.

Accordingly, the second peptide partner may be linked or fused to an entity. This entity may be anything which it is desired to be attached to an adenoviral vector and is capable of being produced as a fusion to the second peptide partner. The type of entity will depend upon the
30 prophylactic or therapeutic use to which the adenoviral vector will be put. The entity can be a targeting moiety, such as part of a ligand binding pair, an antibody or fragment thereof, or any other entity specifically recognised by a cell surface receptor. Such targeting moieties may be useful for oncolytic viruses and gene therapy applications. However, the entity may also simply have the

function of blocking or shielding the adenovirus from the binding of antibodies present in the host in which the therapeutic is administered. Such a shielding entity may have no further function other than the provision of a shield to the adenoviral capsid core, enabling it to evade clearance. It is preferred that this shielding entity does not alter the tropism (natural infectivity) of the adenovirus.

5 The inventors have observed that when the size of the second peptide partner with an attached shielding entity exceeds about 15kDa, the combination appears to assist the modified adenovirus escape the immune response. This observation is recorded in Figure 8A, where a partial shielding effect is noted for SnoopTagJr-AffiHER2. From gel migration, SnoopTagJr-AffiHER2 is considered to be about 15kDa. This partial shielding effect may be advantageous. However, if the size of the
10 combined second peptide partner plus attached shielding entity is greater than about 25kDa, more complete shielding is observed, as seen in the results for DogCatcher-NANP9 (approximately 25-30kDa) as seen in Figures 8B and 8C. In the case of a vaccine, the inventors have shown that the antigen may have a dual function, to raise an immune response in the host, but also to evade the host immune response to the adenovirus itself. Since it has not previously been possible to
15 covalently attach entities of the size under consideration, this effect has not previously been observed.

Accordingly, the second peptide partner is linked or fused to an antigen or synthesised to include an antigen. The antigen may be attached to prevent future disease (prophylactic) or to assist
20 the immune response in fighting a current disease (therapeutic). The antigen may be any suitable composition, including a peptide, polypeptide, protein, glycoprotein, lipoprotein, saccharide, polysaccharide, and the like. This antigen may be any suitable antigen, including self-antigen, cancer antigen, antigen that is an allergen, bacterial antigen, fungal antigen, viral antigen or an antigen from any pathogenic organism. The antigen may be a whole or entire antigen, or it may be a fragment
25 thereof, such as an epitope. The antigen may be entirely natural or may be modified. The antigen may be a viral antigen or neoepitope or neoantigen. The antigen may be one common to a particular type of cancer, for example, such as shared neoepitope. The neoepitope or neoantigen may be patient-specific. Patient-specific antigens may arise from mutations in the antigen, for example change of coding sequence, frameshift mutation or altered post-translational modification.
30 For example, wild type SnoopTagJr sequence has been synthesised as a fusion peptide to include a neoepitope sequence. In another example, DogCatcher is linked to an antigen to form a DogCatcher fusion.

In one embodiment, a first peptide partner is DogTag and a second peptide partner is DogCatcher. The attachment of a first peptide partner for example, DogTag attached to the hexon capsid protein forms the vector Ad-DogTag. Upon coupling to the second peptide partner DogCatcher linked to an antigen, the vaccine vector formed is called Ad-DogTag:DogCatcher-Antigen. In another embodiment, a first peptide partner is DogTag and a second peptide partner is SnoopTagJr or SnoopTag. The synthesis of SnoopTagJr with an antigen such as a neoepitope results in SnoopTagJr fusion. The synthesis of SnoopTag with an antigen such as a neoepitope results in SnoopTag fusion. The coupling of either SnoopTagJr or SnoopTag fusion to the vector Ad-DogTag results in the vector called Ad-DogTag:SnoopTagJr-fusion or Ad-DogTag:SnoopTag-fusion, respectively. This reaction requires SnoopLigase to facilitate the coupling between DogTag and SnoopTagJr fusion, or SnoopTag fusion. It may be preferred that DogTag is attached to the hexon capsid protein, optionally to a HVR loop. In some embodiments, the DogTag may be used to modify more than one HVR loop within the same hexon protein. This may increase the opportunity for attachment to the viral capsid.

15

In another embodiment, a first peptide partner is SpyCatcher and a second peptide partner is SpyTag. The SpyTag is linked to an antigen to form Ad-SpyCatcher:SpyTag-Antigen. Thus, it can be seen that the first peptide partner can be either what is termed in the art as a "tag" or "catcher"; with the second peptide partner component being the partner for this pair, the "catcher" or the "tag", respectively. Herein both are designated as protein partners as they may be provided in either orientation, modifying the capsid protein or attached to the antigen. The coupling of the first peptide partner to the second peptide partner enables display of the antigens on the surface of the immunogenic adenoviral viral proteins. In this embodiment, the capsid protein is preferably pIX. Other "first peptide partner" and "second peptide partner" combinations that may be used in the context of pIX are primary partner SnoopTagJr and secondary partner SnoopCatcher, primary partner SpyTag and secondary partner SpyCatcher, primary partner SnoopCatcher and secondary partner SnoopTagJr or primary partner DogCatcher and secondary partner DogTag.

In another embodiment, the first peptide partner inserted into pIX may be any one of SnoopCatcher, DogCatcher, SpyTag and SnoopTagJr. These have all been demonstrated to be effective insertions, with good yield viability and are accessible for their respective second binding pair to allow decoration of the adenovirus with a desired entity. The respective second peptide partners are discussed here throughout. The resultant adenoviruses may be termed "Ad –

30

SnoopCatcher", "Ad-DogCatcher", "Ad-SpyTag" and "Ad-SnoopTagJr". Alternatively, these may be named "Ad pIX – SnoopCatcher", "Ad pIX -DogCatcher", "Ad pIX -SpyTag" and "Ad- pIX SnoopTagJr"

In some embodiments, the combination of the second peptide partner and the attached entity for attachment/decoration, such as an antigen is of significant size, for example it over 20kDa, 25 kDa, 30 kDa, 40 kDa, 50 kDa, 60 kDa, 70 kDa, 80 kDa, 90 kDa, 110 kDa, 120 kDa, 130 kDa, 140 kDa, 150 kDa or 160 kDa, 170 kDa, 180 kDa, 190 kDa or more, such as over 200 kDa, over 300 kDa or over 400 kDa in size. Such decoration of a modified adenovirus is significant, since this type of addition is not possible using genetic fusion, due to the size limit imposed by the capsid proteins themselves. The inventors have shown that the addition of a second peptide partner entities of at least around 25-30 kDa has a beneficial effect of shielding the adenovirus from neutralising antibodies. Thus, it is preferred that the combined size of the entity attached to the second peptide partner is greater than 15kDa, preferably greater than 20kDa, optionally greater than 25 kDa in size, optionally at least 30kDa in size, in order to provide a shielding effect.

15

The inventors have demonstrated that with larger entities (over about 30 kDa) attached to the adenoviral particle using the methods of the present invention, the decorated adenovirus of the present invention may evade the usual host immune response to the adenovirus. It is postulated that this is because the entity shields the adenovirus from antibody neutralisation by the host immune system. Evasion of host immunity to the adenoviral particle itself may be useful, since it would permit the adenovirus vector to be effective even in individuals who had previously been exposed to the parental adenovirus strain. Given that a large percentage of the human population is expected to have been previously infected by adenovirus, this would be a useful improvement over the prior art. Host immune clearance of prophylactic or therapeutic adenoviral vectors is a major obstacle to current therapeutics reaching the clinic. The present invention can therefore be used primarily as a way to shield any adenoviral vector from the host immune system. Advantageously, the entity attached using the technology can itself have a therapeutic effect, such as an antigen for a vaccine, or a targeting moiety for cell targeting in gene therapy or oncolytic viruses.

In other embodiments, DogTag is inserted into the surface loops of the hexon capsid protein. Hexon is the major component of the adenoviral capsid proteins with approximately 720 copies per virion. This enables a display of up to 720 ligands per virion, assuming that 100% of the

30

hexon proteins are coupled with a peptide tag. DogTag is therefore the first peptide partner in some embodiments. In one embodiment, DogTag is inserted into at least one HVR loop of the hexon.

In other embodiments, SpyCatcher is fused to the C-terminus of adenovirus minor capsid protein pIX. The attachment of a first peptide partner for example, SpyCatcher fused to the pIX capsid protein forms the vector Ad-SpyCatcher. Upon coupling to the second peptide partner SpyTag linked to an antigen, the vaccine vector formed is called Ad-SpyCatcher:SpyTag-Antigen.

In another embodiment, the first peptide partner inserted into pIX may be any one of SnoopCatcher, DogCatcher, SpyTag and SnoopTagJr. The resultant adenoviruses may be termed "Ad – SnoopCatcher", "Ad-DogCatcher", "Ad-SpyTag" and "Ad-SnoopTagJr". Alternatively, these may be named "Ad pIX – SnoopCatcher", "Ad pIX -DogCatcher", "Ad pIX -SpyTag" and "Ad- pIX SnoopTagJr". Upon coupling to the respective peptide pairs, these may form: "Ad – SnoopCatcher: SnoopTag", "Ad-DogCatcher: DogTag", "Ad-SpyTag:Spycatcher" and "Ad-SnoopTagJr:SnoopTag ". Any entity may be attached to the second peptide partner, such as an antigen for a vaccine composition.

As used herein the colon ":" refers to the presence of a covalent bond between the peptide pairs.

Accordingly, in another aspect of the invention there is provided a composition comprising an adenoviral vector in accordance with the invention. The composition is preferably immunogenic. Said adenoviral vector comprises a modified capsid protein, wherein said modification primes the vector for accepting the attachment of an entity. The modified capsid protein involves the fusion or insertion of a first peptide partner. A therapeutic or prophylactic virus may then be prepared by adding the requisite second peptide partner which is attached to an entity such as an antigen. Together the first and second peptide partners form a covalent bond either spontaneously or assisted by a third entity such as a ligase. Therefore, in the therapeutic or prophylactic composition, the capsid protein is modified by the inclusion of a first peptide partner covalently linked to a second peptide partner attached to an entity such as an antigen. If the entity attached is an antigen, the composition is a vaccine composition. This is a preferred use of the technology, since it capitalises on the highly immunogenic nature of the adenovirus itself. Indeed, in Figure 10 it can be seen that attaching the antigen to the vector (in this case a peptide antigen) is advantageous when compared to the results where the peptide and adenovirus are provided together as separate entities.

In another aspect of the invention there is provided a method of producing an adenoviral vector in accordance with the invention.

5 In another aspect there is provided a method of producing a vaccine comprising the mixing of an adenoviral vector in accordance with the invention with a second peptide partner attached to an antigen. Said method may require the use of a third or helper entity such as a ligase.

10 In a further aspect there is provided a method of producing an oncolytic virus comprising the mixing of an adenoviral vector in accordance with the invention with a second peptide partner attached to an entity such as a targeting moiety or shielding entity. Said method may require the use of a third or helper entity such as a ligase. The targeting moiety may be any suitable entity that permits the virus to be targeted to a cell or tissue type. Advantageously, said moiety also blocks the binding of host antibodies to the modified adenovirus. Alternatively, the shielding entity simply helps the already targeted oncolytic virus to escape the immune response.

15

In a further aspect there is provided a method of producing a gene therapy vector comprising the mixing of an adenoviral vector in accordance with the invention with a second peptide partner attached to a targeting moiety. Said method may require the use of a third or helper entity such as a ligase. The targeting moiety may be any suitable entity that permits the virus to be targeted to a cell or tissue type. Advantageously, said moiety also blocks the binding of host antibodies to the modified adenovirus. Those skilled in the art are aware of numerous gene therapy uses of adenovirus. The present invention may be used to shield vectors from the immune system and/or help with targeting of the vector.

25 In another aspect of the invention there is provided a vaccine comprising an immunogenic adenoviral vector in accordance with the invention for use in the prophylaxis and/or treatment of a disease. Suitably, said vaccine comprises an immunogenic adenoviral vector in accordance with any aspect or embodiment of the invention. Suitably, the vaccine is for use in mammals, including humans and animals. Suitably the vaccine is for use in humans, for example children, adults, women of reproductive age or pregnant women. In another aspect, the invention provides a method of inducing an immunogenic response, for example a protective immune response wherein the method comprises administering a composition in accordance with any aspect or embodiment of the invention. In a further aspect the invention provides a cancer vaccine which targets one or more

30

tumour-specific mutations, permitting the specific targeting of an immune response to cancer cells. Personalised cancer vaccines are also contemplated. Such vaccines include one or more antigens that are specifically present on the cancer cells for that patient. This means that the vaccine is personalised to the particular cancer the patient has. These tumour-associated or cancer-associated
5 antigens may be neoantigens, which are antigens newly expressed by the cancer cell.

In another aspect of the invention there is provided a kit comprising an adenoviral vector in accordance with the invention. The kit may also include the second peptide partner linked to an antigen, the second peptide partner ready for protein fusion to an antigen, or the genetic sequence for the second peptide partner to allow the genetic fusion of the second peptide partner to the gene
10 for the antigen.

The present invention also extends to a kit for the preparation of a vaccine, said kit comprising an adenoviral vector as described herein. Also present in said kit may be the gene sequence for the second peptide partner, ready for fusing with the antigen. A further component may be instructions for use. Also included may be a third entity necessary for facilitating the
15 covalent bond between the peptide partner pair.

In another aspect of the invention there is provided a kit comprising an adenoviral vector in accordance with the invention. The kit may also include the second peptide partner linked to a targeting moiety, the second peptide partner ready for protein fusion to a targeting moiety, or the genetic sequence for the second peptide partner to allow the genetic fusion of the second peptide
20 partner to the gene for the targeting moiety.

The present invention also extends to a kit for the preparation of an oncolytic virus, said kit comprising an adenoviral vector as described herein. Also present in said kit may be the gene sequence for the second peptide partner, ready for fusing with the targeting moiety. A further component may be instructions for use. Also included may be a third entity necessary for facilitating
25 the covalent bond between the peptide partner pair. The adenoviral vector in this instance would be replication competent and may be modified to include genes to ensure destruction of the infected cancer cell.

The present inventors are aware that peptide binding partners have previously been used in vaccine preparation, in particular for use in virus-like particles. However, this technology is distinct
30 from the use of a viral vector, which may have a different utility in vaccine preparation due to the immunological response the viral vector itself generates. A viral vector is efficient at gaining entry to the cytoplasm and often the nucleus as well, which leads to an enhanced cytotoxic T cell response to viral vectors, compared to virus like particles. For many infectious diseases and for cancer, the

cytotoxic T cell response is a major component of protective immunity. Virus like particles (VLPs) resemble viruses in their size (approx. 20–200 nm), their shape and their repetitive protein arrangement but lack any genetic material from a pathogen. Therefore, the method of their synthesis and the challenges faced in preparing vaccines from VLPs is very different to the method of preparation and the challenges faced with preparing a vaccine from a viral vector. These peptide partner pairs have not previously been used or suggested for use for modifying a capsid protein in an immunogenic viral vector.

Further, the inventors are aware that others have used peptide binding partners, most notably SpyTag, to modify the surfaces of other viruses. The other viruses selected for modification by other groups present different challenges to those at hand with adenovirus. Primarily, the majority of viruses previously modified are enveloped. Thus, the modifications are taking place on proteins that are part of the lipid envelope. In adenovirus, the present inventors have found that modifying capsid proteins in a non-enveloped virus is not as straightforward to do as expected, and that structural constraints mean that it is not possible in some instances to include the modification and retain infectivity to a satisfactory level. Further, the previous work conducted to modify viruses with peptide partner pairs that form a covalent bond has focussed on re-targeting the virus or altering tropism. This is different to the main focus of the present application, which is the correct display of antigens on the capsid surface in order to raise an immune response.

Detailed Description of the Invention

Figures

Figure 1 (A-D). Modular covalent decoration of the adenovirus capsid via insertion of SpyTag or DogTag into hexon HVR loops.

Figure 1 shows four representations of embodiments of the present invention. Figure 1A) Reaction of SpyCatcher with SpyTag via an isopeptide bond. Figure 1B) Reaction of DogCatcher with DogTag via an isopeptide bond. Figure 1C) Coupling reaction between SnoopTagJr and DogTag, catalysed by SnoopLigase. Figure 1D) Modular hexon decoration, showing surface display of DogTag on the viral capsid and subsequent coupling of peptides or protein antigens via SnoopTagJr or DogCatcher. Figure 1E) Multiple sequence alignment of the adenovirus hexon protein indicating location of hypervariable region (HVR) loops 1, 2 and 5 and the deletions generated at the insertion site prior to insertion of SpyTag or DogTag at each locus. Shaded residues indicate differing residue identity to Ad5. Hexon sequences from the following Human adenovirus serotypes are shown; Ad5 and Ad2 (species C), Ad12 and Ad18 (species A), Ad3 and Ad35 (species B), Ad4 (species E), Ad40 and Ad41

(species F). Note that the insertions sites indicated are identical between SpyTag and DogTag recombinants at each of the three HVRs tested. At each locus, SpyTag or DogTag sequences are flanked by GSGGSG sequences.

Figure 2 (A-D). Reactivity of SpyTag following insertion into Ad5 HVR loops. Figure 2A: SDS-PAGE and Coomassie staining analysis of Ad5 displaying SpyTag in the loop HVR1, HVR2 or HVR5 (1E+10 viral particles) incubated with SpyCatcher at 4°C for 16 h. Figure 2B: Vector infectivity assay of the samples shown in Figure 2A. Data show infectious units (ifu) per ml mean + range for duplicate wells. Figure 2(C-D): Ad5(GFP) vectors displaying SpyTag at HVR1 (Ad5(GFP)HVR1-SpyTag) (1E+10 viral particles) were incubated with biotinylated SpyCatcher at 15 μ M or 40 μ M under different conditions as shown. Figure 2C: SDS-PAGE Coomassie staining analysis of Ad5 displaying SpyTag incubated with SpyCatcher at 20°C or 37°C for 3 hours or at 20°C or 4 °C for 16 hours. Figure 2D: Vector infectivity assay was performed on the same samples shown in Figure 2C. Data show mean + range for duplicate wells.

Figure 3 (A-D). Reactivity of DogTag following insertion into Ad5 HVR loops. Figure 3A: Yield comparison of Ad5 vectors displaying DogTag on hexon surfaces (in HVR 1, 2 or 5) versus Ad5 vectors with an unmodified hexon (WT). P:I ratios (ratio of total viral particles calculated by UV spectrophotometry to infectious units calculated by GFP focus assay) for each vector batch are indicated above each bar. Figure 3B: SDS-PAGE and Coomassie staining analysis of Ad5 displaying DogTag at HVR1, HVR2 or HVR5 (1E+10 viral particles) incubated with DogCatcher (5 μ M) at 4°C for 16 h. Figure 3C: Vector infectivity assay was performed on the samples shown in Figure 3B. Data show mean + SD of triplicate wells. Figure 3D: SDS-PAGE and Coomassie staining of Ad5 displaying DogTag incubated with DogCatcher for 0.1, 1 or 16 hours at 4 °C.

Figure 4 (A-C). Reactivity of Ad5 HVR-DogTag with SnoopTagJr directed by SnoopLigase. Figure 4A: Reactivity of SnoopTagJr fused to an affibody to HER2 (SnJr-AffiHER2) with DogTag inserted into different HVR loops, catalysed by SnoopLigase, assessed by SDS-PAGE and Coomassie staining. Figure 4B-C: Temperature-dependence of reactivity of SnJr-AffiHER2 with Ad5(GFP)HVR5-DogTag. Figure 4B: SDS-PAGE and Coomassie staining analysis of the reaction between SnJr-AffiHER2 and Ad5(GFP)HVR5-DogTag, catalysed by SnoopLigase at 4°C or 20°C. Figure 4C: A vector infectivity assay was performed on the same samples described in Figure 4B. Data show mean +range of duplicate wells. Figure 4D: SDS-PAGE and Coomassie staining analysis on the effect of glycerol (15% w/v) and salt addition on SnoopLigase-mediated reactivity.

Figure 5 (A-B). Assessment of vector infectivity using an anti-hexon immunostaining assay for non-fluorescent recombinant vectors.

Figure 5A: Anti-hexon immunostaining of HEK293A cells infected with Ad5 vectors with a WT hexon protein or Ad5 vectors displaying DogTag at HVR5. Brightfield microscopy images using a 4× objective, with hexon-positive cells shown in black. Scale bar = 1000 μm. Figure 5B: Comparison of the infectious titre for Ad5(GFP) hexon WT and Ad5(GFP) HVR5 DogTag using both GFP fluorescence and hexon immunostaining assays. Both assays were performed using the same wells on the same plate, n=4. A two-tailed t-test was performed, but no statistically significant difference was observed between groups. Bars show mean ± SD; dots represent spot counts from individual wells.

Figure 6 (A-F). Reactivity of DogTag inserted into hexon loops with SnoopTagJr tagged peptides.

Figure 6A: Illustration of a competition assay using DogCatcher (DC) to assess the efficiency of SnoopTagJr-peptide (SnJr-peptide) coupling to hexon-DogTag (hexon-DT), catalysed by SnoopLigase (SnL). Figure 6B: SDS-PAGE and Coomassie analysis of the coupling efficiency of SnoopTagJr-hTERT peptide to hexon-DT using the DogCatcher competition assay. Figure 6C: SDS-PAGE and Coomassie analysis of the coupling efficiency of SnoopTagJr-SIINFEKL peptide (PEP1; SnJr-GGS-SIINFEKL, PEP2; SnJr-AAY-SIINFEKL) to hexon-DT using the DogCatcher competition assay. Figure 6D: Illustration of assessment of SnJr-peptide coupling to hexon-DT using monovalent streptavidin (mSA) direct gel shift assay with Western blotting using anti-hexon antibody. If added after boiling, the biotin-streptavidin interaction is stable on SDS-PAGE. Figure 6E: SDS-PAGE and Coomassie analysis of SnJr-biotin coupling to Ad5-DT using the direct gel shift assay with mSA. Figure 6F: A vector infectivity assay was performed on the same samples shown in Figure 6C. Bars show mean and range of duplicate wells.

Figure 7 (A-C). Coupling of Ad5 HVR DogTag to DogCatcher fusion proteins.

Figure 7A: Illustration of three DogCatcher fusion constructs; NANP9, NANP18, and NANPD, derived from the *Plasmodium falciparum* circumsporozoite protein (PfCSP), isolate 3D7. NDVP and NANP tetrapeptide repeats are illustrated. Figure 7B: SDS-PAGE and Coomassie analysis of the reactivity of DogCatcher-NANPn with DogTag inserted into hexon HVR5 loop. Figure 7C: A vector infectivity assay was performed on the same samples shown in Figure 7B. Bars show mean and range of duplicate wells. Sizes of surface decoration: DogCatcher-NANP9 (~25-30kDa), DogCatcher-NANP18 (~35-40kDa) and DogCatcher-NANP Domain (~60kDa)

Figure 8 (A-C). Coupling via isopeptide bonds to the surface of Ad5 via hexon reduces the potency of virus-neutralising antibodies.

Figure 8A: Coupling via SnoopLigase to the surface of Ad5 via hexon

reduces the potency of virus-neutralising antibodies. Adenovirus was added to cells in the presence of varying concentration of the monoclonal antibody targeting the adenovirus hexon (mAb 9C12). Productive adenovirus infection was detected from the fluorescence of adenovirus-encoded GFP expressed in the cells. Intensity of fluorescence of Ad5-DT alone, Ad5-DT + SnJr-AffiHER2 and Ad5-DT + SnL + SnJr-AffiHER2. Figure 8B: Coupling of DogCatcher-NANPn to the surface of Ad5 via hexon reduces the potency of virus-neutralising antibodies, analysed as in Figure 8A. Intensity of fluorescence from Ad5-DT alone, or DogCatcher-NANPn coupled to Ad5 DogTag. Figure 8C: Adenovirus was added to cells in the presence of varying dilutions of adenovirus-neutralising serum. Productive adenovirus infection was detected from the fluorescence of adenovirus-encoded GFP expressed in the cells. Intensity of fluorescence of Ad5-DT alone, or DogCatcher-NANPn coupled to Ad5 DogTag. In A-C, bars indicate mean and range of duplicate values.

Figure 9: Human coagulation Factor X-dependent vector transduction of SKOV3 cells. Ad5(GFP)-DogTag (Ad5) or Ad5(GFP)-DogTag:DogCatcher-NANP18 (Ad5-NANP18) vectors (2×10^9 viral particles) were incubated in the presence or absence of human coagulation Factor X ($8 \mu\text{g/mL}$) on SKOV3 cells for 2 h at 37°C in serum-free media. Then media was replaced with fresh complete media and plates were incubated for a further 48 h. Infectious titres were then calculated by enumeration of GFP-positive foci by fluorescence microscopy. Samples were plated in duplicate and bars show mean and range of data values.

Figure 10 (A-C). Ad5(GFP) vectors displaying SIINFEKL peptides on the capsid surface generate CD8^+ T cell responses against both the capsid-displayed peptide and internally-encoded GFP antigens. Figure 10A: Design and immunisation schedule for mouse immunogenicity experiment to assess CD8^+ T cell responses to Ad5 surface-displayed peptide antigens. To confirm the importance of physical attachment of peptide epitopes to the capsid surface, SIINFEKL specific T cell responses after administration of Ad5(GFP) HVR5 DogTag with SIINFEKL attached (Ad5-DT:SIINFEKL) were compared to co-administration of Ad5(GFP) HVR5 DogTag (Ad5-DT) with free SIINFEKL peptide (Groups 1 and 2, vs Group 3), and to SIINFEKL peptide with poly I:C adjuvant (Group 4). Figure 10B: Spleen *ex vivo* IFN γ -ELISPOT responses to SIINFEKL (spot forming cells per million splenocytes). Figure 10C: Spleen *ex vivo* IFN γ -ELISPOT responses to the epitope DTLVNRIEL (EGFP₁₁₈₋₁₂₆). In Figure 10B and Figure 10C, spots represent responses in individual animals, while bars represent median values with range.

Figure 11 (A-D). Modular covalent decoration of the adenovirus capsid via fusion of SpyCatcher at the C-terminus of pIX. Figure 11A: Modular adenovirus capsid decoration, showing surface display of

SpyCatcher on the viral capsid via fusion to pIX, and subsequent coupling of peptide or protein antigens via SpyTag. Figure 11B: SDS-PAGE analysis of Ad5(GFP) pIX-SpyCatcher coupled with SpyTag-Maltose binding protein (SpyTag-MBP, 5 μ M) or SpyTag-Human cytomegalovirus (HCMV) pentamer (SpyTag-Pentamer, 2.5 μ M) for 16 h at 4 $^{\circ}$ C. gH is the pentamer subunit containing the
 5 SpyTag. Proteins detected by Western blotting using anti-SpyCatcher polyclonal mouse sera. Figure 11C: SDS-PAGE analysis of Ad5(GFP) pIX-SpyCatcher coupled to SpyTag-peptides. Monovalent streptavidin (mSA) was added to induce a clear gel shift, and proteins detected by Western blotting using anti-SpyCatcher polyclonal mouse sera. Figure 11D: Vector infectivity assay was performed on the same samples as shown in Figure 11B and Figure 11C. Bars show mean and SD of triplicate wells.

10 **Figure 12 (A-B). Viability, genetic stability, and yield of different recombinant adenovirus vectors with SpyCatcher, SnoopCatcher or DogCatcher fused to the C-terminus of pIX.** Figure 12A: Schematic representation of the pIX amino acid sequence for different Ad5(GFP) vectors with versions of SpyCatcher, SnoopCatcher or DogCatcher fused to the C-terminus of pIX, with corresponding information regarding vector viability in HEK293A cells and genetic stability (after >3
 15 passages). SpyCatcher dN1 (delta N1) refers to the same N-terminally truncated version of SpyCatcher used in the other Figures from this document. SpyCatcher dN1dC2 (delta N1, delta C2) refers to a shorter version of SpyCatcher with an additional C terminal truncation. Figure 12B: Yield comparison of viable Ad5 vectors (as indicated in Figure 12A) displaying SpyCatcher, SnoopCatcher or DogCatcher at the C-terminus of pIX. Yields of vectors with pIX-Catcher fusions are compared to
 20 Ad5(GFP) HVR5 DogTag, using equivalent volumes of cultured cells and the same vector harvest / purification protocols. For SnoopCatcher and DogCatcher fusions, bars indicate mean and range of n=2 batches.

Figure 13 (A-C). Reactivity of SnoopCatcher and DogCatcher fused to the C-terminus of pIX. Figure 13A: Reactivity of Ad5(GFP) pIX-SnoopCatcher vector with SnoopTagJr-fused to the full length spike protein from SARS CoV2 (Spike) or SnoopTagJr fused to the receptor binding domain (RBD) of SARS
 25 CoV2 spike. Ad5(GFP) pIX-SnoopCatcher (3E+9 viral particles) was incubated alone or co-incubated with Spike-SnoopTagJr (0.75 μ M) or RBD-SnoopTagJr (5 μ M) for 16h at 4 $^{\circ}$ C. Samples were run on SDS-PAGE and western blotting performed using polyclonal mouse sera with reactivity against SnoopCatcher. Species representing pIX-SnoopCatcher (pIX-SnC), pIX-SnoopCatcher:SnoopTagJr-RBD
 30 (pIX-SnC:SnJr-RBD) and pIX-SnoopCatcher:SnoopTagJr-Spike (pIX-SnC:SnJr-Spike) are indicated. Figure 13B: Vector infectivity assay was performed using the same samples shown in Figure 13A. Bars show mean and SD of triplicate samples. Figure 13C: Reactivity of Ad5(GFP) pIX-DogCatcher

vector with DogTag-fused to Small Ubiquitin Modifier (SUMO). Ad5(GFP) pIX-DogCatcher (1E+9 viral particles) was incubated alone or co-incubated with SUMO-DogTag (17 μ M) for 16h at 4 °C. Samples were run on SDS-PAGE and western blotting performed using polyclonal mouse sera with reactivity against DogCatcher. Species representing pIX-DogCatcher (pIX-DC) and pIX-DogCatcher:DogTag-SUMO (pIX-DC:DT-SUMO) are indicated.

Figure 14 (A-C). Reactivity of SnoopTagJr and SpyTag fused to the C-terminus of pIX. Figure 14A: Yield comparison of Ad5 vectors displaying SnoopTagJr or SpyTag fused to the C-terminus of pIX. Both vectors have GGS (EAAAK)₃ GS linker sequences between pIX and Tag. Yields of vectors in HEK293A cells with pIX-Catcher fusions are compared to Ad5(GFP) HVR5 DogTag, using equivalent volumes of cultured cells and the same vector harvest / purification protocols. Figure 14B: Reactivity of Ad5(GFP) pIX-SnoopTagJr with SnoopCatcher fused to SARS CoV2 RBD and reactivity of Ad5(GFP) pIX-SpyTag with SpyCatcher fused to SARS CoV2 RBD. Vectors (1E+10 viral particles) were incubated alone, or co-incubated with RBD-SnoopCatcher, SnoopCatcher-RBD, or RBD-SpyCatcher (all 3.5 μ M) for 16h at 4 °C. Samples were run on SDS-PAGE and western blotting performed using a polyclonal anti-RBD antibody. Species representing pIX-SnoopTagJr:SnoopCatcher-RBD (pIX-SnJr:SnC-RBD), pIX-SpyTag:SpyCatcher-RBD (pIX-ST:SC-RBD) and non-coupled SnoopCatcher-RBD / SpyCatcher-RBD (SnC/SC-RBD) are indicated and labelled (*). Figure 14C: Vector infectivity assay was performed using the same samples shown in Figure 14B. Bars show mean and range of duplicate samples.

Adenovirus

Adenoviruses (Ad) are a non-enveloped double stranded DNA virus with a genome of approximately 36 kilobases (kb). There are over 60 human adenovirus serotypes grouped into species A-G. Each group comprises of a number of adenoviral serotypes, for example, the subgroup species C includes Ad5 and Ad2. Ad5 is the most extensively studied serotype, and the most widely used platform for the development of oncolytic viruses. In the development of oncolytic viruses, it is desirable to be able to target particular tissues, and therefore the tropism may be altered. A major issue with using some adenovirus serotypes, including Ad5, in clinical settings is the pre-existing immunity in humans. Adenoviruses are typically 70-90 nm in size with an icosahedral capsid shape. The outer capsid structure, also known as 'capsid protein' comprises three major types of protein (hexon, fiber and penton base). There are additional minor proteins in the outer capsid including VI, VIII, IX, IIIa and IVa2. Hexon is the major component of the adenoviral capsid accounting for more than 83% of the capsid protein. Hexon modification has been shown to allow for circumvention of

pre-existing neutralising antibodies in some circumstances, including the swapping of HVR from different serotypes.

Adenovirus for modification

Adenovirus can be replication-defective: certain genes are deleted from the genome in order to ensure that when the adenovirus is used as a therapeutic, it is no longer capable of replication. This may result from the deletion of a set of genes from the genome, and is within the skills of those working with adenoviruses. This may be an advantage for use in vaccines, where the aim of the adenoviral vector is to present the antigen to the immune system in a format that makes it highly immunogenic, while limiting cytotoxicity. However, for other applications such as oncolytic viruses, being replication-competent is key. Replication-competent adenoviruses may still contain some modifications to prevent replication in normal cells, for example by deletion of a key gene. Oncolytic Ad vectors lyse cancer cells at the end of their life cycle and it is important that the progeny do not infect normal tissue. Cancer cells are generally more permissive for adenoviral replication, whilst normal cells require the adenovirus to have a full complement of genes to assist replication.

The adenovirus may be from any serotype or strain of adenovirus. Therefore, suitable adenoviruses for modification may come from those that infect mammals other than humans, in order to minimise prior exposure effects. The capsid structure is strongly conserved, and therefore the adenoviral serotypes and species may be interchangeable.

The adenovirus may be any modified adenovirus. Thus, the modified adenovirus may additionally encode antigens for example. These encoded antigens would then be expressed after infection. This provides the possibility of a multi-faceted prophylactic or therapeutic, such that an antigen can be displayed on the surface of the virus and another antigen expressed upon vector transduction using host cell machinery. Thus, the adenovirus may be genetically modified, such that, for example it includes a transgene. This transgene is designed for delivery to the host cell and may be a gene encoding an antigen, for example.

Adenovirus-mediated infectivity

Adenovirus infectivity in cells that express the Coxsackievirus and adenovirus receptor (CAR) is mediated via the fiber protein. An example of a cell line that expresses the CAR receptor is HEK293 cells. Fiber binds to the CAR receptor on the surface of cells and this mediates the initial attachment

of the virus. However, it was recently demonstrated that instead of a fiber-mediated entry of the adenovirus, Factor X (FX) - a coagulation factor present in human serum can bind to the hexon proteins of some adenovirus serotypes to facilitate the entry of the virus in some cell types. An example of a cell line that mediates infection via the hexon protein is SKOV3. It is believed that FX mediated infection via the adenovirus hexon can enhance liver tropism of adenovirus vectors *in vivo*. Modifications of the hexon protein such as insertion of DogTag and coupling to an antigen reduces hexon-mediated infectivity of the cells, as demonstrated in the Examples. This is a desirable effect as the natural tropism of adenovirus when injected intravenously can cause liver toxicity in patients at very high doses. Reduction of hexon-mediated infectivity to reduce liver toxicity would be advantageous to the present invention.

Hexon capsid protein

The hexon capsid protein is approximately 100 kDa in size, with 720 monomers per virion. Hexon monomers organise into trimers so that 12 lie on each of the 20 facets, resulting in 240 trimers per virion. Hexon sequences contain hypervariable regions (HVR) corresponding to loops on the external surface on the virus and therefore cover almost the entire surface of the virus. Each monomer has seven HVRs identified as HVR1-HVR7 which are serotype specific. As the loops are on the external surface of the virus, hexon loops are the main antigen recognition site, a target for host immune responses. Hexon protein varies in length, for example, Ad2 is the longest known hexon protein with a length of 968 amino acids (UniProt ID: P03277). Ad5, the most commonly used adenovirus for gene therapy has a length of 952 amino acids (UniProt ID: P04133). Modifying hexon HVRs which contain the serotype-specific epitope seems to be a promising approach to overcome the host neutralisation response. Any one of the HVRs could be modified. Exemplified herein, modifications were successfully made to HVR1, HVR2 and HVR5, surprisingly using DogTag. When the hexon protein was modified according to the invention and an antigen was attached via the peptide partner pair, neutralisation by anti-adenovirus neutralising antibodies was reduced.

pIX capsid protein

pIX protein is a minor capsid protein which is approximately 14.3 kDa in size. There are approximately 240 pIX monomers per virion. The pIX protein functions to stabilise the hexons on the viral surface. The C-terminus of the pIX protein is exposed on the surface of the virus and is therefore a desirable site for fusion of small and large peptides. Ad5 pIX has two domains connected by a flexible linker. The Ad5 pIX protein has a length of 196 amino acids (UniProt ID: Q2KS03).

Modifications to the capsid proteins

Modification to the capsid proteins can be genetic or non-genetic, including chemical. The capsid proteins can be genetically modified through the incorporation of antigens into the capsid. Alternatively, the viral particle surface may be directly modified. Modification of all three major capsid proteins has been demonstrated previously. However, the results from these modifications has been mixed, and there is a major obstacle in the size of the insert that the most promising approaches offer, particularly regarding modification of hexon.

“At least one modification” as used herein refers to the inclusion of a first peptide partner insertion into the viral capsid protein using any appropriate means. For example, the insertion of the first peptide partner into the adenoviral hexon loops or the fusion of a first peptide partner to the adenoviral pIX minor capsid protein. This modification may be made genetically through gene fusion, for example, or chemically.

Insertion

The first peptide partner may be directly inserted into the relevant capsid protein. As discussed herein, such an insertion is achieved by genetic manipulation. Alternatively, the first peptide partner can be inserted with a peptide sequence of any suitable length which separates the first peptide partner from the capsid protein. This peptide sequence may be described as a linker sequence, a spacer sequence, a structural sequence such as a helix, or even a hinge sequence. Linker or spacer sequences may simply separate the capsid protein and the first peptide partner and act as a “link” between the two entities. A structural sequence may provide a physical separation of the first peptide partner from the capsid protein. A hinge sequence may act as a linker between the capsid protein and the first peptide partner but permit a degree of motion to occur, such that the first peptide partner can move relative to the capsid protein. Various linkers, spacers and hinge sequences are exemplified herein, most notably those depicted in Figure 12.

Where the insertion is into a loop of sequence, the first peptide partner may be separated from the capsid protein on one or both sides, i.e. it may be flanked by sequences which are linkers, spacers, structures or hinges. Each flanking side may be the same or different.

Peptide partner pairs

Proteins that are capable of spontaneous isopeptide bond formation (so-called “isopeptide proteins”) have been advantageously used to develop peptide partner pairs (i.e. two-part linkers)

which covalently bind to each other and provide irreversible interactions (see e.g. WO2011/098772 and WO 2016/193746 both herein incorporated by reference, together with WO2018/189517 and WO2018/197854 both incorporated herein by reference). In this respect, proteins which are capable of spontaneous isopeptide bond formation may be expressed as separate fragments, to give a first peptide partner and a second peptide partner which is the peptide binding partner for the first peptide partner, where the two fragments are capable of covalently reconstituting by isopeptide bond formation. This covalent reconstitution links molecules or components fused to the second peptide partner and the requisite first peptide partner. The isopeptide bond formed by the peptide partner pair is stable under conditions where non-covalent interactions would rapidly dissociate, e.g. over long periods of time (e.g. weeks), at high temperature (to at least 95°C), at high force, or with harsh chemical treatment (e.g. pH 2-11, organic solvent, detergents or denaturants).

Isopeptide bonds are amide bonds formed between carboxyl/carboxamide and amino groups, where at least one of the carboxyl or amino groups is outside of the protein main-chain (the backbone of the protein). Such bonds are chemically irreversible under typical biological conditions and they are resistant to most proteases. As isopeptide bonds are covalent in nature, they result in some of the strongest measured protein-protein interactions.

In brief, a two-part linker, i.e. a peptide partner pair (a so-called peptide tag/binding partner or catcher pair) may be derived from a protein capable of spontaneously forming an isopeptide bond (an isopeptide protein), wherein the domains of the protein are expressed separately to produce a peptide "tag" that comprises one of the residues involved in the isopeptide bond (e.g. an aspartate or asparagine, or a lysine) and a peptide or peptide binding partner (or "catcher") that comprises the other residue involved in the isopeptide bond (e.g. a lysine, or an aspartate or asparagine) and at least one other residue required to form the isopeptide bond (e.g. a glutamate). Mixing the peptide tag and binding/catcher partner results in the spontaneous formation of an isopeptide bond between the tag and binding partner. Thus, by separately incorporating the peptide tag and binding partner into different molecules or components, e.g. proteins, it is possible to covalently link said molecules or components together via an isopeptide bond formed between the peptide tag and binding partner, i.e. to form a linker between the molecules or components incorporating the peptide tag and binding partner.

The spontaneous formation of the isopeptide bond may be in isolation, and not require the addition of any other entity. For some peptide tag and binding/catcher partner pairs, the presence

of a third or helper entity, such as a ligase, may be required in order to generate the isopeptide bond.

A peptide tag/binding partner pair (two-part linker), termed SpyTag/SpyCatcher, has been derived from the CnaB2 domain of the *Streptococcus pyogenes* FbaB protein (Zakeri et al., 2012, Proc Natl Acad Sci U S A 109, E690-697) and used in diverse applications including vaccine development (Brune et al., 2016, Scientific reports 6, 19234; Thrane et al., 2016, Journal of Nanobiotechnology 14, 30).

Variants, derivatives and modifications of the binding pairs may be made by any suitable means. Variants, derivatives and functionally operative modifications may involve amino acid additions, substitutions, alterations or deletions that retain the same function in relation to the ability to form an isopeptide bond with the relevant binding partner.

For some of the binding pairs, mediation by a third entity such as an enzyme is required. For example, SnoopLigase may be used to mediate the bond formation between SnoopTagJr/SnoopTag and DogTag. Thus, the pairing may require the assistance of an enzyme such as a ligase.

It will be understood that as used herein, either the first peptide partner or the second peptide partner may be the peptide "tag" and the other is the "binding partner/catcher".

Suitably, the first and second peptide partners form the peptide partner pair termed SpyTag/SpyCatcher. Suitably, the SpyCatcher component is DeltaN1 (Δ N1) SpyCatcher (as described in Li, L., Fierer, J. O., Rapoport, T. A. & Howarth, M. Structural analysis and optimization of the covalent association between SpyCatcher and a peptide Tag. *J. Mol. Biol.* **426**, 309–317 (2014)) which has a 23 amino acid truncation at the N-terminus compared to "SpyCatcher".

In other embodiments, the first and second peptide partners form a peptide partner pair which is a mutated version of SpyTag/SpyCatcher displaying an increased rate of reaction for isopeptide bond formation such as, for example, those described in co-pending application, GB1706430.4. In some embodiments, these mutated forms may be useful for the attachment of large proteins (e.g. >50 kDa or >100 kDa, such as the >160 kDa HCMV pentameric protein exemplified herein) and/or where slow reactions or steric hindrance may be an issue.

In other embodiments, the isopeptide proteins forming the peptide partner pair may include SnoopTag/SnoopCatcher, described, for example in WO 2016/193746.

In some embodiments, one or both of the isopeptide proteins forming the peptide partner pair may have N- or C-terminal truncations, whilst still retaining the reactivity of the isopeptide bond.

- 5 Exemplary first and second peptide partner pairs (peptide tag/binding partner pairs; reactive pairs) are described in the following table:

	Reactive pairs	
(a)	SpyTag	SpyCatcher
	SpyTag002	
	SpyTag002 RG T3H	
(b)	SpyTag	SpyCatcher002
	SpyTag002	
	SpyTag002 RG T3H	
(c)	SpyTag	SpyCatcher002 D5A A92P Q100D
	SpyTag002	
	SpyTag002 RG T3H	
(d)	SnoopTag	SnoopCatcher
	SnoopTagJr	
(e)	RrgATag	RrgACatcher – denoted here also as DogCatcher
	RrgATag2	
	DogTag	
(f)	Isopeptag	Pilin-C
(g)	Isopeptag-N	Pilin-N

(h)	PsCsTag	PsCsCatcher
(i)	SnoopTagJr SnoopTag	DogTag [mediated by SnoopLigase]

These entities are described, for example, in WO2011/098772, WO2016/193746, GB1706430.4 GB 1705750.6 or Li L., *et al.*, J. Mol. Biol. 426, 309–317 (2014).

5 Variants, derivatives and modifications of the binding pairs may be made by any suitable means. Variants, derivatives and functionally operative modifications may involve amino acid additions, substitutions, alterations or deletions that retain the same function in relation to the ability to form an isopeptide bond with the relevant binding partner.

10 For some of the binding pairs, mediation by a third entity such as an enzyme is required. For example, SnoopLigase may be used to mediate the bond formation between SnoopTagJr and DogTag. Thus, the pairing may require the assistance of an enzyme such as a ligase.

Antigen

15 An antigen as used herein refers to any molecule that is capable of inducing immune responses. An antigen can be a self-antigen, cancer antigen, allergenic antigen, tumour antigen, viral antigen, bacterial antigen, parasitic antigen or fungal antigen. A tumour antigen includes tumour-specific antigen, tumour-associated antigen and neoantigens, newly formed antigens by cancerous cells. "Tumour-specific antigen" refers to antigens that are only found on tumour cells. "Tumour-associated antigen" refers to antigens presented by both tumour and normal cells. "Neoantigen" refers to newly formed antigens by tumour cells. "Antigen" as used herein includes peptides and epitopes, variants and derivatives thereof.

25 Tumour-associated antigens include, but are not limited to adipophilin, AIM-2, ALDH1A1, alpha-actinin-4, alpha-fetoprotein ("AFP"), ARTC1, B-RAF, BAGE-1, BCLX (L), BCR-ABL fusion protein b3a2, beta-catenin, BING-4, CA-125, CALCA, carcinoembryonic antigen (CEA), CAGE 1 to 8, CASP-5, CASP-8, CD274, CD45, Cdc27, CDK12, CDK4, CDKN2A, CEA, CLPP, COA-1, CPSF, CSNK1A1, CTAG1, CTAG2, cyclin D1, Cyclin-A1, dek-can fusion protein, DKK1, EFTUD2, Elongation factor 2, ENAH

(hMena), Ep-CAM, EpCAM, EphA3, epithelial tumor antigen (ETA), ETV6-AML1 fusion protein, EZH2, ErbB receptors, E6, E7, FGF5, FLT3-ITD, FN1, G250/MN/CAIX, GAGE-1,2,8, GAGE-3,4,5,6,7, GAS7, glypican-3, GnTV, gp100/Pmel 17, GPNMB, HAUS3, Hepsin, HER-2/neu, HERV-K-MEL, HLA-A11, HLA-A2, HLA-DOB, hsp70-2, , HPV E2, HPV E6, HPV E7 antigen, IDO1, IGF2B3, IL13Ralpha2, Intestinal

5 carboxyl esterase, K-ras, Kallikrein 4, KIF20A, KK-LC-1, KKLC1, KM-HN-1, KMHN1 also known as CCDC110, LAGE-1, LDLR-fucosyltransferase fusion protein, Lengsin, M-CSF, MAGE-A1, MAGE- A 10, MAGE-A12, MAGE-A2, MAGE- A3, MAGE-A4, MAGE-A6, MAGE-A9, MAGE-C1, MAGE-C2, malic enzyme, mammaglobin-A, MART2, MATN, MC1R, MCSP, mdm-2, ME1, Melan- A/MART- 1 , Meloe, Midkine, MMP-2, MMP-7, MUC1, MUC5AC, mucin, MUM-1, MUM-2, MUM-3, Myosin, Myosin class

10 I, N-ras, NA88-A, neo-PAP, NFYC, NY-BR-1, NY-ESO-1/LAGE-2, OA1, OGT, OS-9, P polypeptide, p53, PAP, PAX5, PBF, pml-RARalpha fusion protein, polymorphic epithelial mucin (PEM), PPP1R3B, PRAME, PRDX5, PSA, PSMA, PTPRK, RAB 38/N Y-MEL- 1 , RAGE-1, RBAF600, RGS5, RhoC, R F43, RU2AS, SAGE, secernin 1, SIRT2, SNRPD1, SOX10, Spl7, SPA17, SSX-2, SSX-4, STEAP1, survivin, SYT-SSX1 or -SSX2 fusion protein, TAG-1, TAG-2, Telomerase, TGF-betaRII, TPBG, TRAG-3,

15 Triosephosphate isomerase, TRP-I/gp75, TRP-2, TRP2-INT2, tyrosinase (TYR), VEGF, WT1, XAGE-Ib/GAGED2a,

Those skilled in the art of identifying tumour-associated antigens will appreciate that new antigens, including neoantigens, are continually identified, and as such this list is not exhaustive.

Viral antigens include, but are not limited to antigens of the following viruses or class of

20 viruses; Human Papilloma Viruses (HPV), Human Immunodeficiency virus (HIV), Herpes Simplex Virus (HSV2/HSV1), Influenza virus (types A, B and C), Polio virus, Respiratory Syncytial Virus (RSV), Rhinoviruses, Rotaviruses, Hepatitis A virus, Norwalk Virus Group, Enteroviruses, Astroviruses, Measles virus, Parainfluenza virus, Mumps virus, Varicella-Zoster virus, Human Cytomegalovirus (HCMV), Epstein-Barr virus, Adenoviruses, Rubella virus, Human T-cell Lymphoma type I virus (HTLV-

25 I), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Hepatitis D virus, Poxviruses, Marburg virus and Ebola virus, SARS-CoV-2

Bacterial antigens include, but are not limited to antigens of the following bacteria: *Mycobacterium tuberculosis*, *Chlamydia*, *Neisseria gonorrhoeae*, *Shigella*, *Salmonella*, *Vibrio cholerae*, *Treponema*

30 *pallidum*, *Pseudomonas*, *Bordetella pertussis*, *Brucella*, *Francisella tularensis*, *Helicobacter pylori*, *Leptospira interrogans*, *Legionella pneumophila*, *Yersinia pestis*, *Streptococcus* (types A and B),

Pneumococcus, Meningococcus, Haemophilus influenzae (type b), Toxoplasma gondii, Campylobacter, Moraxella catarrhalis, Klebsiella granulomatis and Actinomyces.

Fungal antigens include, but are not limited to antigens of the following fungal pathogens:

- 5 Candida and Aspergillus, Cryptococcus, Histoplasma and Pneumocystis.

Parasitic antigens include, but are not limited to antigens of the following parasitic pathogens: Taenia, Flukes, Roundworms, Plasmodium, Amoeba, Giardia, Cryptosporidium, Schistosoma, Trichomonas, Trypanosoma and Trichinella.

10

In order to enhance expression of the antigen-second peptide partner prior to coupling, a leader sequence may be used. Those skilled in the art are aware of appropriate leader sequences to enhance expression. Such are exemplified herein.

15 **Pharmaceutical composition and use**

The compositions of the invention may be incorporated into a vaccine or therapeutic composition. Suitably, a vaccine or immunogenic composition will comprise particles of the invention in an immunogenic dose.

- 20 A pharmaceutical composition may comprise a particle or composition in accordance with the invention provided with a pharmaceutically acceptable carrier. Suitable carriers are well known to those skilled in the art. In one embodiment a pharmaceutical composition comprises a buffer, excipient or carrier. Suitably a pharmaceutical composition may comprise suitable excipients and formulations to maintain stability of the composition. Suitably the formulation may comprise an adjuvant. In one embodiment, the formulation may comprise AddaVax™ or a similar squalene-based
- 25 oil-in-water nano-emulsion with a formulation similar to MF59®. Other suitable adjuvants include liposome-based adjuvants such as Matrix M and AS01. Other suitable adjuvants include aluminium-based formulations such as Alhydrogel®. In one embodiment the formulation may comprise EDTA, for example at a concentration of 5 mM. Suitable excipients or formulations may depend on the properties of the particle or immunogenic composition; for example, the choice of expression
- 30 system may affect the stability, glycosylation or folding of the proteins of the composition, which may in turn affect the optimal formulation of the composition. Methods of determination of a suitable excipient, formulation or adjuvant will be known to those skilled in the art.

Vaccine

A vaccine is a preparation that comprises a fragment or entire entity against which it is possible to raise an immune response. It is an entity such as a protein, peptide, lipoprotein, glycoprotein or fragments thereof that are capable of inducing an immune response. For example, the vaccine may comprise micro-organisms or a part thereof capable of inducing an immune response against said micro-organism. A vaccine comprising an immunogenic adenoviral vector in accordance with the invention can be used against any pathogen for which the antigen displayed is crucial for the induction of an immune response. Further, the vaccine may comprise an immunogenic adenoviral vector in accordance with the invention displaying tumour related antigens. These tumour-related antigens may be modified self-proteins and the like. The vaccine may therefore raise an immune response to the tumour cells.

Such vaccine compositions (or other immunogenic) are formulated in a suitable delivery vehicle. Generally, doses for the immunogenic compositions are within the ranges defined for therapeutic compositions. Optionally, a vaccine composition of the invention may be formulated to contain other components, including, for example, adjuvants, stabilizers, pH adjusters, preservatives and the like. Such components are well known to those skilled in the art of vaccines. Examples of suitable adjuvants include, without limitation, liposomes, alum, monophosphoryl lipid A, and any biologically active factor, such as a cytokine, an interleukin, a chemokine and optimally combinations thereof.

The present invention can be administered intravenously, intradermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrapleurally, intratracheally, intranasally, intravitreally, intravaginally, rectally, topically, intratumorally, intramuscularly, intraperitoneally, subcutaneously, intravesicularly, mucosally, intrapericardially, orally, locally and/or using aerosol, injection, infusion, continuous infusion, localized perfusion bathing target cells directly or via a catheter and/or lavage.

Vaccines for the treatment or prevention of a disease as used herein includes but is not limited to urogenital cancers (such as prostate cancer, renal cell cancers, bladder cancers), gynaecological cancers (such as ovarian cancers, cervical cancers, endometrial cancers), lung cancer, gastrointestinal cancers (such as non-metastatic or metastatic colorectal cancers, pancreatic cancer, gastric cancer, oesophageal cancers, hepatocellular cancers, cholangiocellular cancers), head and neck cancer (e.g. head and neck squamous cell cancer), malignant glioblastoma, malignant

mesothelioma, non-metastatic or metastatic breast cancer (e.g. hormone refractory metastatic breast cancer), malignant melanoma, Merkel Cell Carcinoma or bone and soft tissue sarcomas, and haematologic neoplasias, such as multiple myeloma, acute myelogenous leukaemia, chronic myelogenous leukaemia, myelodysplastic syndrome and acute lymphoblastic leukaemia. In a preferred embodiment, the disease is non-small cell lung cancer (NSCLC), breast cancer (e.g. hormone refractory metastatic breast cancer), head and neck cancer (e.g. head and neck squamous cell cancer), hormone sensitive or hormone refractory prostate cancer, colorectal cancer, ovarian cancer, hepatocellular cancer, renal cell cancer, soft tissue sarcoma, or small cell lung cancer.

The vaccine may be used to treat or prevent infection with any one of the disease-causing pathogens hereinbefore described.

Ad-DogTag

The "Ad-DogTag" viral vector comprises the insertion of DogTag into surface loops of the hexon capsid protein enabling display of up to ~720 ligands/virion. Coupling of an antigen to hexon-DogTag has been achieved by the present inventors using SnoopTagJr -tagged antigens (using SnoopLigase as a catalyst) or directly via DogCatcher linked antigens. Previous technologies have only been capable of inserting small immunogenic T cell or B cell epitopes with a length of <100 amino acids into adenovirus hexon loops. The present invention demonstrates the coupling of peptides of 10-60 kDa to hexon, which has not previously been possible to achieve. This represents a big step forwards in the development of vaccines based upon adenovirus in particular.

Ad-SpyCatcher

The "Ad-SpyCatcher" viral vector comprises the fusion of SpyCatcher onto the C-terminus of adenovirus minor capsid protein pIX. The recent invention was successful in modifying the pIX minor capsid protein without loss of viral infectivity.

Ad-SnoopCatcher

The "Ad-SnoopCatcher" viral vector comprises the fusion of SnoopCatcher onto the C-terminus of adenovirus minor capsid protein pIX. The work here shows success in modifying the pIX minor capsid protein without loss of viral infectivity.

Ad-DogCatcher

The “Ad-DogCatcher” viral vector comprises the fusion of DogCatcher onto the C-terminus of adenovirus minor capsid protein pIX. The work here shows success in modifying the pIX minor capsid protein without loss of viral infectivity.

Ad-SnoopTagJr

- 5 The “Ad- SnoopTagJr” viral vector comprises the fusion of SnoopTagJr onto the C-terminus of adenovirus minor capsid protein pIX. The work here shows success in modifying the pIX minor capsid protein without loss of viral infectivity.

Ad-SpyTag

- 10 The “Ad- SpyTag” viral vector comprises the fusion of SpyTag onto the C-terminus of adenovirus minor capsid protein pIX. The work here shows success in modifying the pIX minor capsid protein without loss of viral infectivity.

All references mentioned herein are incorporated by reference where permitted.

Examples

- 15 Certain aspects and embodiments of the invention will now be illustrated by way of example and with reference to the figures described above.

Examples – Materials and Methods:

Generating a bacterial artificial chromosome (BAC)-derived replication-defective molecular clone of Ad5 expressing GFP

- 20 Plasmid pAd-PL-DEST, an E1/E3-deleted (and therefore replication-defective) molecular clone of Ad5, was obtained from Invitrogen. An expression construct, consisting of an immediate early cytomegalovirus promoter (CMVp) driving expression of enhanced green fluorescent protein (EGFP), was cloned into shuttle vector pENTR4 (Invitrogen). The CMVp EGFP expression construct was then inserted into the Ad5 E1 locus using Invitrogen Gateway site-specific recombination (LR
25 clonase) technology. BAC sequences from pBELOBAC11 (NEB) were amplified using forward (5'-TTAATTAAcgtcgaccaattctcatg) and reverse (5'-TTAATTAAgtcgacgacgacacttg) primers to introduce *PacI* sites at either end of the BAC cassette. The entire Ad5(GFP) genome sequence was subsequently cloned into the BAC with *PacI*, to generate pBAC-Ad5(GFP).

Genetic modification of pBAC-Ad5(GFP) to insert protein superglue technology into viral capsid proteins using BAC *Galk* recombineering

SW102, an *E. coli* strain required for *Galk* recombineering, was obtained from the National Cancer Institute, National Institutes of Health, USA. Modified from DH10B, SW102 cells contain λ -Red-
5 encoded recombination genes (*exo*, *bet*, *gam*) under the control of a temperature-sensitive repressor with a deleted galactokinase (*Galk*) gene (which is necessary for bacterial growth using galactose as the sole carbon source). The *Galk* recombineering system enables the *Galk* gene to be used for both positive and negative selection, and *Galk* recombineering was performed exactly as described in Warming *et al*, 2005 [Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG.
10 Simple and highly efficient BAC recombineering using *galk* selection. Nucleic Acids Res. 2005;33(4):e36]. Insertion sites were created in hexon HVR loops (as described in Figure 1E) or at the C-terminus of pIX by insertion of the *Galk* gene at these specific loci by recombineering followed by positive selection for the presence of *Galk*. Insertion of SpyTag / DogTag / SnoopTagJr / SpyCatcher / SnoopCatcher / DogCatcher sequences was performed by recombineering to replace *Galk*, and
15 subsequent selection against the presence of the *Galk* gene using 2-deoxygalactose.

Rescue of recombinant adenoviruses incorporating protein superglue technology

BAC DNA from recombinant adenovirus molecular clones was linearised with *PacI* to release left and right viral inverted terminal repeats (ITRs). Linearised DNA was transfected into E1-complementing Human Embryonic Kidney (HEK) 293A cells (Invitrogen) in 25 cm² flasks (T25) using Lipofectamine
20 2000 reagent (Invitrogen). After cytopathic effect (CPE) was observed, the cells were harvested, subjected to three cycles of freeze-thaw, and the virus amplified further in HEK293A cells. Upon infection of 10 × 150cm² flasks (T150), virus was harvested from infected cells after 48 hours and purified by CsCl gradient ultracentrifugation according to standard protocols. Purified virus was dialysed against sucrose storage buffer (10 mM Tris-HCl, 7.5% w/v sucrose, pH 7.8) and stored at
25 -80°C.

Estimation of viral particle count for purified viral vector preparations

The number of adenovirus particles in a purified preparation can be estimated by measuring viral DNA content by spectrophotometric absorption at 260 nm as described by Maizel *et al*, 1968. [J. Maizel, D. White, M. Scharff, The polypeptides of adenovirus: I. Evidence for multiple protein
30 components in the virion and a comparison of types 2, 7A, and 12. Virology, Volume 36, Issue 1, September 1968, Pages 115-125]. Briefly, samples were diluted 1:10 in virus storage buffer

containing 1% w/v sodium dodecyl sulphate (SDS) to release viral DNA from capsids and absorbance at 260 nm was measured using a spectrophotometer. An absorbance of 1.00 (AU, 1 cm path length) at 260 nm corresponds to 1.1×10^{12} viral particles/mL.

Infectious titration of recombinant adenoviruses in HEK293A cells

- 5 Infectious titre of vector preparations was assessed by single cell infectivity assay on HEK293A cells. For vectors expressing EGFP, infected HEK293 cells were visualised and enumerated directly by fluorescent microscopy. An alternative assay for vectors without a fluorescent marker, by immunostaining for expression of the hexon capsid protein, was also tested (Figure 5). Tenfold serial dilutions of virus in complete media (Dulbecco's Modified Eagles Medium, plus 1× GlutaMAX and
- 10 10% v/v foetal bovine serum) were performed in sterile 96-well deep well plates. Two or three serial dilutions were performed per virus, and 50 µL of each dilution (10^3 to 10^{10} dilution) was added per well of a 96-well plate containing adherent HEK293 cells at 80-90% confluency. For hexon immunostaining, 96-well plates pre coated with poly-L-Lysine were used to improve cell adhesion to the plate surface. Plates were incubated for 48 hours at 37°C, 5% CO₂. For titration of EGFP-
- 15 expressing vectors, 48 hours post infection, single GFP-positive cells were enumerated by fluorescence microscopy, and an infectious titre was calculated in infectious units (ifu) per mL. For hexon immunostaining, media was aspirated from the cell monolayer and cells were fixed with ice-cold methanol. Plates were then washed three times in Dulbecco's phosphate buffered saline (PBS 1X, Gibco) before blocking for an hour with 3% w/v low-fat milk (Marvel). Detecting mouse
- 20 monoclonal anti-hexon antibody (B025/AD51, Thermo-Fisher) was added at 1:1000 dilution in 1% w/v milk in PBS and incubated for an hour at 25°C. After incubation of the primary antibody, cells were washed a further three times with 1% w/v milk in PBS prior to addition of a secondary goat anti-mouse alkaline phosphatase (ALP) conjugated antibody (STAR117A, BioRad) at 1:1000 dilution in 1% w/v milk in PBS. After a further hour incubation, plates were washed five times in PBS prior to
- 25 development. To develop, 100 µL of freshly prepared SIGMAfast BCIP/NBT solution (Sigma) was added to each well and plates incubated at 25°C until the appearance of dark stained foci, representing single infected cells. P:I ratios for CsCl-purified vector preparations were calculated by dividing the estimated no. of viral particles per mL with the no. of infectious units (ifu) per mL.

Assessment of coagulation Factor X-mediated vector transduction of SKOV3 cells

- 30 SKOV3 cells (human ovary adenocarcinoma) were obtained from Public Health England and cultured in McCoy's 5a media with 2 mM Glutamine and 15% v/v foetal bovine serum (complete McCoy's

media). For the assay, GFP-expressing vectors were serially diluted (1:10 to 1:10⁷) in serum free media. Human coagulation Factor X (FX) was added to diluted vectors at a final concentration of 8 µg/mL (control samples without addition of FX were included). Vector-FX mixtures were added to monolayers of SKOV3 cells (80-90% confluent) in 96-well plates, and incubated with cells for 2h at 37°C and 5% CO₂. After 2h, vector-FX mixtures were replaced with complete McCoy's media, and plates incubated at 37°C, 5%CO₂ for a further 48h. Infectivity was assessed after 48h by enumeration of GFP-positive foci as described above.

Production of protein and peptide ligands

SpyTag- and SnoopTagJr-fused peptide ligands were produced using solid-phase synthesis techniques by Insight Biotechnology at >95% purity. Peptides were quality control tested by HPLC and mass spectrometry.

DNA constructs for expression of polyhistidine-tagged recombinant DogCatcher-NANP fusion proteins were cloned into expression plasmid pET45(+) (EMD Millipore) for protein production in BL21(DE3) *E. coli*. (NEB). DNA sequences for DogCatcher and *Plasmodium falciparum* circumsporozoite protein (PfCSP) from the 3D7 strain of malaria were synthesised separately (GeneArt, Thermo Fisher), DNA fragments required for individual constructs amplified by PCR, and assembled in pET45(+) by restriction cloning. Recombinant proteins were purified using affinity Ni-NTA resin (Qiagen) according to a previously published protocol [SnoopLigase Catalyzes Peptide-Peptide Locking and Enables Solid-Phase Conjugate Isolation. Buldun CM, Jean JX, Bedford MR, Howarth M. J Am Chem Soc. 2018 Feb 28;140(8):3008-3018. doi: 10.1021/jacs.7b13237], dialysed into PBS, and stored at -80°C.

SpyCatcher (GenBank: AFD50637.1) and SpyTag-MBP (Addgene Plasmid #35050) were expressed in *E. coli* and purified by Ni-NTA exactly as described (Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Zakeri B, Fierer JO, Celik E, Chittock EC, Schwarz-Linek U, Moy VT, Howarth M. Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):E690-7. doi: 10.1073/pnas.1115485109).

Monovalent streptavidin (mSA) was expressed in *E. coli*, refolded from exclusion bodies and purified by ion-exchange chromatography exactly as described (Plug-and-play pairing via defined divalent streptavidins. Fairhead M, Krndija D, Lowe ED, Howarth M. J Mol Biol. 2014 Jan 9;426(1):199-214. doi: 10.1016/j.jmb.2013.09.016.).

SnoopLigase (GenBank: AVD97783.1), SnoopTagJr-AffiHER2, and SUMO-DogTag (GenBank:MG867376) were expressed in *E. coli* and purified by Ni-NTA exactly as described (SnoopLigase Catalyzes Peptide-Peptide Locking and Enables Solid-Phase Conjugate Isolation. Buldun CM, Jean JX, Bedford MR, Howarth M. J Am Chem Soc. 2018 Feb 28;140(8):3008-3018. doi: 10.1021/jacs.7b13237).

DogCatcher (previously termed RrgACatcher in the patent "Methods and products for fusion protein synthesis" Howarth M, Veggiani G, Gayet R. 2015, United Kingdom Patent application WO2016193746A1) was expressed in *E. coli* and purified by Ni-NTA following standard protocols (Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Zakeri B, Fierer JO, Celik E, Chittock EC, Schwarz-Linek U, Moy VT, Howarth M. Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):E690-7. doi: 10.1073/pnas.1115485109).

HCMV pentamer (with SpyTag-gH) is described in patent application PCT/GB2019/051245. Protein was expressed in suspension 293F cells by transient transfection using five separate plasmids (sequences provided). Protein was harvested, concentrated by tangential flow filtration, affinity purified by C-tag affinity resin (Thermo Fisher), and further purified by size exclusion chromatography on a Superdex 200 column (GE) using an AKTA chromatography system (GE).

DNA constructs for expression of SARS CoV2 Spike and RBD fusion proteins were cloned into mammalian protein expression plasmid pcDNA3.4. DNA sequences for SARS CoV2 Spike and RBD were synthesised separately (GeneArt, Thermo Fisher), and assembled in frame with SnoopTagJr, SpyCatcher, or SnoopCatcher by PCR amplification and restriction cloning. To facilitate secretion of RBD fusion constructs, a leader sequence was introduced at the N-terminus (for RBD-SnoopTagJr, RBD-SpyCatcher and RBD-SnoopCatcher the leader sequence from SARS CoV2 spike MFVFLVLLPLVSSQC was used, for SnoopCatcher-RBD the IgK leader sequence METDTLLLWVLLLWVPGSTGD was used). Spike-SnoopTagJr and RBD-SnoopTagJr proteins were expressed in suspension Expi293F cells, and SnoopCatcher-RBD, RBD-SnoopCatcher and RBD-SpyCatcher proteins were expressed in suspension ExpiCHO-S cells. Protein was harvested from culture supernatant, affinity purified using C-tag affinity resin (Thermo Fisher) using an AKTA chromatography system (GE), and dialysed into tris-buffered saline (TBS) pH 7.4.

Coupling reactions

For *in vitro* assays, coupling reactions between SpyCatcher and SpyTag, DogCatcher and DogTag, SnoopCatcher and SnoopTagJr, and SnoopTagJr and DogTag (catalysed by SnoopLigase) partners

were performed by co-incubation of spontaneously reacting components in a total volume of 20-25 μ L, with individual components at concentrations described in the figure legends. Reactions between Ad5-HVR-DogTag and DogCatcher (including DogCatcher fusions), between Ad5-HVR-SpyTag or Ad5-pIX-SpyTag and SpyCatcher (including SpyCatcher fusions), between Ad5-pIX-SpyCatcher and SpyTag (including SpyTag fusions), between Ad5-pIX-SnoopCatcher and SnoopTagJr (including SnoopTagJr fusions), between Ad5-pIX-DogCatcher and DogTag (including DogTag fusions) and between Ad5-pIX-SnoopTagJr and SnoopCatcher (including SnoopCatcher fusions) were incubated for 16 h at 4°C. Reactions between Ad5-HVR-DogTag and SnoopTagJr (including SnoopTagJr fusions) catalysed by SnoopLigase were incubated for 48 h at 4°C. SnoopLigase catalysed reactions were performed in buffers containing a final concentration of 15% v/v glycerol and minimal salt to increase the efficiency of coupling.

Peptide-decorated vector batches for immunisation studies were prepared by co-incubating 5×10^{11} viral particles of Ad5(GFP)-HVR5-DogTag with 35 μ M SnoopTagJr-GGSSIINFEKL, 30 μ M SnoopLigase, and 15% v/v glycerol in a total volume of 400 μ L for 48 hours at 4°C. To remove excess peptide and SnoopLigase (Figure 10A, Group 1) coupled vectors were dialysed into sucrose storage buffer using SpectraPor dialysis cassettes (100 kDa MWCO). No excess peptide was detectable post-dialysis on a coomassie-stained SDS-PAGE gel. Peptide-decorated vectors were stored at -80°C, endotoxin tested, and infectious titration of stored batches was repeated prior to immunisation.

Assessment of coupling efficiency by SDS-PAGE

Coupling reactions were performed as described above and stopped by addition of SDS loading buffer (BioRad, 31.5 mM Tris-HCl, pH 6.8, 10% glycerol, 1% SDS, 0.005% Bromophenol Blue, 300mM DTT). Samples were boiled at 95°C for 5 min and loaded on SDS-PAGE (NuPAGE 4-12% Bis-Tris, Invitrogen) gels. For direct gel shift assays to assess coupling of ligands to Ad5-HVR-DogTag or Ad5-HVR-SpyTag, proteins were resolved by SDS-PAGE (200V, 40-55 min) and visualized by Coomassie staining [16 h staining with Quick Coomassie (Generon), destained with water]. Coupling efficiency was assessed by comparing band intensities of uncoupled hexon-DogTag/hexon-SpyTag with hexon-DogTag:DogCatcher/hexon-SpyTag:SpyCatcher using Image J (For hexon-SpyTag:SpyCatcher coupling efficiency, % hexon coupled = band intensity of hexon-SpyTag:SpyCatcher divided by the sum of band intensities of hexon-SpyTag:SpyCatcher and uncoupled hexon-SpyTag, multiplied by 100).

For assessment of coupling of Ad5-HVR-DogTag to SnoopTagJr fused peptides, a competition assay using DogCatcher (DC) protein was performed due to the fact that coupling of low molecular weight

peptides could not be accurately assessed using the direct gel shift assay. After coupling, an excess of DogCatcher protein (30 μ M) was added to the reaction and samples incubated at 4°C for a further 24 hours. Since DC binds ~100% of free (uncoupled) hexon-DogTag molecules on the surface of Ad5 (see Figure 3B) the proportion of hexon-DogTag coupled to SnoopTagJr-peptide can be estimated to be the proportion of hexon that *does not* undergo a gel shift of ~20 kDa (molecular weight of DogCatcher) on Coomassie-stained SDS-PAGE after incubation with DogCatcher.

An alternative assay to the DogCatcher competition assay, enabling assessment of SnoopTagJr-peptide coupling to hexon-DogTag by direct gel shift, exploited the high affinity biotin:streptavidin interaction (stable in room temperature SDS loading buffer). Biotinylated SnoopTagJr-peptide was incubated with SnoopLigase and Ad5-HVR-DogTag as described previously. After 48 hours, the coupling reaction was stopped by boiling in SDS loading buffer to denature all proteins and virion structures. Samples were briefly cooled on ice, before incubation with an excess of monovalent streptavidin (mSA, 2-fold excess over biotin peptide) for 30 min at 25°C. Samples were run on SDS-PAGE, transferred to nitrocellulose, and Western blotting performed using an anti-hexon primary mouse monoclonal antibody (clone 65H6, ThermoFisher). Migration of the hexon protein was visualised using a goat anti-mouse-alkaline phosphatase secondary (1:1000 dilution) followed by BCIP/NBT substrate for development (Sigma). A gel-shift (~50 kDa) was observed for hexon-DogTag protein coupled to SnoopTagJr-biotin by virtue of the interaction between mSA and biotin.

For assessment of coupling of protein ligands to Ad5-pIX-SpyCatcher, Ad5-pIX-SnoopCatcher, Ad5-pIX-DogCatcher, Ad5-pIX-SpyTag or Ad5-pIX-SnoopTagJr, samples were run on SDS-PAGE and then transferred to nitrocellulose for Western blotting. Protein species covalently coupled to pIX-fusions were detected using primary antibodies or mouse antisera and alkaline-phosphatase conjugated secondary antibodies as described in figure legends. Western blots were developed as described above.

Antibody neutralisation assay

For assessment of vector neutralisation by potent neutralising mouse monoclonal antibody (mAb) 9C12 (Developmental Studies Hybridoma Bank, University of Iowa), Ad5(GFP) vectors were incubated with serially diluted mAb 9C12 antibody at a 1:1 ratio in complete media for 1 hour at 37°C. The vector-antibody mix was then added to an 80% confluent monolayer of HEK293A cells in a 96-well plate format (cells were infected at a multiplicity of infection of 200 ifu/cell). Cells were incubated with the vector-antibody mix for 2 hours at 37°C 5% CO₂, before the mix was replaced

with fresh media and the plates returned to 37°C 5% CO₂ for a further 24 h. After 24 h, GFP expression within HEK293A cells was used as a readout of vector infectivity; bulk fluorescence was measured on a fluorimeter (Tecan) using an excitation wavelength of 395 nm and emission wavelength of 509 nm.

- 5 For assessment of vector neutralisation by Ad5-positive serum, serum samples were obtained by immunising mice with 1E+8 ifu of an Ad5 vector expressing ovalbumin (vector had an unmodified hexon). Serum was harvested two-weeks post immunization, stored at -80°C, and then serially diluted for the neutralisation assay (two-fold dilutions were prepared from 1:8 to 1:1024 in complete media, to give a final range of 1:16 to 1:2048 on cell monolayers). Diluted serum was
- 10 incubated with Ad5(GFP) vectors, the mix incubated on HEK293 cells and bulk GFP fluorescence read 24 h later exactly as described above.

Mouse immunisations

- All mouse procedures were performed in accordance with the terms of the UK Animals (Scientific Procedures) Act Project Licence (PA7D20B85) and approved by the Oxford University Ethical Review
- 15 Body. Female C57BL/6 mice (6 weeks of age, Charles River), housed in specific-pathogen free environments, were immunised intramuscularly by injection of 50 µL of vaccine formulated in endotoxin-free PBS (Gibco) into both hind limbs of each animal (100 µL total). Adenoviral vectors were administered at a dose of 5E+9 viral particles, peptides administered at a dose of 5 µg, and poly I:C (InvivoGen) administered at a dose of 10 µg. Endotoxin dose was <1 EU per mouse.
- 20 Experiments were performed at Biomedical Services, University of Oxford, and completed two-weeks post-immunisation.

Ex-vivo IFN-gamma ELISPOT

- Spleen *ex vivo* interferon-gamma (IFN-γ) ELISpot was performed according to standard protocols as described previously [Larsen KC, Spencer AJ, Goodman AL, Gilchrist A, Furze J, Rollier CS, Kiss-Toth E,
- 25 Gilbert SC, Bregu M, Soilleux EJ, Hill AV, Wyllie DH, Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines. Vaccine. 2009 Sep 18;27(41):5589-98]. To measure antigen specific responses, cells were re-stimulated for 18–20 hours with peptides at a final concentration of 5 µg/mL. To measure SIINFEKL-specific responses, SIINFEKL peptide (Cambridge Bioscience) was used. For GFP-specific responses, EGFP peptide DTLVNRIEL (EGFP_{118–126})
- 30 (synthesised by Insight Biotechnology) was used. Spot forming cells (SFC) were measured using an automated ELISpot reader system (AID).

Modified adenovirus sequences:**Ad5-HVR-SpyTag sequences****Ad5-HVR1-SpyTag Hexon sequence**5 **Amino acid (SEQ ID NO: 1):**

MATPSMMPQWSYMHISGQDASEYLSPLVQFARATETYFSLNNKFRNPTVAPTHDVTDRSQRLTLRFIPVDREDTAYSYKA
 RFTLAVGDNRLVDMASTYFDIRGVLDRGPTFKPYSGTAYNALAPKGAPNPCEWDEAGSGGSGAHIVMVDAYKPTKSGGSG
 THVFGQAPYSGINITKEGIQIGVEGQTPKYADKTFQPEPQIGESQWYETEINHAAGRVLKKTPMKPCYGSYAKPTNENGGQGI
 LVKQQNGKLESQVEMQFFSTTEATAGNGDNLTPKVLYSEDVDIETPDTHISYMPITKEGNSRELMGQQSMPNRPNYIAFRD
 10 NFIGLMYYNSTGNMGVLAGQASQLNAVVDLQDRNTELSYQLLLDSIGDRTRYFSMWNQAVDSYDPDVRIENHGTEDLPNY
 CFPLGGVINTETLTQVVKPTGQENGWEKDATEFSDKNEIRVGNNFAMEINLNANLWRNFLYSNIALYLPDKLYSPSNVKISDN
 PNTYDYMNRKRVVAPGLVDCYINLGARWSLDYMDNVNPFNHHRNAGLRYSMLLGNGRYVPFHIQVPQKFFAIKNLLLPGSY
 TYEWNFRKDVNMVLQSSLGNDLRVDGASIKFDSICLYATFFPMAHNTASTLEAMLRNDTNDQSFNDYLSAANMLYPIPANAT
 NVPISSIPSRNWAAFRGWAFRLKTKETPSLGSYDPPYYTSGSIPYLDGTFYLNHTFKKVAITFDSSVSWPGNDRLLTPNEFEIKR
 15 SVDGEGYNVAQCNMTKDWFLVQMLANYNIGYQGFYIPESYKDRMYSFFRNFPMSRQVVDTKYKDYQQVGILHQHNNS
 GFVGYLAPTMREGQAYPANFPYPLIGKTAVDISITQKKFLCDRTLWRIPFSSNFMSMGALDGLQNLLYANSAHALDMTFEVD
 MDEPTLLYVLFVFDVVRVHRPHRGVIETVYLRTPFSAAGNATT

DNA (incl. STOP) (SEQ ID NO: 2):

ATGGCTACCCCTTCGATGATGCCGAGTGGTCTTACATGCACATCTCGGGCCAGGACGCCTCGGAGTACCTGAGCCCCGG
 20 GCTGGTGCAGTTTGCCCGGCCACCGAGACGTACTTCAGCCTGAATAACAAGTTAGAAACCCACGGTGGCGCCTACGC
 ACGACGTGACCACAGACCGGTCCCAGCGTTTGACGCTGCGGTTTCATCCTGTGGACCGTGAGGATACTGCGTACTCGTAC
 AAGGCGCGGTTACCCCTAGCTGTGGGTGATAACCGTGTGCTGGACATGGCTTCCACGTACTTTGACATCCGCGCGGTGCT
 GGACAGGGGCCCTACTTTTAAGCCCTACTCTGGCACTGCCTACAACGCCCTGGCTCCCAAGGGTGCCCCAAATCCTTGCGA
 ATGGGATGAAGCTGGCAGCGGAGGATCCGGCGCCCATATCGTGATGGTGGACGCCTACAAGCCTACCAAGGCTCTGGC
 25 GGAAGCGGCACTACGTATTTGGGCAGGCGCCTTATTCTGGTATAAATATTACAAAGGAGGGTATTCAAATAGGTGTCTGA
 AGGTCAAACACCTAAATATGCCGATAAAACATTTCAACCTGAACCTCAAATAGGAGAATCTCAGTGGTACGAACTGAAA
 TTAATCATGCAGCTGGGAGAGTCCTTAAAAAGACTACCCCAATGAAACCATGTTACGGTTCATATGCAAAACCCACAAATG
 AAAATGGAGGGCAAGGCATTCTGTAAAGCAACAAAATGGAAAGCTAGAAAGTCAAGTGGAATGCAATTTTCTCAACT
 ACTGAGGCGACCGCAGGCAATGGTGATAACTTGACTCCTAAAGTGGTATTGTACAGTGAAGATGTAGATATAGAAACCCC
 30 AGACACTCATATTTCTTACATGCCCACTATTAAGGAAGTAACCTACGAGAACTAATGGGCCAACAATCTATGCCCAACAG
 GCCTAATTACATTGCTTTTAGGGACAATTTATTGGTCTAATGTATTACAACAGCACGGGTAATATGGGTGTTCTGGCGGG
 CCAAGCATCGCAGTTGAATGCTGTTGTAGATTTGCAAGACAGAAACACAGAGCTTTCATACCAGCTTTTGCTTGATTCCAT
 TGGTGATAGAACCAGGTACTTTTCTATGTGGAATCAGGCTGTTGACAGCTATGATCCAGATGTTAGAATTATTGAAAATCA
 TGGAAGTGAAGATGAACCTCAAATTACTGCTTCCACTGGGAGGTGTGATTAATACAGAGACTCTTACCAAGGTAAAC
 35 TAAACAGGTCAGGAAAATGGATGGGAAAAAGATGCTACAGAATTTTCAGATAAAAAATGAAATAAGAGTTGGAAATAAT

TTTGCCATGGAAATCAATCTAAATGCCAACCTGTGGAGAAATTTCTGTACTCCAACATAGCGCTGTATTTGCCCCACAAG
CTAAAGTACAGTCCTTCCAACGTAAAAATTTCTGATAACCCAAACACCTACGACTACATGAACAAGCGAGTGGTGGCTCCC
GGGTTAGTGGACTGCTACATTAACTTGGAGCACGCTGGTCCCTTGACTATATGGACAACGTCAACCCATTTAACCACCAC
CGCAATGCTGGCCTGCGCTACCGCTCAATGTTGCTGGGCAATGGTCGCTATGTGCCCTTCCACATCCAGGTGCCTCAGAAG
5 TTCTTTGCCATTAATAAACCTCTCTCTGCGGGGCTCATACACCTACGAGTGGAACCTCAGGAAGGATGTTAACATGGTTC
TGCAGAGCTCCCTAGGAAATGACCTAAGGGTTGACGGAGCCAGCATTAAAGTTTGATAGCATTGCTTTACGCCACCTTCT
TCCCCATGGCCACAACACCGCCTCCACGCTTGAGGCCATGCTTAGAAACGACACCAACGACCACTCCTTTAACGACTATC
TCTCCGCCGCCAACATGCTCTACCTATACCCGCCAACGCTACCAACGTGCCCATATCCATCCCCTCCCGCAACTGGGCGGC
TTTCCGCGGCTGGGCTTACGCGCCTTAAGACTAAGGAAACCCCATCACTGGGCTCGGGCTACGACCCTTATTACACCTA
10 CTCTGGCTCTATACCTACCTAGATGGAACCTTTACCTCAACCACACCTTTAAGAAGGTGGCCATTACCTTTGACTCTTCTG
TCAGTGGCCTGGAATGACCGCTGCTTACCCCAACGAGTTTGAATTAAGCGCTCAGTTGACGGGGAGGGTTACAAAC
GTTGCCAGTGTAACATGACCAAAGACTGGTTCCTGGTACAAATGCTAGCTAACTACAACATTGGCTACCAGGGCTTCTAT
ATCCCAGAGAGCTACAAGGACCGCATGTACTCTTCTTTAGAACTTCCAGCCCATGAGCCGTCAGGTGGTGGATGATACT
AAATACAAGGACTACCAACAGGTGGGCATCCTACACCAACACAACAACTCTGGATTTGTTGGCTACCTTGCCCCACCATG
15 CGCGAAGGACAGGCCTACCTGCTAACTTCCCTATCCGCTTATAGGCAAGACCGCAGTTGACAGCATTACCCAGAAAAA
GTTTCTTTGCGATCGCACCTTTGGCGCATCCATTCTCCAGTAACCTTTATGTCCATGGGCGCACTCACAGACCTGGGCCAA
AACCTTCTCTACGCCAACTCCGCCACGCGCTAGACATGACTTTTGAAGTGGATCCCATGGACGAGCCCACTTCTTTAT
GTTTTGTTGAAGTCTTTGACGTGGTCCGTGTGCACCGGCCGACCGCGGCGTCATCGAAACCGTGTACCTGCGCACGCC
TTCTCGGCCGCAACGCCACAACATAA

20 **Ad5-HVR2-SpyTag Hexon sequence**

Amino acid (SEQ ID NO: 3):

MATPSMMPQWSYMHISGQDASEYLSPLVQFARATETYFSLNNKFRNPTVAPTHDVTDRSRLTLRFIPVDREDTAYSKA
RFTLAVGDNRLDMASTYFDIRGVLDRGPTFKPYSGTAYNALAPKGAPNPCEWDEAATALEINLEEEDDDNEDEVDEQAEQQ
KTHVFGQAPYSYINITKEGIQIGVSGSGSAHIVMVDAYKPTKSGSGSPKYADKTFQPEPQIGESQWYETEINHAAGRVLKKT
25 TPMKPCYGSYAKPTNENGGQILVKQNGKLESQVEMQFFSTTEATAGNGDNLTPKVLYSEDVDIETPDTHISYMPITKEGN
SREL MGQQSMPNRPNYIAFRDNFIGLMYYNSTGNMGVLAGQASQLNAVVDLQDRNTELSYQLLLDSIGDRTRYFSMW NQA
VDSYDPDVRIIENHGTEDELPNYCFPLGGVINTETLTVKPKTGQENGWEKDATEFSDKNEIRVGNNFAMEINLNANLWRNFL
YSNIALYLPDKLYSPSNVKISDNPTDYDMNKR VVAPGLVDCYNL GARWSLDYMDNVNPFNHHRNAGLRYRSM LLGNRGY
VPFHIQVPQKFFAIKNLLLLPGSYTYEWNFRKDVNMVLQSSLGNDLRVDGASIKFDSICLYATFFPMAHNTASTLEAMLRNDTN
30 DQSFNDYLSAANMLYPIPANATNPISIPSRNWAAF RGWAFTR LKTKETPSLGSGYDPYTYSGSIPYLDGTFYLNHTFKKVAITF
DSSVSWPGNDRLLTPNEFEIKRSVDGEGYNVAQCNMTKDWFLVQMLANYNIGYQGFYIPESYKDRMYSFFRNFPMSRQVV
DDTKYKDYQVQVILHQHNNSGFVGYLAPTMREGQAYPANFPYPLIGKTAVD SITQKKFLCDRTLWRIPSSNFMSMGALTDLG
QNLLYANSAHALDMTFEVDPMDEPTLLYVLFVFDVVRVHRPHRGVIETVYLRTPF SAGNATT

DNA (incl. STOP) (SEQ ID NO: 4):

35 ATGGCTACCCCTTCGATGATGCCGCAGTGGTCTTACATGCACATCTCGGGCCAGGACGCCTCGGAGTACCTGAGCCCCGG

GCTGGTGCAGTTTGCCCGCGCCACCGAGACGTACTTCAGCCTGAATAACAAGTTTAGAAACCCACGGTGGCGCCTACGC
ACGACGTGACCACAGACCGGTCCCAGCGTTTGACGCTGCGGTTTCATCCCTGTGGACCGTGAGGATACTGCGTACTCGTAC
AAGGCGCGGTTACCCCTAGCTGTGGGTGATAACCGTGTGCTGGACATGGCTTCCACGTACTTTGACATCCGCGCGTGCT
GGACAGGGGCCCTACTTTTAAGCCCTACTCTGGCACTGCCTACAACGCCCTGGCTCCCAAGGGTGCCCCAAATCCTTGCGA
5 ATGGGATGAAGCTGCTACTGCTCTTGAAATAAACCTAGAAGAAGAGGACGATGACAACGAAGACGAAGTAGACGAGCA
AGCTGAGCAGCAAAAACTCACGTATTTGGGAGGCGCCTTATTCTGGTATAAATATTACAAAGGAGGGTATTCAAATAG
GTGTCGGCAGCGGAGGATCCGGCGCCCATATCGTGATGGTGGACGCCTACAAGCCTACCAAAGGCTCTGGCGGAAGCG
GCCCTAAATATGCCGATAAAACATTTCAACCTGAACCTCAAATAGGAGAATCTCAGTGGTACGAAACTGAAATTAATCATG
CAGCTGGGAGAGTCTTAAAAAGACTACCCCAATGAAACCATGTTACGGTTCATATGCAAAACCCACAAATGAAATGGA
10 GGGCAAGGCATTCTGTAAAGCAACAAAATGGAAAGCTAGAAAGTCAAGTGGAATGCAATTTTTCTCAACTACTGAGGC
GACCGCAGGCAATGGTGATACTTGAAGTGGTATTGTACAGTGAAGATGTAGATATAGAAACCCAGACACTC
ATATTTCTTACATGCCCACTATTAAGGAAGGTAACCTCACGAGAACTAATGGGCCAACAATCTATGCCCAACAGGCCTAATT
ACATTGCTTTTAGGGACAATTTTATTGGTCTAATGTATTACAACAGCACGGGTAATATGGGTGTTCTGGCGGGCCAAGCAT
CGCAGTTGAATGCTGTTGTAGATTTGCAAGACAGAAACACAGAGCTTTCATACCAGCTTTTGCTTGATTCCATTGGTGATA
15 GAACCAGGTACTTTCTATGTGGAATCAGGCTGTTGACAGCTATGATCCAGATGTTAGAATTATTGAAATCATGGAAGT
AAGATGAACTTCCAAATTAAGTCTTTCCACTGGGAGGTGTGATTAATACAGAGACTCTTACCAAGGTAAACCTAAAACAG
GTCAGGAAAATGGATGGGAAAAAGATGCTACAGAATTTTCAGATAAAAATGAAATAAGAGTTGGAAATAATTTTGCCAT
GGAAATCAATCTAAATGCCAACCTGTGGAGAAATTTCTGTACTCCAACATAGCGCTGTATTTGCCGACAAGCTAAAGTA
CAGTCCTTCCAACGTAAAAATTTCTGATAACCCAAACACCTACGACTACATGAACAAGCGAGTGGTGGCTCCCGGGTTAGT
20 GGACTGCTACATTAACCTTGGAGCACGCTGGTCCCTTACTATATGGACAACGTCAACCCATTTAACCAACACCGCAATGC
TGGCCTGCGCTACCGCTCAATGTTGCTGGGCAATGGTGCCTATGTGCCCTTCCACATCCAGGTGCCTCAGAAGTCTTTGTC
CATTAAAAACCTCCTTCTCTGCGGGCTCATACCTACGAGTGGAACTTCAGGAAGGATGTTAACATGGTCTGCAGAG
CTCCCTAGGAAATGACCTAAGGGTTGACGGAGCCAGCATTAAAGTTGATAGCATTGCTTTACGCCACCTTCTTCCCAT
GGCCACAACACCGCTCCACGCTTGAGGCCATGCTTAGAAACGACACCAACGACCAAGTCTTTAACGACTATCTCTCCGC
25 CGCCAACATGCTCTACCCTATACCCGCCAACGCTACCAACGTGCCATATCCATCCCCTCCCGCAACTGGGCGGCTTTCCGC
GGCTGGGCCTTACGCGCCTTAAGACTAAGGAAACCCATCACTGGGCTCGGGCTACGACCTTATTACACCTACTCTGGC
TCTATACCCTACCTAGATGGAACCTTTTACCTCAACCACACCTTTAAGAAGGTGGCCATTACCTTTGACTCTTCTGTCACT
GGCCTGGCAATGACCGCTGCTTACCCCAACGAGTTTGAAATTAAGCGCTCAGTTGACGGGGAGGGTTACAACGTTGCC
CAGTGTAACATGACCAAAGACTGGTTCCTGGTACAATGCTAGCTAACTACAACATTGGCTACCAAGGCTTCTATATCCCA
30 GAGAGCTACAAGGACCGCATGTACTCTTCTTAGAACTTCCAGCCCATGAGCCGTCAGGTGGTGGATGATACTAAATA
CAAGGACTACCAACAGGTGGGCATCTACCAACACAACAACCTCTGGATTTGTTGGCTACCTTGCCCCACCATGCGCGA
AGGACAGGCCTACCTGCTAACTCCCTATCCGCTTATAGGCAAGACCGCAGTTGACAGCATTACCCAGAAAAAGTTTCT
TTGCGATCGACCCCTTTGGCGCATCCATTCTCCAGTAACCTTTATGTCCATGGGCGCACTCACAGACCTGGGCCAAAACTT
CTCTACGCCAACTCCGCCACGCGCTAGACATGACTTTTGAGGTGGATCCCATGGACGAGCCACCTTCTTATGTTTTGT
35 TTGAAGTCTTTGACGTGGTCCGTGTGCACCGGCCGACCGCGCGTCAATCGAAACCGGTACCTGCGCACGCCCTTCTCG
GCCGGAACGCCACAACATAA

Ad5-HVR5-SpyTag Hexon sequence**Amino acid (SEQ ID NO: 5):**

MATPSMMPQWSYMHISGQDASEYLSPLVQFARATETYFSLNNKFRNPTVAPTHDVTDRSQRLLRFIPVDREDTAYSYKA
5 RFTLAVGDNRLVDMASTYFDIRGVLDRGPTFKPYSGTAYNALAPKGAPNPCEWDEAATALEINLEEDDDNEDEVDEQAEQQ
KTHVFGQAPYSGINITKEGIQIGVEGQTPKYADKTFQPEPQIGESQWYETEINHAAGRVLKKTTPMKPCYGSYAKPTNENGGQ
GILVKQQNGKLESQVEMQFFSGSGSGAHIVMVDAYKPTKSGSGSGPKVVLYSEDVDIETPDTHISYMPITKEGNSRELMGQ
QSMPNRPNYIAFRDNFIGLMYYNSTGNMGVLAGQASQLNAVVDLQDRNTELSYQLLLDSIGDRTRYFSMWNQAVDSYDPD
VRIENHGTEDELPNYCFPLGGVINTETLTKVKPKTGQENGWEKDATEFSDKNEIRVGNNFAMEINLNANLWRNFLYSNIALYLP
10 DKLKYSPSNVKISDNPNITYDYMKNRVVAPGLVDCYINLGARWSLDYMDNVNPFNHHRNAGLRYRSMLLGNRGYVPFHIQVP
QKFFAIKNLLLLPGSYTYEWNFRKDVNMVLQSSLGNDLRVDGASIKFDSICLYATFFPMAHNTASTLEAMLNDTNDQSFNDYL
SAANMLYPIPANATNPISIPSRNWAAFRGWAFRLTKETPSLGSYDPYYTSGSIPYLDGTFYLNHTFKKVAITFDSVSWP
GNDRLTLPNEFEIKRSVDGEGYNVAQCNMTKDWFLVQMLANYNIGYQGFYIPESYKDRMYSFFRNFPMSRQVDDTKYKD
YQQVGILHQHNNSGFVGYLAPTMREGQAYPANFPYPLIGKTAVDISITQKKFLCDRTLWRIPFSSNFMSMGALDGLQNLLYAN
15 SAHALDMTFEVDPMDEPTLLYVLFVFDVVRVHRPHRGVIETVYLRTFSAGNATT

DNA (incl. STOP) (SEQ ID NO: 6):

ATGGCTACCCCTTCGATGATGCCGAGTGGTCTTACATGCACATCTCGGGCCAGGACGCCTCGGAGTACCTGAGCCCCGG
GCTGGTGAGTTTGCCCGCGCCACCGAGACGTACTTCAGCCTGAATAACAAGTTAGAAACCCACGGTGGCGCCTACGC
ACGACGTGACCACAGACCGGTCCCAGCGTTTGACGCTGCGGTTTCATCCTGTGGACCGTGAGGATACTGCGTACTCGTAC
20 AAGGCGCGGTTACCCCTAGCTGTGGGTGATAACCGTGTGCTGGACATGGCTTCCAGTACTTTGACATCCGCGCGTGCT
GGACAGGGGCCCTACTTTTAAGCCCTACTCTGGCACTGCCTACAACGCCCTGGCTCCCAAGGGTGCCCCAAATCCTTGCGA
ATGGGATGAAGCTGCTACTGCTCTTGAAATAAACCTAGAAGAAGAGGACGATGACAACGAAGACGAAGTAGACGAGCA
AGCTGAGCAGCAAAAACTCACGTATTTGGGCGAGCGCCTTATTCTGGTATAAATATTACAAAGGAGGGTATTCAAATAG
GTGTCGAAGGTCAAACACCTAAATATGCCGATAAAACATTTCAACCTGAACCTCAAATAGGAGAATCTCAGTGGTACGAA
25 ACTGAAATTAATCATGCAGCTGGGAGAGTCCTAAAAAGACTACCCCAATGAAACCATGTTACGGTTCATATGCAAAACCC
ACAAATGAAATGGAGGGCAAGGCATTCTGTAAAGCAACAAATGGAAAGCTAGAAAGTCAAGTGAAATGCAATTTT
TCTCAGGCAGCGGAGGATCCGGCGCCCATATCGTGATGGTGGACGCCTACAAGCCTACCAAAGGCTCTGGCGGAAGCGG
CCCTAAAGTGGTATTGTACAGTGAAGATGTAGATATAGAAACCCAGACACTCATATTTCTTACATGCCCACTATTAAGGA
AGGTAACCTACGAGAACTAATGGGCCAACATCTATGCCCAACAGGCCTAATTACATTGCTTTAGGGACAATTTATTGG
30 TCTAATGTATTACAACAGCACGGGTAATATGGGTGTTCTGGCGGGCCAAGCATCGCAGTTGAATGCTGTTGTAGATTTGC
AAGACAGAAACACAGAGCTTTTCATACCAGCTTTTGCTTGATTCCATTGGTGATAGAACCAGGTACTTTTCTATGTGGAATC
AGGCTGTTGACAGCTATGATCCAGATGTTAGAATTATTGAAAATCATGGAAGTGAAGATGAACCTCAAATTAAGTCTTTC
CACTGGGAGGTGTGATTAATACAGAGACTCTTACCAAGGTAAACCTAAACAGGTCAGGAAATGGATGGGAAAAAGA
TGCTACAGAATTTTCAGATAAAAAATGAAATAAGAGTTGAAATAATTTTGCCATGGAAATCAATCTAAATGCCAACCTGTG
35 GAGAAATTCCTGTACTCCAACATAGCGCTGTATTTGCCCGACAAGCTAAAGTACAGTCCTTCCAACGTAAAAATTTCTGAT

AACCCAAACACCTACGACTACATGAACAAGCGAGTGGTGGCTCCCGGGTTAGTGGACTGCTACATTAACTTGGAGCAG
 CTGGTCCCTTGACTATATGGACAACGTCAACCCATTTAACACCACCGCAATGCTGGCCTGCGCTACCGCTCAATGTTGCT
 GGGCAATGGTCGCTATGTGCCCTCCACATCCAGGTGCCTCAGAAGTTCTTTGCCATTAACAACTCCTTCTCCTGCCGGG
 CTCATACACCTACGAGTGGAACCTCAGGAAGGATGTTAACATGGTTCTGCAGAGCTCCCTAGGAAATGACCTAAGGGTTG
 5 ACGGAGCCAGCATTAAGTTTGATAGCATTTCCTTTACGCCACCTTCTCCCATGGCCACAACACCGCTCCACGCTTGA
 GGCCATGCTTAGAAACGACACCAACGACCAGTCCTTAACGACTATCTCTCCGCCCAACATGCTCTACCTATACCCGCC
 AACGCTACCAACGTGCCATATCCATCCCCTCCGCAACTGGGCGGCTTCCGCGGCTGGGCCTTACGCGCCTTAAGACT
 AAGGAAACCCATCACTGGGCTCGGGCTACGACCTTATTACCTACTCTGGCTCTATACCTACCTAGATGGAACCTTTT
 ACCTCAACCACACCTTTAAGAAGGTGGCCATTACCTTTGACTCTTCTGTGAGCTGGCCTGGCAATGACCGCTGCTTACCCC
 10 CAACGAGTTTGAAATTAAGCGCTCAGTTGACGGGGAGGGTTACAACGTTGCCAGTGAACATGACCAAAGACTGGTTCC
 TGGTACAAATGCTAGCTAACTACAACATTGGCTACCAGGGCTTCTATATCCAGAGAGCTACAAGGACCGCATGTACTCT
 TCTTTAGAACTTCCAGCCCATGAGCCGTGAGTGGTGGATGATACTAAATACAAGGACTACCAACAGGTGGGCATCTA
 CACCAACACAACAACTCTGGATTGTTGGCTACCTTGCCCCACCATGCGCGAAGGACAGGCCTACCCTGCTAACTCCCC
 TATCCGCTTATAGGCAAGACCGCAGTTGACAGCATTACCCAGAAAAAGTTTCTTTGCGATCGACCTTTGGCGCATCCCA
 15 TTCTCCAGTAACCTTATGTCCATGGGCGCACTCACAGACCTGGGCCAAAACCTTCTCTACGCCAACTCCGCCCACGCGCTA
 GACATGACTTTTGAGGTGGATCCCATGGACGAGCCACCTTCTTTATGTTTTGTTGAAGCTTTGACGTGGTCCGTGTG
 CACCGGCCCGCACCGCGCGTCATCGAAACCGGTACCTGCGCACGCCCTTCTCGGCCGGCAACGCCACAACATAA

Ad5-HVR-DogTag sequences

Ad5-HVR1-DogTag Hexon sequence

20 Amino acid (SEQ ID NO: 7):
 MATPSMMPQWSYMHISGQDASEYLSPLVQFARATETYFSLNNKFRNPTVAPTHDVTDRSQRLLRFIPVDREDTAYSYKA
 RFTLAVGDNRLDMASTYFDIRGVLDRGPTFKPYSGTAYNALAPKGAPNPCEWDEAGSGSGDIPATYFTDGKHYITNEPIPP
 KSGSGSGTHVFGQAPYSGINITKEGIQIGVEGQTPKYADKTFQPEPQIGESQWYETEINHAAGRVLKKTPMKPCYGSYAKPTN
 ENGGQGILVKQNGKLESQVEMQFFSTTEATAGNGDNLTPKVVLYSEDVDIETPDTHISYMPITKEGNSRELMGQQSMPNRP
 25 NYIAFRDNFIGLMYYNSTGNMGVLAGQASQLNAVVDLQDRNTELSYQLLLDSIGDRTRYFSMWNQAVDSYDPDVRIENHGT
 EDELPNYCFPLGGVINTETLTKVKPKTGQENGWEKDATEFSDKNEIRVGNNFAMEINLNANLWRNFLYSNIALYLPDKLKYS
 NVKISDNPNITYDMNKRVPVAPGLVDCYINLGARWSLDYMDNVNPFNHHRNAGLRYSMLLGNGRYVPFHIQVPQKFFAIKN
 LLLPGSYTYEWNFRKDVNMVLQSSLGNDLRVDGASIKFDSICLYATFFPMAHNTASTLEAMLRNDTNDQSFNDYLSAANMLY
 PIPANATNPISIPSRNWAAFRGWAFRLKTKETPSLGSYDPYTYSGSIPYLDGTFYLNHTFKKVAITFDSSVSWPGNDRLLTP
 30 NEFEIKRSVDGEGYNVAQCNMTKDWFLVQMLANYNIGYQGFYIPESYKDRMYSFFRNFPMSRQVVDTKYKDYQQVGILH
 QHNNSGFVGYLAPTMREGQAYPANFPYPLIGKTAVDSITQKKFLCDRTLWRIPFSSNFMMSGALTDLGQNLLYANSAHALDM
 TFEVDPMDEPTLLYVLFVFDVVRVHRPHRGVIETVYLRTFPSAGNATT

DNA (incl. STOP) (SEQ ID NO: 8):

ATGGCTACCCCTTCGATGATGCCGCACTGGTCTTACATGCACATCTCGGGCCAGGACGCCTCGGAGTACCTGAGCCCCGG
 35 GCTGGTGCAGTTTGCCGCGCCACCGAGACGTACTTCAGCCTGAATAACAAGTTTAGAAACCCACGGTGGCGCCTACGC

ACGACGTGACCACAGACCGGTCCCAGCGTTTGACGCTGCGGTTTCATCCCTGTGGACCGTGAGGATACTGCGTACTCGTAC
AAGGCGCGGTTACCCCTAGCTGTGGGTGATAACCGTGTGCTGGACATGGCTTCCACGTACTTTGACATCCGCGGCGTGCT
GGACAGGGGCCCTACTTTTAAGCCCTACTCTGGCACTGCCTACAACGCCCTGGCTCCCAAGGGTGCCCCAAATCCTTGCGA
ATGGGATGAAGCTGGCAGCGGAGGATCCGGCgatatccggctacatatgaatttaccgatggtaaacattatatcaccaatgaaccgataccg
5 ccgaaaGGCTCTGGCGGAAGCGGCACTCACGTATTTGGGCAGGCGCCTTATTCTGGTATAAATATTACAAAGGAGGGTATT
CAAATAGGTGTGGAAGGTCAAACACCTAAATATGCCGATAAAACATTTCAACCTGAACCTCAAATAGGAGAATCTCAGTG
GTACGAACTGAAATTAATCATGCAGCTGGGAGAGTCCTAAAAAGACTACCCAATGAAACCATGTTACGGTTCATATG
CAAAACCCACAAATGAAATGAGGGCAAGGCATTCTGTAAAGCAACAAATGAAAGCTAGAAAGTCAAGTGAAAT
GCAATTTTTCTCACTACTGAGGCGACCGCAGGCAATGGTGATAACTTGACTCCTAAAGTGGTATTGTACAGTGAAGATG
10 TAGATATAGAAACCCAGACACTCATATTTCTTACATGCCACTATTAAGGAAGGTAACCTACGAGAACTAATGGGCCAAC
AATCTATGCCAACAGGCCAATTACATTGCTTTAGGGACAATTTATTGGTCTAATGTATTACAACAGCAGGGTAATAT
GGGTGTTCTGGCGGGCAAGCATCGCAGTTGAATGCTGTTGTAGATTGCAAGACAGAAACACAGAGCTTTCATACCAGC
TTTTGCTTGATTCCATTGGTGATAGAACCAGGTACTTTCTATGTGGAATCAGGCTGTTGACAGCTATGATCCAGATGTTA
GAATTATTGAAATCATGGAACCTGAAGATGAACCTCAAATTAAGTCTTTCCACTGGGAGGTGTGATTAATACAGAGACTC
15 TTACCAAGGTAAACCTAAACAGGTCAGGAAATGGATGGGAAAAAGATGCTACAGAAATTTTTCAGATAAAATGAAAT
AAGAGTTGAAATAATTTTGCATGGAAATCAATCTAAATGCCAACCTGTGGAGAAATTCCTGTACTCCAACATAGCGCT
GTATTTGCCCCACAAGCTAAAGTACAGTCCCTCAACGTAATAATTTCTGATAACCCAAACACCTACGACTACATGAACAA
GCGAGTGGTGGCTCCCGGGTGTAGTGGACTGCTACATTAACCTTGAGACACGCTGGTCCCTTGACTATATGGACAACGTCA
ACCCATTTAACCACCACCGCAATGCTGGCTGCGCTACCGCTCAATGTTGCTGGGCAATGGTCGCTATGTGCCCTTCACA
20 TCCAGGTGCCTCAGAAGTCTTTGCCATTAATAACCTCCTTCTCCTGCCGGGCTCATACACCTACGAGTGGAACCTCAGGA
AGGATGTTAATAGTGTCTGCAGAGCTCCCTAGGAAATGACCTAAGGGTTGACGGAGCCAGCATTAAAGTTTGATAGCATT
TGCTTTACGCCACCTTCTTCCCATGGCCACAACACCGCTCCACGCTTGAGGCCATGCTTAGAAACGACACCAACGAC
CAGTCTTTAACGACTATCTCTCCGCCCAACATGCTCTACCCTATACCCGCCAACGCTACCAACGTGCCATATCCATCC
CCTCCGCAACTGGGCGGCTTTCCGCGGCTGGGCCTTACGCGCCTTAAGACTAAGGAAACCCATCACTGGGCTCGGGC
25 TACGACCCTTATTACCTACTCTGGCTCTATACCCTACCTAGATGGAACCTTTTACCTCAACCACCTTTAAGAAGGTGG
CCATTACCTTGACTCTTCTGTAGCTGGCTGGCAATGACCGCTGCTTACCCCAACGAGTTTGAATTAAGCGCTCAGT
TGACGGGGAGGGTTACAACGTTGCCAGTGTAACATGACCAAAGACTGGTTCCTGGTACAAATGCTAGCTAACTACAACA
TTGGCTACCAGGGCTTCTATATCCAGAGAGCTACAAGGACCGCATGTAATCCTTCTTTAGAACTTCCAGCCATGAGCC
GTCAGGTGGTGATGATACTAAATACAAGGACTACCAACAGGTGGGCATCTACCAACACAACAACCTCTGGATTTGTT
30 GGCTACCTTGCCCCACCATGCGGAAGGACAGGCCTACCCTGCTAACTTCCCTATCCGCTTATAGGCAAGACCGCAGTT
GACAGCATTACCCAGAAAAAGTTTCTTTGCGATCGCACCTTTGGCGCATCCATTCTCCAGTAACTTTATGTCCATGGGCG
CACTACAGACCTGGGCCAAAACCTTCTACGCCAACTCCGCCACGCGTAGACATGACTTTTGAGGTGGATCCCATGG
ACGAGCCCACTTCTTTATGTTTTGTTGAAGTCTTTGACGTGGTCCGTGTGCACCGGCCGACCGGGCGTCATCGAAA
CCGTGTACCTGCGCACGCCCTTCTCGGCCGGCAACGCCACAACATAA

Ad5-HVR2-DogTag Hexon sequence**Amino acid (SEQ ID NO: 9):**

MATPSMMPQWSYMHISGQDASEYLSPLVQFARATETYFSLNNKFRNPTVAPTHDVTDRSQRLTLRFIPVDREDTAYSYKA
 RFTLAVGDNRLVDMASTYFDIRGVLDRGPTFKPYSGTAYNALAPKGAPNPCEWDEAATALEINLEEEDDDNEDEVDEQAEQQ
 5 KTHVFGQAPYSGINITKEGIQIGVSGSGSDIPATYEFTDGKHYITNEPIPPKSGSGSGPKYADKTFQPEPQIGESQWYETEINHA
 AGRVLKKTTPMKPCYGSYAKPTNENGGQILVKQNGKLESQVEMQFFSTTEATAGNGDNLTPKVVLYSEDVDIETPDTHISY
 MPTIKEGNSRELMGQQSMPNRPNYIAFRDNFIGLMYYNSTGNMGVLAGQASQLNAVVDLQDRNTELSYQLLLDSIGDRTRYF
 SMWNQAVDSYDPPVRIENHGTEDELPNYCFPLGGVINTETLTKVPKTGQENGWEKDATEFSKDKEIRVGNNFAMEINLNA
 NLWRNFLYSNIALYLPDKLKYSNPKISDNPNNTYDYMKNRVVAPGLVDCYINLGARWSLDYMDNVNPFNHHRNAGLRYRSM
 10 LLGNGRYVPFHIQVPQKFFAIKNLLLPGSYTYEWNFRKDVNMVLQSSLGNDLRVDGASIKFDSICLYATFFPMAHNTASTLEA
 MLRNDTNDQSFNDYLSAANMLYPIANATNPVISPSRNWAAFRGWAFTRLKTETPSLGSYDPPYTYSGSIPYLDGTFYLNH
 TFKKVAITFDSSVSWPGNDRLLTPNEFEIKRSVDGEGYNVAQCNMTKDWFLVQMLANYNIGYQGFYIPESYKDRMYSFFRNF
 QPMSRQVVDTKYQYQVQILGHQHNNSGFVGYLAPTMREGQAYPANFPYPLIGKTAVDSITQKKFLCDRTLWRIPFSSNFM
 SMGALTDLQNLLYANSAHALDMTFEVDPMDEPTLLYVLFEVFDVVRVHRPHRGVIETVYLRTFPSAGNATT

DNA (incl. STOP) (SEQ ID NO: 10):

ATGGCTACCCCTTCGATGATGCCGAGTGGTCTTACATGCACATCTCGGGCCAGGACGCCTCGGAGTACCTGAGCCCCGG
 GCTGGTGAGTTTGCCCGGCCACCGAGACGTACTTCAGCCTGAATAACAAGTTAGAAACCCACGGTGGCGCCTACGC
 ACGACGTGACCACAGACCGGTCCCAGCGTTTGACGCTGCGGTTTCATCCTGTGGACCGTGAGGATACTGCGTACTCGTAC
 AAGGCGCGGTTACCCCTAGCTGTGGGTGATAACCGTGTGCTGGACATGGCTTCCACGTACTTTGACATCCGCGCGTGCT
 20 GGACAGGGGCCCTACTTTTAAGCCCTACTCTGGCACTGCCTACAACGCCCTGGCTCCCAAGGGTGCCCCAAATCCTTGCGA
 ATGGGATGAAGCTGCTACTGCTCTTGAAATAAACCTAGAAGAAGAGGACGATGACAACGAAGACGAAGTAGACGAGCA
 AGCTGAGCAGCAAAAACTCACGTATTTGGGCAGGCGCCTTATTCTGGTATAAATATTACAAAGAGGGTATTCAAATAG
 GTGTCGGCAGCGGAGGATCCGGCgatattccggctacatatgaattaccgatgtaaacattatatcaccaatgaaccgataccgcaaaGGC
 TCTGGCGGAAGCGGCCCTAAATATGCCGATAAAACATTTCAACCTGAACCTCAAATAGGAGAATCTCAGTGGTACGAAAC
 25 TGAAATTAATCATGCAGCTGGGAGAGTCCTTAAAAAGACTACCCCAATGAAACCATGTTACGGTTCATATGCAAAACCCAC
 AAATGAAATGGAGGGCAAGGCATTCTGTAAAGCAACAAAATGGAAAGCTAGAAAGTCAAGTGGAAATGCAATTTTTC
 TCACTACTGAGGCGACCGCAGGCAATGGTGATAAATTGACTCTAAAGTGGTATTGTACAGTGAAGATGTAGATATAGA
 AACCCAGACACTCATATTTCTACATGCCCACTATTAAGGAAGGTAACACGAGAACTAATGGGCCAACAACTATATGCC
 CAACAGGCCTAATTACATTGCTTTTAGGGACAATTTATTGGTCTAATGTATTACAACAGCACGGGTAATATGGGTGTTCT
 30 GCGGGGCCAAGCATCGCAGTTGAATGCTGTTGTAGATTGCAAGACAGAAACACAGAGCTTTCATACCAGCTTTTGCTTG
 ATTCCATTGGTGATAGAACCAGGTAATTTCTATGTGAATCAGGCTGTTGACAGCTATGATCCAGATGTTAGAATTATG
 AAAATCATGGAAGTGAAGATGAACTTCAAATTACTGCTTTCCACTGGGAGGTGTGATTAATACAGAGACTCTTACCAAG
 GTAAACCTAAACAGGTCAGGAAAAATGGATGGGAAAAAGATGCTACAGAATTTTCAGATAAAATGAAATAAGAGTTG
 GAAATAATTTTGCCATGAAATCAATCTAAATGCCAACCTGTGGAGAAATTTCTGTACTCAACATAGCGCTGTATTGCG
 35 CCGACAAGCTAAAGTACAGTCCTTCCAACGTAAAAATTTCTGATAACCCAAACACCTACGACTACATGAACAAGCGAGTG
 GTGGCTCCCGGTTAGTGGACTGCTACATTAACCTTGAGACGCTGGTCCCTTGACTATATGGACAACGTCAACCCATTT

AACCACCACCGCAATGCTGGCCTGCGCTACCGCTCAATGTTGCTGGGCAATGGTCGCTATGTGCCCTCCACATCCAGGTG
 CCTCAGAAAGTTCTTTGCCATTAAAAACCTCCTTCTCCTGCCGGGCTCATACACCTACGAGTGGAACCTCAGGAAGGATGTT
 AACATGGTTCTGCAGAGCTCCCTAGGAAATGACCTAAGGGTTGACGGAGCCAGCATTAAAGTTTGATAGCATTTGCCTTTA
 CGCCACCTTCTCCCCATGGCCCAACACCGCTCCACGCTTGAGGCCATGCTTAGAAACGACACCAACGACCAGTCCTT
 5 TAACGACTATCTCTCCGCCGCAACATGCTCTACCCTATACCGCCAACGCTACCAACGTGCCCATATCCATCCCCTCCCGC
 AACTGGGCGGCTTTCCGCGGCTGGGCCTTACGCGCCTTAAGACTAAGGAAACCCCATCACTGGGCTCGGGCTACGACCC
 TTATTACCTACTCTGGCTCTATACCCTACCTAGATGGAACCTTTACCTCAACCACACCTTTAAGAAGGTGGCCATTACCT
 TTGACTCTTCTGTACGTGGCTGGCAATGACCGCTGTTACCCCAACGAGTTTGAAATTAAGCGCTCAGTTGACGGGG
 AGGGTTACAACGTTGCCAGTGTAACATGACCAAAGACTGGTTCCTGGTACAAATGCTAGCTAACTACAACATTGGCTACC
 10 AGGGCTTCTATATCCCAGAGAGCTACAAGGACCGCATGTACTCCTTCTTTAGAACTTCCAGCCCATGAGCCGTCAGGTGG
 TGGATGATACTAAATACAAGGACTACCAACAGGTGGGCATCCTACCAACACAACAACCTCTGGATTGTGGCTACCTTG
 CCCCCACCATGCGCGAAGGACAGGCCTACCCTGCTAACTTCCCCTATCCGCTTATAGGCAAGACCGCAGTTGACAGCATT
 CCCAGAAAAAGTTTCTTTGCGATCGCACCTTTGGCGCATCCCATTCTCCAGTAACTTTATGTCCATGGGCGCACTCACAGA
 CCTGGGCCAAAACCTTCTCTACGCCAACTCCGCCACGCGCTAGACATGACTTTTGAGGTGGATCCCATGGACGAGCCAC
 15 CTTCTTTATGTTTTGTTGAAGTCTTTGACGTGGTCCGTGTGCACCGCGCACCGCGGCGTCATCGAAACCGTGTACCT
 GCGCACGCCCTTCTCGGCCGGCAACGCCACAACATAA

Ad5-HVR5-DogTag Hexon sequence

Amino acid (SEQ ID NO: 11):

MATPSMMPQWSYMHISGQDASEYLSPLVQFARATETYFSLNNKFRNPTVAPTHDVTDRSQRLLRFIPVDREDTAYSYKA
 20 RFTLAVGDNRLDMASTYFDIRGVLDRGPTFKPYSGTAYNALAPKGAPNPCEWDEAATALEINLEEEDDDNEDEVDEQAEQQ
 KTHVFGQAPYSINITKEGIQIGVEGQTPKYADKTFQPEPQIGESQWYETEINHAAGRVLKKTTPMKPCYGSYAKPTNENGGQ
 GILVKQQNGKLESQVEMQFFSGSGSGDIPATYFTDGKHITNEPIPPKSGSGSGPKVVLSEVDVETPDTHISYMPIKEGN
 SRELMGQQSMPNRPNYIAFRDNFIGLMYYNSTGNMGVLAGQASQLNAVVDLQDRNTELSYQLLLDSIGDRTRYFSMWNQ
 VDSYDPDVRIENHGTEDLPNYCFPLGGVINTETLTVKPKTGQENGWEKDATEFSDKNEIRVGNFAMEINLNANLWRNFL
 25 YSNIALYLPDKLKYSNPKISDNPNNTYDYMNRVVPGLVDCYNLGRWSLDYMDNVNPFNHHRNAGLRYSMLLNGR
 VPFHIQVPQKFFAIKNLLLLPGSYTYEWNFRKDVNMVLQSSLGNDLRVDGASIKFDSICLYATFFPMAHNTASTLEAMLRNDTN
 DQSFNDYLSAANMLYPIANATNVPISIPSRNWAAFRGWAFRLKTKETPSLGSYDPYTYSGSIPYLDGTFYLNHTFKKVAITF
 DSSVSWPGNDRLLTPNEFEIKRSVDGEGYNVAQCNMTKDWFLVQMLANYNIGYQGFYIPESYKDRMYSFFRNFPMSRQVV
 DDTKYKDYQVQVILHQHNNSGFVGYLAPTMREGQAYPANFPYPLIGKTAVDISITQKKFLCDRTLWRIPSSNFMSMGALTDLG
 30 QNLLYANSAHALDMTFEVDPMDEPTLLVYLFVFDVVRVHRPHRGVIETVYLRTPFSAAGNATT

DNA (incl. STOP) (SEQ ID NO: 12):

ATGGCTACCCCTTCGATGATGCCGCAAGTGGTCTTACATGCACATCTCGGGCCAGGACGCCTCGGAGTACCTGAGCCCCGG
 GCTGGTGCAATTTGCCCGCCACCGAGACGTACTTCAGCCTGAATAACAAGTTTAGAAACCCACGGTGGCGCCTACGC
 ACGACGTGACCACAGACCGGTCCCAGCGTTTGACGCTGCGGTTTCATCCCTGTGGACCGTGAGGATACTGCGTACTCGTAC
 35 AAGGCGCGGTTACCCCTAGCTGTGGGTGATAACCGTGTGCTGGACATGGCTTCCACGTACTTTGACATCCGCGCGTGCT

GGACAGGGGCCCTACTTTTAAGCCCTACTCTGGCACTGCCTACAACGCCCTGGCTCCCAAGGGTGCCCCAAATCCTTGCGA
ATGGGATGAAGCTGCTACTGCTCTTGAATAAACCTAGAGAAGAGGACGATGACAACGAAGACGAAGTAGACGAGCA
AGCTGAGCAGCAAAAACTCACGTATTTGGGCAGGCGCCTTATTCTGGTATAAATATTACAAAGGAGGGTATTCAAATAG
GTGTCGAAGGTCAAACACCTAAATATGCCGATAAAACATTTCAACCTGAACCTCAAATAGGAGAATCTCAGTGGTACGAA
5 ACTGAAATTAATCATGCAGCTGGGAGAGTCTTAAAAAGACTACCCCAATGAAACCATGTTACGGTTCATATGCAAAACCC
ACAAATGAAATGGAGGGCAAGGCATTCTTGTAAGCAACAAATGGAAAGCTAGAAAGTCAAGTGAAATGCAATTTT
TCTCAGGCAGCGGAGGATCCGGCgatattccggctacatatgaatttaccgatggtaaacattatatcaccaatgaaccgataccgccgaaaGGCT
CTGGCGGAAGCGGCCCTAAAGTGGTATTGTACAGTGAAGATGTAGATATAGAAACCCAGACACTCATATTTCTTACATG
CCCACTATTAAGGAAGGTAACCTCACGAGAACTAATGGGCCAACATCTATGCCAACAGGCCTAATTACATTGCTTTTAGG
10 GACAATTTTATTGGTCTAATGTATTACAACAGCACGGGTAAATATGGGTGTTCTGGCGGGCCAAGCATCGCAGTTGAATGC
TGTTGTAGATTTGCAAGACAGAAACACAGAGCTTTCATACCAGCTTTTGCTTGATTCCATTGGTGATAGAACCAGGTACTT
TTCTATGTGGAATCAGGCTGTTGACAGCTATGATCCAGATGTTAGAATTATTGAAAATCATGGAAGTGAAGATGAAGTCC
AAATTACTGCTTTCCACTGGGAGGTGTGATTAATACAGAGACTCTTACCAAGGTAAAACCTAAAACAGGTCAGGAAAATG
GATGGGAAAAAGATGTACAGAAATTTTCAGATAAAAAATGAAATAAGAGTTGGAAATAATTTTGCCATGGAAATCAATCTA
15 AATGCCAACCTGTGGAGAAATTTCTGTACTCCAACATAGCGCTGTATTGCCCCGACAAGCTAAAGTACAGTCCCTTCCAAC
GTAAAAATTTCTGATAACCCAAACACCTACGACTACATGAACAAGCGAGTGGTGGCTCCCGGGTTAGTGGACTGCTACAT
TAACCTTGGAGCACGCTGGTCCCTTGACTATATGGACAACGTCAACCCATTTAACCACCACCGCAATGCTGGCCTGCGCTA
CCGCTCAATGTTGCTGGGCAATGGTCGCTATGTGCCCTTCCACATCCAGGTGCCTCAGAAGTCTTTGCCATTAACAACTC
CTTCTCTGCCGGGCTCATACCTACGAGTGGAATTCAGGAAGGATGTTAACATGGTTCTGCAGAGCTCCCTAGGAAA
20 TGACCTAAGGGTTGACGGAGCCAGCATTAAAGTTGATAGCATTTGCCCTTACGCCACCTTCTTCCCATGGCCACAACAC
CGCTCCACGCTTGAGGCCATGCTTAGAAACGACACCAACGACCAAGTCTTTAACGACTATCTCTCCGCCGCCAACATGCT
CTACCTATACCCGCCAACGCTACCAACGTGCCATATCCATCCCCTCCCGCAACTGGGCGGCTTCCGCGGCTGGGCCTT
CACGCGCTTAAGACTAAGGAAACCCCATCACTGGGCTCGGGCTACGACCCTTATTACACCTACTCTGGCTCTATACCTA
CCTAGATGGAACCTTTTACCTCAACCACACCTTTAAGAAGGTGGCCATTACCTTTGACTCTTGTGCTAGCTGGCCTGGCAAT
25 GACCGCTGCTTACCCCAACGAGTTTGAAATTAAGCGCTCAGTTGACGGGGAGGGTTACAACGTTGCCAGTGTAACAT
GACCAAAGACTGGTTCCTGGTACAAATGCTAGCTAACTACAACATTGGCTACCAGGGCTTCTATATCCAGAGAGCTACAA
GGACCGCATGTACTCTTCTTTAGAACTTCCAGCCCATGAGCCGTGAGGTGGTGGATGATACTAAATACAAGGACTACCA
ACAGGTGGGCATCTACACCAACACAACAACTCTGGATTTGTTGGCTACCTTGCCCCACCATGCGCGAAGGACAGGCCT
ACCCTGCTAACTTCCCTATCCGCTTATAGGCAAGACCGCAGTTGACAGCATTACCCAGAAAAAGTTTCTTTGCGATCGCA
30 CCTTTGGCGCATCCCATTTCTCAGTAACTTTATGTCCATGGGCGCACTCACAGACCTGGGCCAAAACCTTCTCTACGCCAA
CTCCGCCACGCGCTAGACATGACTTTTGAGGTGGATCCCATGGACGAGCCACCTTCTTTATGTTTTGTTGAAGTCTTT
GACGTGGTCCGTGTGCACCGGCCGACCGCGGCGTCATCGAAACCGTGTACCTGCGCACGCCCTTCTCGGCCGGCAACGC
CACAAACATAA

Amino acid (SEQ ID NO: 13):

DNA (incl. STOP) (SEQ ID NO: 14):

Ligands for capsid decoration described in this patent:

20 DogCatcher

Amino acid (SEQ ID NO: 15):

DNA (incl. STOP) (SEQ ID NO: 16):

30 DogCatcher-NANP9

Amino acid (SEQ ID NO: 17):

MAHHHHHHVGTGKLGDI EFIKVNKNDKKPLRGAVFSLQKQHDPYDIIYGAI DQNGTYQNVRTGEDGKLTFKNLSDGKYRLF E
NSEPAGYKP VQNKP IVAFOI VNGEVRDVTSIV PQSGSGSGGSNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANP

DogCatcher-NANP18

Amino acid (SEQ ID NO: 19):

DNA (incl. STOP) (SEQ ID NO: 20):

DogCatcher-NANP Domain

Amino acid (SEQ ID NO: 21):

DNA (incl. STOP) (SEQ ID NO: 22):

30 ATGGCACATCACCACCACCATCACGTGGGTACCGGTAAACTGGGCGATATTGAATTTATTAAGTGAACAAAAACGATAA
AAAGCCGCTGCGTGGTGCCGTGTTTAGCTGCAGAAACAGCATCCCGACTATCCCGATATCTATGGCGCGATTGATCAGA
ATGGGACCTATCAAAATGTGCGTACCGGCGAAGATGGTAAACTGACCTTTAAGAATCTGAGCGATGGCAAATATCGCCTG
TTTGAAAATAGCGAACCCGCTGGCTATAAACCGGTGCAGAATAAGCCGATTGTGGCGTTTCAGATTGTGAATGGCGAAGT
GCGTGATGTGACCAGCATTGTGCCGAGGGCTCTGGCGGAAGCGGCGGATCCAATGCAATCCGAATGTTGATCCGAAC
GCGAACCCGAACGTGGACCCTAACGCCAATCCTAATGTGGACCCAAATGCGAATCCAATGCTAACCCAAACGCAACCC

GAATGCGAACCCCAATGCCAATCCGAACGCTAATCCAATGCTAATCCTAATGCAAATCCAAACGCGAATCCGAACGCCA
ATCCTAACGCAAACCCGAACGCAAATCCAAATGCAAACCCAAATGCTAATCCTAATGCGAACCCGAATGCTAACCCGAAT
GCAAACCCTAACGTTGACCCTAATGCTAACCCCTAACGCTAACCCCAACGCCAATCCGAATGCGAATCCTAACGCCAATCCA
AATGCCAATCCGAACGCGAACCCAAACGCTAATCCAAACGCGAATCCAAATGCGAACCCCTAATGCGAATCCCAATGCAAA
5 TCCCAATGCGAACCCCTAACGCAAATCCGAACGCAAACCCCTAACGCGAACCCCTAATGCTAATCCTAACGCCAATCCTTAA

SpyTag-MBPAmino acid (SEQ ID NO: 23):

MGSSHHHHHHSSGLVPRGSHMGAHIVMVDAYKPTKSGESGKIEEGKLVWINGDKGYNGLAIEVGKKFEKDTGIKVTVEHPD
KLEEKFPQVAATGDGPDIIFWAHDREFGGYAQSGLLAEITPDKAFQDKLYPFTWDVRYNGKLIAYPIAVEALSLIYNKDLLPNPP
10 KTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIADGGYAFKYENGKYDIKDVGVNAGAKAGLTFVLVDLIKXHMNADTD
YSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAV
NKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMPNIQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSS

DNA (incl. STOP) (SEQ ID NO: 24):

ATGGGCAGCAGCCATCATCATCATCACAGCAGCGGCTGGTGCCGCGCGCAGCCATATGGGAGCCACATCGTGAT
15 GGTGGACGCCTACAAGCCGACGAAGggtagtggtgaaagtggtaaATCGAAGAAGGTAACTGGTAATCTGGATTAACGGCG
ATAAAGGCTATAACGGTCTCGCTGAAGTCGTAAGAAATTCGAGAAAGATACCGGAATTAAAGTCACCGTTGAGCATCCG
GATAAATGGAAGAGAAATCCACAGGTTGCGGCAACTGGCGATGGCCCTGACATTATCTTCTGGGCACACGACCGCTT
TGGTGGCTACGCTCAATCTGGCCTGTTGGCTGAAATCACCCCGGACAAAGCGTTCCAGGACAAGCTGTATCCGTTTACCTG
GGATGCCGTACGTTACAACGCAAGCTGATTGCTTACCCGATCGCTGTTGAAGCGTTATCGCTGATTTATAACAAAGATCT
20 GCTGCCGAACCCGCCAAAAACCTGGGAAGAGATCCCGGCGCTGGATAAAGAACTGAAAGCGAAAGGTAAGAGCGCGCT
GATGTTCAACCTGCAAGAACCGTACTTCACCTGGCCGCTGATTGCTGCTGACGGGGGTTATGCGTTCAAGTATGAAAACG
GCAAGTACGACATTAAAGACGTGGGCGTGGATAACGCTGGCGCGAAAGCGGGTCTGACCTTCTGGTTGACCTGATTAA
AAACAAACACATGAATGCAGACACCGATTACTCCATCGCAGAAGCTGCCTTTAATAAAGGCGAAACAGCGATGACCATCA
ACGGCCCGTGGGCATGGTCCAACATCGACACCAGCAAAGTGAATTATGGTGTAAACGGTACTGCCGACCTTCAAGGGTCAA
25 CCATCCAAACCGTTCTGTTGGCGTCTGAGCGCAGGTATTAACGCCGCCAGTCCGAACAAAGAGCTGGCAAAAGAGTTTCT
CGAAAATCTATCTGCTGACTGATGAAGGTCTGGAAGCGGTTAATAAAGACAAACCGCTGGGTGCCGTAGCGCTGAAGTCTT
ACGAGGAAGAGTTGGCGAAAGATCCACGTATTGCCGCCACTATGGAAAACGCCAGAAAGGTGAAATCATGCCGAACAT
CCCGCAGATGTCCGCTTCTGTTATGCCGTGCGTACTGCGGTGATCAACGCCGCCAGCGGTCTGTCAGACTGTGATGAAG
CCCTGAAAGACGCGCAGACTAATTCGAGCTCGTAA

30 **SnoopLigase**Amino acid (SEQ ID NO: 25):

MGSWSHHHHHSSGGSGVNKNDKKPLRGAVFSLQKQHPDYPDIYGAIDQNGTYQNVRTGEDGKLTfKNLSDGKYRLFENSE
PPGYKPVQNKPIVAFQIVNGEVRDVTIVPPGVPATYEFT

DNA (incl. STOP) (SEQ ID NO: 26):

atgggcagctggagccatcatcatcatcacagctctggtagtggtgtaataagaacgataaaaagccgctgctggtggtccgtgttagcctgcagaa
acagcatcccgactatcccgatatctatggcgcgattgatcagaatgggacatatcaaatgtgctaccggcgaagatggtaaactgacctttaagaatctga
gcatggcaaatatcgctgtttgaaaatagcgaacccccgggctataaaccggtgcagaataagccgatttggtggtttcagattgtaatggcgaagtgcgt
5 gatgtgaccagcattgtgccgcccgggtgtgccggctacatatgaatttacctaa

SnoopTagJr-AffiHER2Amino acid (SEQ ID NO: 27):

MGSSHHHHHHSSGGKLSIEFIKVNKSGSGSGASMTGGQQMGRDPGVDNKFNKEMRNAYWEIALLPNNQKRAFIR
SLYDDPSQSANLLAEAKKLNDAPKGL

10 DNA (incl. STOP) (SEQ ID NO: 28):

atgggcagcagccatcatcatcatcatcacagcagcggcgaggaaactgggctctattgaatttattaaagtgaacaaaggcagtggtgagtcgggatccggag
ctagcatgactggtggacagcaaatgggtcgggatccggcgctggacaacaaattcaacaaagaaatgaggaaacgcttactgggagatagctctttaccctaa
cttaaacatcaacagaaaagggtcttcataaggtcgttatcatgacccaagcgaagcgtaaccttttagcagaagctaaaaagctaaatgatgctcag
gcgccgaaaggcctcgagtaa

15 SpyCatcherAmino acid (SEQ ID NO: 29):

MSYYHHHHHHHDYDIPTTENLYFQGAMVDTLSGLSSEQGQSGDMTIEEDSATHIKFSKRDEDEGKELAGATMELRDSSGKTISTW
ISDGQVKDFLYLPKYTFVETAAPDGYEVATAITFTVNEQQQVTVNGKATKGDHAI

DNA (incl. STOP) (SEQ ID NO: 30):

20 ATGTCGTACTACCATCACCATCACCATCACGATTACGACATCCCAACGACCGAAAAACCTGTATTTTCAGGGCGCCATGGTT
GATACCTTATCAGGTTTATCAAGTGAGCAAGGTCAGTCCGGTGATATGACAATTGAAGAAGATAGTGCTACCCATATTAA
ATTCTCAAAACGTGATGAGGACGGCAAAGAGTTAGCTGGTGCAACTATGGAGTTGCGTGATTCTCTGGTAAACTATTA
GTACATGGATTTTCAGATGGACAAGTGAAAGATTTCTACCTGTATCCAGGAAAATATACATTTGTGAAACCGCAGCACCA
GACGGTTATGAGGTAGCAACTGCTATTACCTTTACAGTTAATGAGCAAGGTCAGGTTACTGTAAATGGCAAAGCAACTAA
25 AGGTGACGCTCATATTTAA

HCMV PentamerHCMV gH-SpyTagAmino acid (SEQ ID NO: 31):

MRPGLPSYLIILAVCLFSLHSSRYGAEAVSEPLDKAFHLLNNTYGRPIRFLRENTTQCTYNSSLRNSTVVRENAISFNFFQSYNQYY
30 VFHMPRCLFAGPLAEQFLNQVDLTETLERYQQRNLNTYALVSKDLASYRSFSQQLKAQDSLGEQPTTVPPIIDLSIPHVWMPPT
TPHGWTESHTTSLHRPHFNQTCILFDGHDLLFSTVTPCLHQGFYLIDELRYVKITLTEDFFVTVSIDDTPMILLIFGHLPRVLFK
APYQRDNFILRQTEKHELLVLVKDQLNRHSYKDPDFLDAALDFNYLDSALLRNSFHRYAVDVLKSGRCQMLDRRTVEMAF
YALALFAAARQEEAGAQVSVPRALDRQAALLQIQEFMITCLSQTTPRTTLLYPTAVDLAKRALWTPNQITDITSLVRLVYILSKQ

NQQLIPQWALRQIADFALKLHKTHLASFLSAFARQELYLMGSLVHSMVHTTEREIFIVETGLCSLAELSHFTQLLAHPHHEYL
SDLYTPCSSSGRRDHSRLRLFPDATVPATVPAALSILSTMQPSTLETFPDLFCLPLGESFSALTVEHVSIVITNQYLIKISYPV
STTVVGQSLIITQDSQTKCELTRNMHTTHSITVALNISLENCAFCQSALLEYDDTQGVINIMYMHDSDDVLFALDPYNEVVVSS
PRTHYMLLLKNGTVLEVTDVVVDATDSRLLGSGGSGAHIVMVDAYKPTKHHHHHH

5 DNA (incl. STOP) (SEQ ID NO: 32):

ATGCGGCCAGGCCTCCCCTCTACCTCATCATCTCGCCGTCTGTCTCTTCAGCCACCTACTTTCGTACGATATGGCGCAG
AAGCCGTATCCGAACCGCTGGACAAAGCGTTTCACCTACTGCTCAACACCTACGGGAGACCCATCCGCTTCTGCGTGAAA
ATACCACCCAGTGATCTACAACAGCAGCCTCCGTAACAGCAGCGTCTCAGGAAAACGCCATCAGTTTCAACTTTTTCC
AAAGCTATAATCAATACTATGTATTCCATATGCCTCGATGTCTTTTTCGCGGTCTCTGGCGGAGCAGTTTCTGAACAGGT
10 AGATCTGACCGAAACCTGGAAAGATACCAACAGAGACTTAACACTTACGCGTGGTATCCAAGACCTGGCCAGCTACC
GATCTTTTTCGCAGCAGCTAAAGGCACAAGACAGCCTAGGTGAACAGCCCACTGTGCCACCGCCATTGACCTGTCA
ATACCTCACGTTTGGATGCCACCGCAAACCACTCCACACGGCTGGACAGAATCACATACCACCTCAGGACTACACCGACCA
CACTTTAACCAGACCTGTATCTCTTTGATGGACAGATCTACTATTAGCAGCCGTACACCTTGTTCGACCAAGGCTTTT
ACCTCATCGACGAACCTACGTTACGTTAAATAAACTGACCGAGGACTTCTTCGTAGTTACGGTGTCCATAGACGACGACA
15 CACCCATGCTGCTTATCTTCGGCCATCTCCACGCGTACTTTTCAAGCGCCCTATCAACGCGACAACCTTTATACTACGACA
AACTGAAAAACAGAGCTCCTGGTGCTAGTTAAGAAAGATCAACTGAACCGTCACTCTTATCTCAAAGACCCGGACTTTCT
TGACGCCGCACTTGACTTCAACTACCTAGACCTCAGCGCACTACTACGTAACAGCTTTCACCGTTACGCCGTGGATGTACT
CAAGAGCGGTGCTGATGTCAGATGCTGGACCGCCGACGGTAGAAATGGCCTTCGCCTACGCATTAGCACTGTTTCGACGAG
CCCGACAAGAAGAGGCCGCGGCCAAGTCTCCGTCCACGGGCCCTAGACCGCCAGGCCGCACTCTTACAAATACAAGA
20 ATTTATGATCACATGCCTCTCACAACACCACCACGACCCACGTTGCTGCTGTATCCCACGGCCGTGGACCTGGCCAAACG
AGCCCTTTGGACACCGAATCAGATCACCGACATCACCGCCTCGTACGCGTGGTCTACATACTCTTAAACAGAATCAGCA
ACATCTCATCCCCAATGGGCACTACGACAGATCGCCGACTTTGCCCTAAACTACACAAAACGCACCTGGCCTCTTTTCTT
TCAGCCTTCGCACGCCAAGAACTCTACCTCATGGGCAGCCTCGTCCACTCCATGCTGGTACATACGACGGAGAGACGCGA
AATCTTCATCGTAGAAACGGGCCTCTGTTCAATTGGCCGAGCTATCACACTTTACGCAGTTGTTAGCTCATCCACACCACGA
25 ATACCTCAGCGACCTGTACACACCCTGTTCCAGTAGCGGGCGACGCGATCACTCGCTCGAACGCTCAGCGTCTCTTCCC
CGATGCCACCGTCCCCGCTACCGTTCCGCGCCCTCTCCATCCTATCTACCATGCAACCAAGCAGCTGGAAACCTTCCCC
GACCTGTTTTGCTTGGCGCTCGGCGAATCCTTCTCCGCGTACCGTCTCCGAACAGTCAGTTATATCGTAACAAACAGT
ACCTGATCAAAGGTATCTCCTACCCTGTCTCCACCACGTCGTAGGCCAGAGCCTCATCATCACCAGACGGACAGTCAAA
CTAAATGCGAACTGACGCGCAACATGCATACCACACACAGCATCACAGTGGCGCTCAACATTTGCTAGAAAACCTGCGCC
30 TTTTGCCAAAGCGCCCTGCTAGAATACGACGACACGCAAGGCGTCATCAACATCATGTACATGCAGACTCGGACGACGT
CCTTTTCGCCCTGGATCCCTACAACGAAGTGGTGGTCTCATCTCCGCGAACTCACTACCTCATGCTTTTGAACAAACGTTACG
GTACTAGAAGTAACTGACGTCGTGTCGGACGCCACCGACAGTCGTCTCCTCGGAAGCGGAGGCTCTGGTGCCCATATCGT
GATGGTGgacgCCTACAAGCCTACCAACATCATCACCATCACCCTAA

HCMV gLAmino acid (SEQ ID NO: 33):

MCRRPDCGFSFSPGPVILLWCCLLLPIVSSAAVSVAPTAAEKVPAECPELTRRCLLGEVFEGDKYESWLRPLVNVTVGRDGPLSQLI
RYPVTPPEAANSVLLDEAFDLTLALLYNPDQLRALLTLSSDTAPRWMTVMRGYSECGDGS PAVYTCVDDLRCGYDLTRLSYG
5 RSIFTEHVLGFELVPPSLFNVVVVAIRNEATRTRNAVRPLPVSTAAAEGITLFYGLYNVAVKEFCLRHQLDPPLLRHLDKYYAGLPPEL
KQTRVNLPAHSRYGPQAVDAR

DNA (incl. STOP) (SEQ ID NO: 34):

ATGTGCCGCCGCCGCGATTGCGGCTTCTCTTCTCACCTGGACCGGTGATACTGCTGTGGTGTTCCTTCTGCTGCCCATTTG
TTTCTCAGCCGCCGTCAGCGTCGCTCTACCGCCGCCGAGAAAGTCCCGCGGAGTGCCCCGAACTAACGCGCCGATGC
10 TTGTTGGGTGAGGTGTTTGAGGGTGACAAGTATGAAAGTTGGCTGCGCCCGTTGGTGAATGTTACCGGGCGCGATGGCC
CGCTATCGCAACTTATCCGTTACCGTCCCGTTACGCCGAGGCCGCCAACTCCGTGCTGTTGGACGAGGCTTCTCTGGACA
CTCTGGCCCTGCTGTACAACAATCCGGATCAATTGCGGGCCCTGCTGACGCTGTTGAGCTCGGACACAGCGCCGCGCTGG
ATGACGGTGATGCGCGGCTACAGCGAGTGCGGCGATGGCTCGCCGGCCGTGTACACGTGCGTGACGACCTGTGCCGC
GGCTACGACCTACGCGACTGTCATACGGGCGCAGCATCTTCACGGAACACGTGTTAGGCTTCGAGCTGGTGCCACCGTC
15 TCTCTTAACGTGGTGGTGCCATACGCAACGAAGCCACGCGTACCAACCGCGCCGTGCGTCTGCCCGTGAGCACCGCTG
CCGCGCCCGAGGGCATCAGCTCTTTACGGCCTGTACAACGCAGTGAAGGAATTCTGCCTGCGTACCAGCTGGACCCG
CCGCTGCTACGCCACCTAGATAAATACTACGCCGGAAGTCCCGCCGAGCTGAAGCAGACGCGCTCAACCTGCCGGCTCA
CTCGCGCTATGGCCCTCAAGCAGTGGATGCTCGCTAA

HCMV UL131A20 Amino acid (SEQ ID NO: 35):

MRLCRVWLSVCLCAVVLGQCQRETAEKNDYYRVPHYWDACSRLPDQTRYKYVEQLVDLTLYHYDASHGLDNFDVLKRINV
TEVSLISDFRRQNRRGGTNKRITTFNAAGSLAPHARSLEFSVRLFAN

DNA (incl. STOP) – contains intron (**bold**) (SEQ ID NO: 36):

ATGCGGCTGTGTCGGGTGTGGCTGTCTGTTGTCTGTGCGCCGTGGTGTGGGTGAGTGCCAGCGGGAAACCGCGGAAA
25 AAAACGATTATTACCGAGTACCGCATTACTGGGACGCGTGCTCTCGCGCGTCCCCGACCAACCCGTTACAAGTATGTG
GAACAGCTCGTGGACCTCACGTTGAACTACCACTACGATGCGAGCCACGGCTTGGACAACTTTGACGTGCTCAAGAG**GTG**
AGGGTACGCGCTAAAGATGCATGACAACGGGAAGGTAAGGGCGAACGGGTAAAGTAACCGCATGGGGTAT
GAAATGACGTTTCGGAACCTGTGCTTGCAGAATCAACGTGACCGAGGTGTCGTTGCTCATCAGCGACTTTAGACGTCAGA
ACCGTCGCGGCGGCACCAACAAAAGGACCACGTTCAACGCCGCCGGTTGCTGGCGCCACACGCCCGGAGCCTCGAGTT
30 CAGCGTGCGGCTCTTGCCAACTAG

HCMV UL128Amino acid (SEQ ID NO: 37):

MSPKDLTPFLTALWLLLGHSRVPRVRAEECCFEINVNHPPERCYDFKMCNRFTVALRCPDGEVCYSPEKTAEIRGIVTTMTHSLT
RQVVHNKLTSCNYPNPLYLEADGRIRCGKVNDKAQYLLGAAGSVPYRWINLEYDKITRIVGLDQYLESVKKHRLDVCRAKMGY
5 MLQ

DNA (incl. STOP) – contains introns (**bold**) (SEQ ID NO: 38):

ATGAGTCCCAAAGATCTGACGCCGTTCTTGACGGCGTTGTGGCTGCTATTGGGTACACAGCCGCTGCCGCGGGTGCGCGC
AGAAGAATGTTGCGAATTCATAAACGTCAACCACCCGCCGAACGCTGTACGATTTCAAAATGTGCAATCGCTTCACCGT
CGCGTACGTATTTTCATGATTGTCTGCGTCTGTGGTGCCTCTGGATCTGTCTCTCGACGTTTCTGATAGCCATGTTCCAT
10 **CGACGATCTCGGGAATGCCAGAGTAGATTTTCATGAATCCACAG**GCTGCGGTGTCCGGACGGCGAAGTCTGCTACAGT
CCCGAGAAAACGGCTGAGATTCGCGGGATCGTCACCACCATGACCCATTCAATTGACACGCCAGGTCGTACACAACAACT
GACGAGCTGCAACTACAATCC**GTAAGTCTCTTCTGAGGGCCTTACAGCCTATGGGAGAGTAAGACAGAGAGGGACAA**
AACATCATTAAAAAAAAGTCTAATTTACGTTTTGTACCCCCCTTCCCTCCGTGTTGTAGTTATACCTCGAAGCTGA
CGGGCGAATACGCTGCGGCAAGTAAACGACAAGGCGCAGTACCTGCTGGGCGCCGCTGGCAGCGTTCCTATcGATGG
15 ATCAATCTGGAATACGACAAGATAACCCGGATCGTGGGCTGGATCAGTACCTGGAGAGCGTTAAGAAACACAAACGGC
TGGATGTGTGCCGCGCTAAATGGGCTATATGCTGCAGTGA

HCMV UL130Amino acid (SEQ ID NO: 39):

MLRLLLRHHFHCLLLCAVWATPCLASPWSTLTANQNPSPPWSKLTYSKPHDAATFYCPFLYSPPRSPQLQFSGFQRVSTGPECR
20 NETLYLLYNREGQTLVERSSTWVKKVIWYLSGRNQTLQRMPTASKPSDGNVQISVEDAKIFGAHMPVKQTKLLRFVNDGT
RYQMCVMKLESWAHVFRDYSVSFQVRLTFTEANNQTYTFCTHPNLIVGGGSGGGSGGGSGGGSEPEA

DNA (incl. STOP) (SEQ ID NO: 40):

ATGCTGCGGCTTCTGCTTCGTCACTTTCACTGCCTGCTTCTGTGCGCGGTTTGGGCAACGCCCTGTCTGGCGTCTCCGT
GGTCGACGCTAACAGCAAACAGAAATCCGTCCCCGCCATGGTCTAACTGACGTATTCAAACCGCATGACGCGGCGACG
25 TTTTACTGTCTTTTCTCTATCCCTCGCCCCACGATCCCCCTTGCAATTCTCGGGGTTCAGCGGGTATCAACGGGTCCCG
AGTGTGCAACGAGACCCTGTATCTGCTGTACAACCGGAAGGCCAGACCTTGGTGGAGAGAAGCTCCACCTGGGTGAA
AAAGGTGATCTGGTACCTGAGCGGTCGGAACCAACCATCCTCCAACGGATGCCCGAACGGCTTCGAAACCGAGCGAC
GGAAACGTGCAGATCAGCGTGGAAGACGCCAAGATTTTGGAGCGCACATGGTGCCCAAGCAGACCAAGCTGCTACGCT
TCGTCGTCACGATGGCACACGTTATCAGATGTGTGTGATGAAGCTGGAGAGCTGGGCTCACGTCTTCCGGGACTACAGC
30 GTGTCTTTTCAAGTGCGATTGACGTTACCGAGGCCAATAACCAGACTTACACCTTCTGCACCCATCCCAATCTCATCGTTG
GAGGCGGAGGATCTGGCGGAGGTGGAAGTGGCGGAGGCGGATCTGAGCCCAGGCCTAA

Peptides (solid phase synthesized – amino acid sequences only):**SnoopTagJr-hTERT (SEQ ID NO: 41):** GKLGSIEFIKVNKGEARPALLTSRLRFIPK**SnoopTagJr-GGS-SIINFEKL (PEP1) (SEQ ID NO: 42):** GKLGSIEFIKVNKGGSSIIINFEKL**SnoopTagJr-AAI-SIINFEKL (PEP2) (SEQ ID NO: 43):** GKLGSIEFIKVNKGAAYSIIINFEKL5 **Biotin-SnoopTagJr (SEQ ID NO: 44):** Biotin-GKLGSIEFIKVNK (N-terminal biotin)**Biotin-SpyTag003 (SEQ ID NO: 45):** Biotin-GSRGVPHIVMVDAYKRYK (N-terminal biotin)**Modified adenovirus sequences:****Ad5-pIX-SpyCatcher sequences****Ad5-pIX-SpyCatcher (no linker) pIX sequence**10 **Amino acid (SEQ ID NO: 46):**

MSTNSFDGSIVSSYLTRMPPWAGVRQNVMGSSIDGRPVL PANSTTLTYETVSGTPLETAASAAASAAAATARGIVTDF AFLSP
 LASSAASRSSARDDKLTALLAQLDSL TRELVVVSQQLDLRQQVSALKASSPPNAVDSATHIKFSKRDE DGKELAGATMELRDSS
 GKTISTWISDGQVKDFLYPGKYTFVETAAPDGYEVATAITFTVNEQGQVTVNGKATKGDAHI

DNA (incl. STOP) (SEQ ID NO: 47):

15 ATGAGCACCAACTCGTTTGATGGAAGCATTGTGAGCTCATATTTGACAACGCGCATGCCCCATGGGCCGGGGTGCGTCA
 GAATGTGATGGGCTCCAGCATTGATGGTCGCCCCGCTCTGCCCGCAAACCTCTACTACCTTGACCTACGAGACCGTGTCTGG
 AACGCCGTTGGAGACTGCAGCCTCCGCCGCCGCTTACGCCGCTGCAGCCACCGCCCGCGGATTGTGACTGACTTTGCTT
 TCCTGAGCCCGCTTGCAAGCAGTGAGCTTCCCGTTTATCCGCCGCGATGACAAGTTGACGGCTCTTTGGCACAATTGG
 ATTCTTTGACCCGGGAACCTTAATGTCGTTTCTCAGCAGCTGTTGGATCTGCGCCAGCAGGTTTCTGCCCTGAAGGCTTCCTC
 20 CCTCCCAATGCGGTTGACAGCGCCACACATCAAGTTGACGAAGAGAGATGAGGACGGCAAGAGCTGGCTGGCGCA
 ACAATGGAAGTGAAGATAGCAGCGGCAAGACCATCAGCACTGGATCTCCGACGGCCAAGTGAAGGACTTCTATCTGT
 ACCCCGGCAAGTACACCTTCGTGGAAACCGCCGCTCCTGACGGATATGAAGTGGCCACCGCCATCACCTTCACCGTGAAT
 GAGCAGGGACAAGTGACCGTGAACGGCAAGGCCACAAAAGGCGACGCCACATTTAA

Ad5-pIX-SpyCatcher (EAAAK3-GS linker) pIX sequence25 **Amino acid (SEQ ID NO: 48):**

MSTNSFDGSIVSSYLTRMPPWAGVRQNVMGSSIDGRPVL PANSTTLTYETVSGTPLETAASAAASAAAATARGIVTDF AFLSP
 LASSAASRSSARDDKLTALLAQLDSL TRELVVVSQQLDLRQQVSALKASSPPNAVEAAAKEAAKEAAKGS DSATHIKFSKRD
 EDGKELAGATMELRDSSGKTISTWISDGQVKDFLYPGKYTFVETAAPDGYEVATAITFTVNEQGQVTVNGKATKGDAHI

DNA (incl. STOP) (SEQ ID NO: 49):

30 ATGAGCACCAACTCGTTTGATGGAAGCATTGTGAGCTCATATTTGACAACGCGCATGCCCCATGGGCCGGGGTGCGTCA
 GAATGTGATGGGCTCCAGCATTGATGGTCGCCCCGCTCTGCCCGCAAACCTCTACTACCTTGACCTACGAGACCGTGTCTGG

AACGCCGTTGGAGACTGCAGCCTCCGCCGCCGCTTCAGCCGCTGCAGCCACCGCCCGGGATTGTGACTGACTTTGCTT
 TCCTGAGCCCGCTTGCAAGCAGTGACGCTTCCCGTTTCATCCGCCGCGATGACAAGTTGACGGCTCTTTGGCACAATTGG
 ATTCTTTGACCCGGAACTTAATGTCGTTTCTCAGCAGCTGTTGGATCTGCGCCAGCAGGTTTCTGCCCTGAAGGCTTCCTC
 CCTCCCAATGCGGTTGAAGCCGCCGCTAAAGAAGCTGCTGCCAAAGAGGCCGCTGCAAAGggatccGACAGCGCCACAC
 5 ACATCAAGTTGACGAAGAGAGATGAGGACGGCAAAGAGCTGGCTGGCGCAACAATGGAAGTGAAGATAGCAGCGGCA
 AGACCATCAGCACCTGGATCTCCGACGGCCAAGTGAAGGACTTCTATCTGTACCCCGCAAGTACACCTTCGTGGAAACC
 GCCGCTCCTGACGGATATGAAGTGGCCACCGCCATCACCTTCACCGTGAATGAGCAGGGACAAGTGACCGTGAACGGCA
 AGGCCACAAAAGGCGACGCCACATTAA

Ad5-pIX-SpyCatcher (GGG-EAAA3 linker) pIX sequence

10 Amino acid (SEQ ID NO: 50):

MSTNSFDGSIVSSYLTRMPPWAGVRQNVMSGIDGRPVLPANSTTLTYETVSGTPLETAASAAASAAAATARGIVTDFAFSLP
 LASSAASRSSARDKLTALLAQLDSLRELNVSQQLDLRQQVSALKASSPPNAVGGSEAAAKEAAAKEAAAKDSATHIKFSKR
 DEDGKELAGATMELRDSSGKTISTWISDGQVKDFLYPGKYTFVETAAPDGYEVATAITFTVNEQGQVTVNGKATKGAHI

DNA (incl. STOP) (SEQ ID NO: 51):

15 ATGAGCACCAACTCGTTTGATGGAAGCATTGTGAGCTCATATTTGACAACGCGCATGCCCCATGGGCCGGGGTGCCTCA
 GAATGTGATGGGCTCCAGCATTGATGGTCGCCCCGCTGCGCCGAACTCTACTACCTTGACCTACGAGACCGTGTCTGG
 AACGCCGTTGGAGACTGCAGCCTCCGCCGCCGCTTCAGCCGCTGCAGCCACCGCCCGGGATTGTGACTGACTTTGCTT
 TCCTGAGCCCGCTTGCAAGCAGTGACGCTTCCCGTTTCATCCGCCGCGATGACAAGTTGACGGCTCTTTGGCACAATTGG
 ATTCTTTGACCCGGAACTTAATGTCGTTTCTCAGCAGCTGTTGGATCTGCGCCAGCAGGTTTCTGCCCTGAAGGCTTCCTC
 20 CCTCCCAATGCGGTTGGAaggctccGAAGCCGCCGCTAAAGAAGCTGCTGCCAAAGAGGCCGCTGCAAAGGACAGCGCCA
 CACACATCAAGTTCAGCAAGAGAGATGAGGACGGCAAAGAGCTGGCTGGCGCAACAATGGAAGTGAAGATAGCAGCG
 GCAAGACCATCAGCACCTGGATCTCCGACGGCCAAGTGAAGGACTTCTATCTGTACCCCGCAAGTACACCTTCGTGGAA
 ACCGCCGCTCCTGACGGATATGAAGTGGCCACCGCCATCACCTTCACCGTGAATGAGCAGGGACAAGTGACCGTGAACG
 GCAAGGCCACAAAAGGCGACGCCACATTAA

25 **Ad5-pIX-SpyCatcher (EAAA3 linker, no GGS or GS hinges) pIX sequence**

Amino acid (SEQ ID NO: 52):

MSTNSFDGSIVSSYLTRMPPWAGVRQNVMSGIDGRPVLPANSTTLTYETVSGTPLETAASAAASAAAATARGIVTDFAFSLP
 LASSAASRSSARDKLTALLAQLDSLRELNVSQQLDLRQQVSALKASSPPNAVEAAAKEAAAKEAAAKDSATHIKFSKRDED
 GKELAGATMELRDSSGKTISTWISDGQVKDFLYPGKYTFVETAAPDGYEVATAITFTVNEQGQVTVNGKATKGAHI

30 DNA (incl. STOP) (SEQ ID NO: 53):

ATGAGCACCAACTCGTTTGATGGAAGCATTGTGAGCTCATATTTGACAACGCGCATGCCCCATGGGCCGGGGTGCCTCA
 GAATGTGATGGGCTCCAGCATTGATGGTCGCCCCGCTGCGCCGAACTCTACTACCTTGACCTACGAGACCGTGTCTGG
 AACGCCGTTGGAGACTGCAGCCTCCGCCGCCGCTTCAGCCGCTGCAGCCACCGCCCGGGATTGTGACTGACTTTGCTT
 TCCTGAGCCCGCTTGCAAGCAGTGACGCTTCCCGTTTCATCCGCCGCGATGACAAGTTGACGGCTCTTTGGCACAATTGG

ATTCTTTGACCCGGAACCTTAATGTCGTTTCTCAGCAGCTGTTGGATCTGCGCCAGCAGGTTTCTGCCCTGAAGGCTTCCTC
 CCCTCCCAATGCGGTTGAAGCCGCCGCTAAAGAAGCTGCTGCCAAAGAGGCCGCTGCAAAGGACAGCGCCACACATC
 AAGTTCAGCAAGAGAGATGAGGACGGCAAAGAGCTGGCTGGCGCAACAATGGAAGTGAAGATAGCAGCGGCAAGAC
 CATCAGCACCTGGATCTCCGACGGCCAAGTGAAGGACTTCTATCTGTACCCCGCAAGTACACCTTCGTGGAAACCGCCG
 5 CTCCTGACGGATATGAAGTGGCCACCGCCATCACCTTACCCTGTAATGAGCAGGGACAAGTGACCGTGAACGGCAAGGC
 CACAAAAGGCGACGCCACATTTAA

Ad5-pIX-SpyCatcher (GG5-EAAAK5-GS linker) pIX sequence

Amino acid (SEQ ID NO: 54):

10 MSTNSFDGSIVSSYLTRMPWAGVRQNVMGSSIDGRPVL PANSTTLTYETVSGTPLETAASAAASAAAATARGIVTDF AFLSP
 LASSAASRSSARDDKLTALLAQLDSLRELVVVSQQLDLRQQVSALKASSPPNAVGGSEAAAKEAAAKEAAAKEAAAKEAAK
 GSDSATHIKFSKRDEDGKELAGATMELRDSSGKTISTWISDGQVKDFLYPGKYTFVETAAPDGYEVATAITFTVNEQGQVTVN
 GKATKGDAHI

DNA (incl. STOP) (SEQ ID NO: 55):

15 ATGAGCACCAACTCGTTTGATGGAAGCATTGTGAGCTCATATTTGACAACGCGCATGCCCCATGGGCCGGGGTGCGTCA
 GAATGTGATGGGCTCCAGCATTGATGGTCGCCCCGCTCTGCCGCAAACCTCTACTACCTTGACCTACGAGACCGTGTCTGG
 AACGCCGTTGGAGACTGCAGCCTCCGCCGCCGCTTCAGCCGCTGCAGCCACCGCCCGCGGGATTGTGACTGACTTTGCTT
 TCCTGAGCCCGCTTGAAGCAGTGCAGCTTCCCGTTTCATCCGCCCGCGATGACAAGTTGACGGCTCTTTTGGACAATTGG
 ATTCTTTGACCCGGAACCTTAATGTCGTTTCTCAGCAGCTGTTGGATCTGCGCCAGCAGGTTTCTGCCCTGAAGGCTTCCTC
 20 CCCTCCCAATGCGGTTGGAGGCTCCGAAGCCGCCGCTAAAGAAGCTGCTGCCAAAGAGGCCGCTGCAAAGGAGGCCGCA
 GCTAAGGAAGCCGCCGCTAAGGGATCCGACAGCGCCACACATCAAGTTCAGCAAGAGAGATGAGGACGGCAAAGAG
 CTGGCTGGCGCAACAATGGAAGTGAAGATAGCAGCGGCAAGACCATCAGCACCTGGATCTCCGACGGCCAAGTGAAG
 GACTTCTATCTGTACCCCGCAAGTACACCTTCGTGGAAACCGCCGCTCTGACGGATATGAAGTGGCCACCGCCATCACC
 TTCACCGTGAATGAGCAGGGACAAGTGACCGTGAACGGCAAGGCCACAAAAGGCGACGCCACATTTAA

25 **Ad5-pIX-SpyCatcher(deltaN1deltaC2) pIX sequence**

Amino acid (SEQ ID NO: 56):

MSTNSFDGSIVSSYLTRMPWAGVRQNVMGSSIDGRPVL PANSTTLTYETVSGTPLETAASAAASAAAATARGIVTDF AFLSP
 LASSAASRSSARDDKLTALLAQLDSLRELVVVSQQLDLRQQVSALKASSPPNAVGGSEAAAKEAAAKEAAAKGSDSATHIKFS
 KRDEDGKELAGATMELRDSSGKTISTWISDGQVKDFLYPGKYTFVETAAPDGYEVATAITFTVNEQGQVTVNG

30 DNA (incl. STOP) (SEQ ID NO: 57):

ATGAGCACCAACTCGTTTGATGGAAGCATTGTGAGCTCATATTTGACAACGCGCATGCCCCATGGGCCGGGGTGCGTCA
 GAATGTGATGGGCTCCAGCATTGATGGTCGCCCCGCTCTGCCGCAAACCTCTACTACCTTGACCTACGAGACCGTGTCTGG
 AACGCCGTTGGAGACTGCAGCCTCCGCCGCCGCTTCAGCCGCTGCAGCCACCGCCCGCGGGATTGTGACTGACTTTGCTT
 TCCTGAGCCCGCTTGAAGCAGTGCAGCTTCCCGTTTCATCCGCCCGCGATGACAAGTTGACGGCTCTTTTGGACAATTGG

ATTCTTTGACCCGGAACTTAATGTCGTTTCTCAGCAGCTGTTGGATCTGCGCCAGCAGGTTTCTGCCCTGAAGGCTTCCTC
CCCTCCCAATGCGGTTGGAggctccGAAGCCGCCGCTAAAGAAGCTGCTGCCAAAGAGGCCGCTGCAAAGggatccGACAGC
GCCACCCACATCAAGTTCAGCAAGAGGGACGAGGACGGCAAGGAGCTGGCCGGCGCAACAATGGAGCTGAGGGACAGC
AGCGGCAAGACCATCAGCACCTGGATCAGCGACGGCCAGGTGAAGGACTTCTACCTGTACCCCGCAAGTACACCTTCGT
5 GGAGACCGCCGCCCGGACGGCTACGAGGTGGCCACCGCCATCACCTTACCCTGAACGAGCAGGGCCAGGTGACCGTG
AACGGCTAA

Ad5-pIX-SnoopCatcher sequences

Ad5-pIX-SnoopCatcher pIX sequence

Amino acid (SEQ ID NO: 58):

10 MSTNSFDGSIVSSYLTRMPWAGVRQNVMGSSIDGRPVL PANSTTLTYETVSGTPLETAASAAASAAAATARGIVTDF AFLSP
LASSAASRSSARDDKLTALLAQLDSL TRELVVSQQLDLRQQVSALKASSPPNAVGGSEAAAKEAAAKEAAKGS HMKPLRG
AVFSLQKQHPDYPDIYGAIDQNGTYQNVRTGEDGKLT FKNLSDGKYRLFENSEPAGYKPVQNKPIVAFQIVN GEVRDVT SIVPQ
DIPATYEFTNGKH YITNEPIPPK

DNA (incl. STOP) (SEQ ID NO: 59):

15 ATGAGCACCAACTCGTTTGATGGAAGCATTGTGAGCTCATATTTGACAACGCGCATGCCCCATGGGCGGGGGTGCGTCA
GAATGTGATGGGCTCCAGCATTGATGGTCGCCCCGCTGCGCCGAACTCTACTACCTTGACCTACGAGACCGTGTCTG
AACGCCGTTGGAGACTGCAGCCTCCGCCGCCGCTTCAGCCGCTGCAGCCACGCCCGCGGGATTGTGACTGACTTTGCTT
TCCTGAGCCCGCTTGAAGCAGTGCAGCTTCCCGTTTCATCCGCCCGCGATGACAAGTTGACGGCTCTTTTGGCACAATTGG
ATTCTTTGACCCGGAACTTAATGTCGTTTCTCAGCAGCTGTTGGATCTGCGCCAGCAGGTTTCTGCCCTGAAGGCTTCCTC
20 CCCTCCCAATGCGGTTGGAggctccGAAGCCGCCGCTAAAGAAGCTGCTGCCAAAGAGGCCGCTGCAAAGggatccCACATG
AAGCCCCTGAGGGGCGCCGTTCAGCCTGCAGAAGCAGCACCCCGACTACCCCGACATCTACGGCGCCATCGACCAGA
ACGGCACCTACCAGAACGTGAGGACCGGCGAGGACGGCAAGCTGACCTTCAAGAACCTGAGCGACGGCAAGTACAGGC
TGTTGAGAACAGCGAGCCCGCCGGCTACAAGCCCGTGAGAACAAGCCATCGTGGCCTTCAGATCGTGAACGGCGA
GGTGAGGGACGTGACCAGCATCGTGCCCCAGGACATCCCCGCCACCTACGAGTTCACCAACGGCAAGCACTACATCACCA
25 ACGAGCCCATCCCCCAAGTAA

Ad5-pIX-DogCatcher sequences

Ad5-pIX-DogCatcher pIX sequence

Amino acid (SEQ ID NO: 60):

30 MSTNSFDGSIVSSYLTRMPWAGVRQNVMGSSIDGRPVL PANSTTLTYETVSGTPLETAASAAASAAAATARGIVTDF AFLSP
LASSAASRSSARDDKLTALLAQLDSL TRELVVSQQLDLRQQVSALKASSPPNAVGGSEAAAKEAAAKEAAKGS LKGLDIEFIK
VNKNDKKPLRGAVFSLQKQHPDYPDIYGAIDQNGTYQNVRTGEDGKLT FKNLSDGKYRLFENSEPAGYKPVQNKPIVAFQIVN
GEVRDVT SIVPQ

DNA (incl. STOP) (SEQ ID NO: 61):

ATGAGCACCAACTCGTTTGATGGAAGCATTGTGAGCTCATATTTGACAACGCGCATGCCCCATGGGCCGGGGTGCGTCA
GAATGTGATGGGCTCCAGCATTGATGGTCGCCCCGCTGCCCCGAACTCTACTACCTTGACCTACGAGACCGTGTCTGG
AACGCCGTTGGAGACTGCAGCCTCCGCCGCCGCTTCAGCCGCTGCAGCCACCGCCCGGGGATTGTGACTGACTTTGCTT
5 TCCTGAGCCCGCTTGCAAGCAGTGCAGCTTCCCGTTTCATCCGCCGCGATGACAAGTTGACGGCTCTTTGGCACAATTGG
ATTCTTTGACCCGGAACTTAATGTCGTTTCTCAGCAGCTGTTGGATCTGCGCCAGCAGGTTTCTGCCCTGAAGGCTTCCTC
CCCTCCAATGCGGTTGGAggctccGAAGCCGCCGCTAAAGAAGCTGCTGCCAAAGAGGCCGCTGCAAAGggatccAACTG
GGCGATATTGAATTTATTAAAGTGAACAAAAACGATAAAAAGCCGCTGCGTGGTGCCGTGTTAGCCTGCAGAAACAGCA
TCCCGACTATCCCGATATCTATGGCGGATTGATCAGAATGGGACCTATCAAAATGTGCGTACCGGCGAAGATGGTAAAC
10 TGACCTTTAAGAATCTGAGCGATGGCAAATATCGCTGTTTGAAAATAGCGAACCCGCTGGCTATAAACCGGTGCAGAAT
AAGCCGATTGTGGCGTTTCAGATTGTGAATGGCGAAGTGCCTGATGTGACCAGCATTGTGCCGCAGTAA

Ad5-pIX-SpyTag sequencesAd5-pIX-SpyTag pIX sequenceAmino acid (SEQ ID NO: 62):

15 MSTNSFDGSIVSSYLTRMPPWAGVRQNVMGSSIDGRPVL PANSTTLTYETVSGTPLETAASAAASAAAATARGIVTDF AFLSP
LASSAASRSSARDDKLTALLAQLDSL TRELNVSQQLDLRQQVSALKASSPPNAVGGSEAAAKEAAAKEAAKGS AHIVMVD
AYKPTK

DNA (incl. STOP) (SEQ ID NO: 63):

ATGAGCACCAACTCGTTTGATGGAAGCATTGTGAGCTCATATTTGACAACGCGCATGCCCCATGGGCCGGGGTGCGTCA
20 GAATGTGATGGGCTCCAGCATTGATGGTCGCCCCGCTGCCCCGAACTCTACTACCTTGACCTACGAGACCGTGTCTGG
AACGCCGTTGGAGACTGCAGCCTCCGCCGCCGCTTCAGCCGCTGCAGCCACCGCCCGGGGATTGTGACTGACTTTGCTT
TCCTGAGCCCGCTTGCAAGCAGTGCAGCTTCCCGTTTCATCCGCCGCGATGACAAGTTGACGGCTCTTTGGCACAATTGG
ATTCTTTGACCCGGAACTTAATGTCGTTTCTCAGCAGCTGTTGGATCTGCGCCAGCAGGTTTCTGCCCTGAAGGCTTCCTC
CCCTCCAATGCGGTTGGAGGCTCCGAAGCCGCCGCTAAAGAAGCTGCTGCCAAAGAGGCCGCTGCAAAGGGATCCGCC
25 CACATCGTTATGGTGGATGCCTACAAGCCACCAAATAA

Ad5-pIX-SnoopTagJr sequencesAd5-pIX-SnoopTagJr pIX sequenceAmino acid (SEQ ID NO: 64):

30 MSTNSFDGSIVSSYLTRMPPWAGVRQNVMGSSIDGRPVL PANSTTLTYETVSGTPLETAASAAASAAAATARGIVTDF AFLSP
LASSAASRSSARDDKLTALLAQLDSL TRELNVSQQLDLRQQVSALKASSPPNAVGGSEAAAKEAAAKEAAKGS KLGSIEFIK
V NK

DNA (incl. STOP) (SEQ ID NO: 65):

ATGAGCACCAACTCGTTTGATGGAAGCATTGTGAGCTCATATTTGACAACGCGCATGCCCCATGGGCCGGGGTGCGTCA
GAATGTGATGGGCTCCAGCATTGATGGTCGCCCCGCTGCCCCGAACTCTACTACCTTGACCTACGAGACCGTGTCTGG

AACGCCGTTGGAGACTGCAGCTCCGCCGCCGCTTCAGCCGCTGCAGCCACCGCCCGGGATTGTGACTGACTTTGCTT
 TCCTGAGCCCGCTTGAAGCAGTGACGCTTCCCGTTCATCCGCCGCGATGACAAGTTGACGGCTCTTTGGCACAATTGG
 ATTCTTTGACCCGGAACTTAATGTCGTTTCTCAGCAGCTGTTGGATCTGCGCCAGCAGGTTTCTGCCCTGAAGGCTTCCTC
 CCTCCCAATGCGGTTGGAGGCTCCGAAGCCGCCGCTAAAGAAGCTGCTGCCAAAGAGGCCGCTGCAAAGGGATCCaaac
 5 tgggctctattgaattattaaagtgaacaaaTAA

Ligands for capsid decoration described in this application:

Recombinant Proteins:

SARS CoV2 Spike-SnoopTagJr

Amino acid (SEQ ID NO: 66):

10 MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFAIHVSGTNGTKRFDNPVLP
 FNDGVYFASTEKSNIIIRGWIFGTTLDSTQSLIVNNATNVVIVKCEFCNDPFLGVVYHKNNKSWMESEFRVYSSANNCTFEY
 VSQPFLLDLEGKQGNFKNLREFVFNIDGYFKIYKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLALHRSYLTTPGDSSSG
 WTAGAAAYYVGYLQPRFTLLKYNENGTITDAVDCALDPLSETKCTLSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFN
 ATRFASVYAWNRRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVQRQIAPGQGTGKIADYNYKLPDD
 15 FTGCVIAWNSNNLDSKVGNNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYPYRVVV
 LSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTEILDITPCSGGVSVI
 TPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSEYCDIPIGAGICASYQTQTNSP
 GSASSVASQSIAYTMSLGAENSVAYSNNISAIPTNFTISVTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALT
 GIAVEQDKNTQEVFAQVKQYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKF
 20 NGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLS
 STASALGKLQDVVNQNAQALNTLVKQLSSNFGAIVSSVNDILSRDLPPEAEVQIDRLITGRQLSLQTYVTQQLIRAAEIRASANLA
 ATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFHTTAPAICHGKAHFPREGVFSNGTHWFVTQ
 RNFYEPQIITDNTFVSGNCDVVIGVNNNTVYDPLQPELDSFKEELDKYFKNHTSPDVLGDISGINASVVNIQKIDRLNEVAKN
 LNESLIDLQELGKYEQSGSIVQQQNNLLRAIEAQHLLQLTVWGKQLQARILAGGSGGHTTWMEWDREINNYTSLIHSLIEES
 25 QNQQEKNEQELLEGGSGKLSIEFIKVNKEPEA

DNA (incl. STOP) (SEQ ID NO: 67):

ATGTTTCGTGTTTCTGGTGCTGCTGCCTCTGGTGTCCAGCCAGTGTGTGAACCTGACCACCAGAACACAGCTGCCTCCAGCC
 TACACCAACAGCTTTACCAGAGGCGTGACTACCCGACAAGGTGTTTCAGATCCAGCGTGCTGCACTCTACCCAGGACCTG
 TTCCTGCCTTTCTTCAGCAACGTGACCTGGTTCCACGCCATCCAGTGTCCGGCACCAATGGCACCAAGAGATTTCGACAAC
 30 CCCGTGCTGCCCTTCAACGACGGGGTGACTTTGCCAGCACCGAGAAGTCCAACATCATCAGAGGCTGGATCTTCGGCAC
 CAACTGGACAGCAAGACCCAGAGCTGCTGATCGTGAACAACGCCACCAACGTGGTCATCAAAGTGTGCGAGTTCCAGT
 TCTGCAACGACCCCTTCTGGGCGTCTACTACCACAAGAACAACAAGAGCTGGATGGAAGCGAGTCCGGGTGTACAGC
 AGCGCCAACAACTGCACCTTCGAGTACGTGTCCAGCCTTCTCTGATGGACCTGGAAGGCAAGCAGGGCAACTTCAAGAA
 CCTGCGCGAGTTCTGTGTTCAAGAACATCGACGGCTACTTCAAGATCTACAGCAAGCACACCCCTATCAACCTCGTGGGG
 35 ATCTGCCTCAGGGCTTCTCTGCTCTGGAACCCCTGGTGGATCTGCCATCGGCATCAACATCACCCGGTTTCAGACACTGC

TGGCCCTGCACAGAAGCTACCTGACACCTGGCGATAGCAGCAGCGGATGGACAGCTGGTGCCGCCGCTTACTATGTGGG
CTACCTGCAGCCTAGAACCTTCCTGCTGAAGTACAACGAGAACGGCACCATCACCGACGCCGTGGATTGTGCTCTGGATC
CTCTGAGCGAGACAAAGTGACCCCTGAAGTCCTTCACCGTGAAAAAGGGCATCTACCAGACCAGCAACTCCGGGTGCAG
CCCACCGAATCCATCGTGCGGTTCCCCAATATACCAATCTGTGCCCTTCGGCGAGGTGTTCAATGCCACCAGATTGCC
5 TCTGTGTACGCTGGAACCGGAAGCGGATCAGCAATTGCGTGGCCGACTACTCCGTGCTGTACAACCTCCGCCAGCTTCAG
CACCTTCAAGTGCTACGGCGTGTCCTACCAAGCTGAACGACCTGTGCTTCACAAACGTGTACGCCGACAGCTTCGTGAT
CCGGGGAGATGAAGTGCGGCAGATTGCCCTGGACAGACAGGCAAGATCGCCGACTACAACCTACAAGCTGCCCCGACGAC
TTCACCGGTGTGTGATTGCTGGAACAGCAACAACCTGGACTCCAAAGTCGGCGGCAACTACAATTACCTGTACCGGT
GTTCCGGAAGTCCAATCTGAAGCCCTTCGAGCGGGACATCTCCACCGAGATCTATCAGGCCGGCAGACCCCTTGTAAACG
10 GCGTGGAAGGCTTCAACTGCTACTTCCACTGCAGTCTACGGCTTCAGCCACAAATGGCGTGGGCTATCAGCCCTACA
GAGTGGTGGTGCTGAGCTTCGAACTGCTGATGCCCTGCCACAGTGTGCGGCCCTAAGAAAAGCACAATCTCGTGAAG
AACAAATGCGTGAACCTTCAACTTCAACGGCCTGACCGGCACCGGCGTGTGACAGAGAGCAACAAGAAGTTCCTGCCATT
CCAGCAGTTTGCCGGGATATCGCCGATACACAGACGCCGTAGAGATCCCCAGACACTGGAAATCCTGGACATCACCC
CTTGACGCTTCGGCGGAGTGTCTGTGATACCCCTGGCACCAACACCAGCAATCAGGTGGCAGTGTGTACCAGGACGTG
15 AACTGTACCGAAGTGCCCGTGGCCATTACGCCGATCAGCTGACACCTACATGGCGGGTGTACTCCACCGGCAGCAATGT
GTTTCAGACCAGAGCCGGCTGTCTGATCGGAGCCGAGCACGTGAACAATAGCTACGAGTGCGACATCCCCATCGGCGCT
GGCATCTGTGCCAGCTACCAGACAGACAAACAGCCCTGGCAGCGCCTCTTCTGTGGCCAGCCAGAGCATATTGCCTA
CACAATGTCTCTGGGCGCCGAGAACAGCGTGGCCTACTCCAACAACTCTATCGCTATCCCCACCAACTTCACCATCAGCGT
GACCACAGAGATCCTGCCTGTGTCCATGACCAAGACCAGCGTGGACTGCACCATGTACATCTGCGGCGATTCCACCGAGT
20 GCTCCAACCTGTGCTGCTGAGTACGGCAGCTTCTGCACCCAGCTGAATAGAGCCCTGACAGGGATCGCCGTGGAACAGGAC
AAGAACACCCAAGAGGTGTTGCCCAAGTGAAGCAGATCTACAAGACCCCTCCTATCAAGGACTTCGGCGGCTTCAATTT
CAGCCAGATTCTGCCCAGTCTAGCAAGCCCAGCAAGCGGAGCTTCATCGAGGACCTGCTGTTCAACAAAGTGACACTGG
CCGACGCCGGCTTCATCAAGCAGTATGGCGATTGTCTGGGCGACATTGCCGCCAGGGATCTGATTGCGCCCAAGATTT
AACGGAAGTACAGTGTGCTCCTCTGCTGACCGATGAGATGATCGCCAGTACACATCTGCCCTGCTGGCCGGCACAAT
25 CACAAGCGGCTGGACATTTGAGCTGGCGCCGCTCTGCAGATCCCCTTTGCTATGCAGATGGCCTACAGGTTCAACGGCA
TCGGAGTGACCCAGAATGTGCTGTACGAGAACCAGAAGCTGATCGCCAACCAAGTTCAACAGCGCCATCGGCAAGATCCA
GGACAGCCTGAGCAGCACAGCAAGCGCCCTGGGAAAGCTGCAGGACGTGGTCAACCAGAATGCCAGGCACTGAACAC
CCTGGTCAAGCAGCTGTCTCCAACCTCGGCGCCATCAGCTCTGTGCTGAACGATATCCTGAGCAGACTGGACCCTCCTGA
GGCCGAGGTGACAGATCGACAGACTGATCACAGGCAGACTGCAGAGCCTCCAGACATACGTGACCCAGCAGCTGATCAGA
30 GCCGCCGAGATTAGAGCCTCTGCCAATCTGGCCGCCACCAAGATGTCTGAGTGTGTGCTGGGCCAGAGCAAGAGAGTGG
ACTTTTGGCGCAAGGGCTACCACCTGATGAGCTTCCCTCAGTCTGCCCTCACGGCGTGGTGTCTGTGACGTGACATATG
TGCCCGCTCAAGAGAAGAATTTACCAACCCCTCCAGCCATCTGCCACGACGGCAAAGCCCACTTCTAGAGAAGGCGTG
TTCGTGTCCAACGGCACCCATTGGTTCGTGACACAGCGGAACCTTACGAGCCCCAGATCATCACCACCGACAACACCTTC
GTGTCTGGCAACTGCGACGTGCTGATCGGCATTGTGAACAATACCGTGTACGACCCTCTGCAGCCCCGAGCTGGACAGCTT
35 CAAAGAGGAACTGGACAAGTACTTTAAGAACCACACAAGCCCCGACGTGGACCTGGGCGATATCAGCGGAATCAATGCC
AGCGTCGTGAACATCCAGAAAGAGATCGACCGGTGAACGAGGTGGCCAAGAATCTGAACGAGAGCCTGATCGACCTGC

AAGAACTGGGGAAGTACGAGCAAGGCTCTGGAATTGTGCAGCAGCAAAACAATCTGCTGCGGGCCATCGAGGCTCAGCA
GCATCTGCTGCAGCTGACCGTGTGGGGAATCAAGCAGCTCCAGGCCAGAATCCTGGCTGGTGGATCTGGCGGCCATACC
ACCTGGATGGAATGGGACAGAGAGATCAACAACCTACCCAGCCTGATCCACAGCCTGATTGAGGAATCCCAGAATCAGC
AAGAGAAGAACGAGCAAGAACTGCTGGAAGGAAGCGGAGGCTCTGGTaaactgggctctattgaatttataaagtgaacaaaGAGC
5 CCGAAGCCTAA

SARS CoV2 Spike RBD-SnoopTagJr

Amino acid (SEQ ID NO: 68):

MFVFLVLLPLVSSQCRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRRKRISNCVADYSVLNSASFSTFKCYGVSP TKLND
LCFTNVYADSFVIRGDEV RQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKP FERDISTEIYQ
10 AGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVLSFELLHAPATVCGPKKSTNGSGGSGKLGSIEFIKVNKEPEA

DNA (incl. STOP) (SEQ ID NO: 69):

ATGTTTCGTGTTTCTGGTGCTGCTGCCTCTGGTGTCCAGCCAGTGTGGGTGCAGCCCACCGAATCCATCGTGGGTTCCCC
AATATACCAATCTGTGCCCCCTTCGGCGAGGTGTTCAATGCCACCAGATTGCGCTCTGTGTACGCCTGGAACCGGAAGCG
GATCAGCAATTGCGTGGCCGACTACTCCGTGCTGTACAACCTCCGCCAGCTTCAGCACCTTCAAGTGCTACGGCGTGTCCCC
15 TACCAAGCTGAACGACCTGTGCTTCACAAACGTGTACGCCGACAGCTTCGTGATCCGGGGAGATGAAGTGCGGCAGATT
GCCCCCTGGACAGACAGGCAAGATCGCCGACTACAACCTACAAGCTGCCCGACGACTTCACCGGCTGTGTGATTGCCTGGAA
CAGCAACAACCTGGACTCCAAAGTCGGCGGCAACTACAATTACCTGTACCGGCTGTTCCGGAAGTCCAATCTGAAGCCCTT
CGAGCGGGACATCTCCACCGAGATCTATCAGGCCGGCAGCACCCCTTGTAAACGGCGTGGAAGGCTTCAACTGCTACTTCC
CACTGCAGTCTACGGCTTTCAGCCCAAAATGGCGTGGGCTATCAGCCCTACAGAGTGGTGGTGTGAGCTTCAAGCTG
20 CTGCATGCCCTGCCACAGTGTGCGGCCCTAAGAAAAGCACCAATGGAAGCGGAGGCTCTGGTaaactgggctctattgaattta
ttaaagtgaacaaaGAGCCCGAAGCCTAA

SARS CoV2 Spike RBD-SnoopCatcher

Amino acid (SEQ ID NO: 70):

MFVFLVLLPLVSSQCRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRRKRISNCVADYSVLNSASFSTFKCYGVSP TKLND
25 LCFTNVYADSFVIRGDEV RQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKP FERDISTEIYQ
AGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVLSFELLHAPATVCGPKKSTNGSGGSGGSGGSGHMKPLRGAVFSL
QKQHPDYPDIYG AIDQNGTYQNVRTGEDGKLT FKNLSDGKYRLFENSEPAGYKPVQNKPIVAFQIVNGEVRDVTSIVPQDIPAT
YEFTNGKHYITNEPIPPKEPEA

DNA (incl. STOP) (SEQ ID NO: 71):

ATGTTTCGTGTTTCTGGTGCTGCTGCCTCTGGTGTCCAGCCAGTGTGGGTGCAGCCCACCGAATCCATCGTGGGTTCCCC
AATATACCAATCTGTGCCCCCTTCGGCGAGGTGTTCAATGCCACCAGATTGCGCTCTGTGTACGCCTGGAACCGGAAGCG
GATCAGCAATTGCGTGGCCGACTACTCCGTGCTGTACAACCTCCGCCAGCTTCAGCACCTTCAAGTGCTACGGCGTGTCCCC
TACCAAGCTGAACGACCTGTGCTTCACAAACGTGTACGCCGACAGCTTCGTGATCCGGGGAGATGAAGTGCGGCAGATT
GCCCCCTGGACAGACAGGCAAGATCGCCGACTACAACCTACAAGCTGCCCGACGACTTCACCGGCTGTGTGATTGCCTGGAA
30

CAGCAACAACCTGGACTCCAAAGTCGGCGGCAACTACAATTACCTGTACCGGCTGTTCCGGAAGTCCAATCTGAAGCCCTT
 CGAGCGGGACATCTCCACCGAGATCTATCAGGCCGGCAGCACCCCTTGTAAACGGCGTGGAAGGCTTCAACTGCTACTTCC
 CACTGCAGTCTACGGCTTTCAGCCCACAAATGGCGTGGGCTATCAGCCCTACAGAGTGGTGGTCTGAGCTTCGAACTG
 CTGCATGCCCTGCCACAGTGTGCGGCCCTAAGAAAAGCACCAATGGAAGCGGAGGCTCTGGTGGATCCGGTGGATCTG
 5 GACACATGAAGCCTCTGAGAGGCGCCGTGTTACGCTGCAGAAACAGCACCTGACTACCCCGATATCTACGGCGCCATC
 GACCAGAACGGCACCTACCAGAATGTTCCGACAGGCGAGGATGGCAAGCTGACCTTCAAGAACCTGAGCGACGGCAAGT
 ACCGGCTGTTTCGAGAATTCTGAGCCTGCCGGCTACAAGCCCGTGCAGAACAACTATCTGCGCCTTCCAGATCGTGAAC
 GGCGAAGTGCGGGATGTGACCAGCATCGTGCTCAGGATATCCCCGCCACCTACGAGTTCACCAACGGCAAGCACTACAT
 CACCAACGAGCCCATCTCTCCAAAGAGCCCGAAGCCTAA

10 **SnoopCatcher-SARS CoV2 Spike RBD**

Amino acid (SEQ ID NO: 72):

METDTLLWVLLWVPGSTGDGHMKPLRGAVFSLQKQHPDYPDIYGAIDQNGTYQNVRTGEDGKLTfKNLSDGKYRLFENSE
 PAGYKPVQNKPIVAFQIVNGEVRDVTISVPQDIPATYEFNGKHITNEPIPPKSGSGSGSRVQPTESIVRFPNITNLCPFGEVF
 NATRFASVYAWNRRKRISNCVADYSVLYNSASFSTFKCYGVSPKLNLDLCTNVYADSFVIRGDEVQRQIAPGQTGKIADYNYKLDP
 15 DFTGCVIAWNSNNLDSKVGNGYNYLRLFRKSNLKPFRDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVV
 VLSFELLHAPATVCGPKKSTNEPEA

DNA (incl. STOP) (SEQ ID NO: 73):

atggagacagacacactcctgctatgggtactgctgctggttccagggttcactggtgacGGTCACATGAAGCCCCTGAGGGGCGCCGTGTT
 CAGCCTGCAGAAGCAGCACCCCGACTACCCCGACATCTACGGCGCCATCGACCAGAACGGCACCTACCAGAACGTGAGG
 20 ACCGGCGAGGACGGCAAGCTGACCTTCAAGAACCTGAGCGACGGCAAGTACAGGCTGTTTCGAGAACAGCGAGCCCGCC
 GGCTACAAGCCCGTGCAGAACAGCCCATCGTGGCCTTCCAGATCGTGAACGGCGAGGTGAGGGACGTGACCAGCATCG
 TGCCCCAGGACATCCCCGCCACCTACGAGTTCACCAACGGCAAGCACTACATCACCAACGAGCCCATCCCCCAAGGGGT
 CTGGCGGAAGCGGCggtatccGGGTGCAGCCACCGAATCCATCGTGCGGTTCCTCAATATCACCAATCTGTGCCCTTCGG
 CGAGGTGTTCAATGCCACCAGATTGCGCTCTGTGTACGCTGGAACCGGAAGCGGATCAGCAATTGCGTGGCCGACTACT
 25 CCGTGCTGTACAACCTCCGCCAGCTTACGACCTTCAAGTGCTACGGCGTGTCCCCTACCAAGCTGAACGACCTGTGCTTCA
 CAAACGTGTACGCCGACAGCTTCGTGATCCGGGGAGATGAAGTGCAGGAGATTGCCCTGGACAGACAGGCAAGATCGC
 CGACTACAACCTACAAGCTGCCGACGACTTACCGGCTGTGTGATTGCCTGGAACAGCAACAACCTGGACTCCAAAGTCG
 GCGGCAACTACAATTACCTGTACCGGCTGTTCCGGAAGTCCAATCTGAAGCCCTTCGAGCGGGACATCTCCACCGAGATCT
 ATCAGGCCCGGCAGCACCCCTTGTAAACGGCGTGAAGGCTTCAACTGCTACTTCCCACTGCAGTCTACGGCTTTCAGCCCA
 30 CAAATGGCGTGGGCTATCAGCCCTACAGAGTGGTGGTGTGAGCTTCAACTGCTGCATGCCCTGCCACAGTGTGCGGC
 CTAAGAAAAGCACCAATGAGCCCGAGGCCTAA

SARS CoV2 Spike RBD-SpyCatcher

Amino acid (SEQ ID NO: 74):

MFVFLVLLPLVSSQCRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRRKRISNCVADYSVLYNSASFSTFKCYGVSPKLNLD
 35 LCFTNVYADSFVIRGDEVQRQIAPGQTGKIADYNYKLDPDFTGCVIAWNSNNLDSKVGNGYNYLRLFRKSNLKPFRDISTEIYQ

AGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVLSFELLHAPATVCGPKKSTNGSGGSGGSGGSDSATHIKFSKRDE
DGKELAGATMELRDSSGKTISTWISDGQVKDFYLYPGKYTFVETAAPDGYEVATAITFTVNEQGQVTVNGKATKGDAHIEPEA

DNA (incl. STOP) (SEQ ID NO: 75):

ATGTTCTGTGTTTCTGGTGCTGCTGCCTCTGGTGTCAGCCAGTGTCGGGTGCAGCCCACCGAATCCATCGTGCGGTTCCCC
5 AATATACCAATCTGTGCCCCCTCGGCGAGGTGTTCAATGCCACCAGATTCGCCTCTGTGTACGCCTGGAACCGGAAGCG
GATCAGCAATTGCGTGCCGACTACTCCGTGCTGTACAACCTCCGCAGCTTCAGCACCTTCAAGTGCTACGGCGTGTCCTCC
TACCAAGCTGAACGACCTGTGCTTACAAACGTGTACGCCGACAGCTTCGTGATCCGGGGAGATGAAGTGCGGCAGATT
GCCCCGACAGACAGGCAAGATCGCCGACTACAACCTACAAGCTGCCCCGACGACTTCACCGGCTGTGTGATTGCCTGGAA
CAGCAACAACCTGGACTCCAAAGTCGGCGGCAACTACAATTACCTGTACCGGCTGTTCCGGAAGTCCAATCTGAAGCCCTT
10 CGAGCGGGACATCTCCACCGAGATCTATCAGGCCGGCAGACCCCTTGTAAACGGCGTGGAAGGCTTCAACTGCTACTTCC
CACTGCAGTCTACGGCTTTCAGCCCACAAATGGCGTGGGCTATCAGCCCTACAGAGTGGTGGTGCTGAGCTTCGAACTG
CTGCATGCCCTGCCACAGTGTGCGGCCCTAAGAAAAGCACCAATGGAAGCGGAGGCTCTGGTGATCCGGTGGATCTG
GCGATTCTGCCACACATCAAGTTCAGCAAGCGGACGAGGACGGCAAAGAAGTGGCTGGCGTACCATGGAAGTGAAG
AGACAGCAGCGGCAAGACCATCAGCACCTGGATCTCCGACGGCCAAGTGAAGGACTTCTATCTGTACCCCGCAAGTACA
15 CCTTCGTGGAACCGCCGCTCCTGACGGATGAAGTGGCCACCGCCATCACCTTCACCGTGAATGAGCAGGGACAAGTG
ACCGTGAACGGCAAGGCCACAAAAGGCGACGCCACATTGAGCCCGAAGCCTAA

Example 1 - Modular covalent decoration of the adenovirus capsid via insertion of SpyTag or DogTag into hexon HVR loops.

In order to modify the hexon proteins of the adenovirus capsid, sequence alignment was undertaken
20 to identify the location of hypervariable region (HVR) loops 1, 2 and 5 in Figure 1E [Sequence
comparison of the following adenoviruses; Ad5 and Ad2 (species C), Ad12 and Ad18 (species A), Ad3
and Ad35 (species B), Ad4 (species E), Ad40 and Ad41 (species F)]. Deletions were generated at the
insertion sites of the HVR loops indicated in Figure 1E. SpyTag and DogTag were inserted at each
locus. The insertion sites indicated are identical between SpyTag and DogTag recombinants at each
25 of the three HVRs tested. At each locus, SpyTag or DogTag sequences are flanked by GSGGSG
sequences on each side.

Example 2 – Coupling of SpyCatcher with SpyTag inserted into HVR loops

Ad5 vectors displaying SpyTag at HVR1, HVR2 or HVR5 were incubated with biotinylated SpyCatcher
at 15 μ M or 40 μ M in order to assess the coupling reaction between SpyTag and SpyCatcher.
30 Samples were run on SDS-PAGE and proteins visualised by Coomassie staining as shown in Figure
2A. Coupling efficiency was assessed by comparing band intensities of uncoupled hexon-SpyTag with
hexon-SpyTag:SpyCatcher using ImageJ software (% hexon coupled = band intensity of hexon-

SpyTag:SpyCatcher divided by the sum of band intensities of hexon-SpyTag:SpyCatcher and uncoupled hexon-SpyTag, multiplied by 100).

Immediately after the coupling reaction described in Figure 2A, a vector infectivity assay was undertaken with the same samples (Figure 2B). Samples were serially diluted, applied to monolayers of HEK293A cells in a 96-well plate, and incubated for 48 h at 37 °C with 5% CO₂. Infectious titres were calculated by enumeration of GFP fluorescent foci by fluorescence microscopy. Infectious titres were calculated as no. of infectious units (ifu) per ml.

Ad5(GFP) vectors displaying SpyTag at HVR1 (Ad5(GFP) HVR1 SpyTag) (1E+10 viral particles) were incubated with biotinylated SpyCatcher at 15 µM or 40 µM under different conditions (Figure 2C). Samples were run on SDS-PAGE and proteins visualised by Coomassie staining. A vector infectivity assay was performed on the same samples as shown in Figure 2C (Figure 2D).

The results demonstrate that SpyTag is poorly reactive after insertion into Ad5 HVR loops, and that vector infectivity is substantially reduced (over 100-fold) upon coupling of SpyCatcher to >50% of hexon protein on the viral capsid.

Example 3 - Coupling of DogCatcher with DogTag inserted into HVR loops

HEK293A cells were infected either with wild type Ad5(GFP) (native hexon protein) or DogTag inserted into HVR1 (HVR1DT), HVR2 (HVR2DT) or HVR5 (HVR5DT). Vector yield from 1500 cm² of adherent HEK293A cells infected with Ad5 displaying DogTag on hexon surfaces is equivalent to vector yield with unmodified hexon Ad5 (Figure 3A).

Ad5(GFP) vectors (1E+10 viral particles) displaying DogTag at either HVR1, HVR2 or HVR5 were incubated with 5 µM DogCatcher. Reactions were performed for 16 h at 4 °C as shown in Figure 3B. Coupling efficiency was assessed by comparing band intensities of uncoupled hexon-DogTag with hexon-DogTag:DogCatcher using ImageJ as described in Example 2. Figure 3C shows an infectivity assay performed on the same samples as in Figure 3B.

Ad5(GFP) vectors displaying DogTag at either HVR1, HVR2 or HVR5 (1E+10 viral particles) were incubated with DogCatcher at 20 µM or 80 µM for 0.1, 1 or 16 hours at 4 °C as shown in Figure 3D. Coupling efficiency was assessed as described above.

The data show that DogTag is highly reactive after insertion into Ad5 HVR loops and that vector infectivity is not inhibited by coupling to DogCatcher, despite coverage of >90% capsid hexon.

Example 4 – Reactivity of SnoopTagJr with DogTag inserted into HVR loops.

Ad5(GFP) vectors (1E+10 viral particles) displaying DogTag at either HVR1, HVR2 or HVR5 were incubated with SnoopTagJr-AffiHER2 (80 μ M) and SnoopLigase (70 μ M). Samples were run on SDS-PAGE and proteins visualised by Coomassie staining. Coupling efficiency was quantified by
5 comparing band intensities of uncoupled hexon-DogTag with hexon-DogTag:SnJr-AffiHER2 using ImageJ (Figure 4A).

To assess the temperature-dependence of hexon-DogTag coupling to SnoopTagJr-AffiHER2, Ad5(GFP) vectors displaying DogTag at HVR5 (1E+10 viral particles) were incubated with SnoopTagJr-AffiHER2 (80 μ M) and SnoopLigase (70 μ M) for 16 h at either 20 °C or 4°C (Figure 4B). A vector
10 infectivity assay was performed as described in Example 3 on the samples used for Figure 4B (Figure 4C).

Ad5(GFP) vectors displaying DogTag at HVR5 (1E+10 viral particles) were incubated with SnoopTagJr-AffiHER2 (80 μ M) and SnoopLigase (70 μ M) for 16 h at 4 °C (Figure 4D). Different concentrations of NaCl were added at either 150 mM or 75 mM, and glycerol was added as indicated at 15% (v/v).
15 Samples were analysed by SDS-PAGE and Coomassie staining.

Example 5 –Assessment of vector infectivity for non-fluorescent recombinant vectors.

A hexon immunostaining assay to assess vector infectivity was performed with Ad5(GFP) (with a WT hexon) and Ad5(GFP) HVR5 DogTag. Both vectors were serially diluted, and 50 μ l of each dilution was transferred to a monolayer of HEK293A cells in a poly-L-lysine coated 96-well plate. After a 48 h
20 incubation at 37 °C with 5% CO₂, GFP-positive cells were counted by fluorescence microscopy. For immunostaining, cells on the same plate were fixed with ice-cold methanol and an anti-hexon mouse monoclonal antibody (clone 65H6, ThermoFisher) was used to detect hexon protein within infected cells. Hexon-positive cells were subsequently stained using an alkaline phosphatase-conjugated secondary antibody, and BCIP/NBT substrate solution. The results demonstrated that HEK293A cells
25 infected with Ad5 vectors with a WT hexon protein and Ad5 vectors displaying DogTag at HVR5 showed equivalent intensity of hexon immunostaining.

The infectious titres for Ad5(GFP) (hexon WT) and Ad5(GFP) HVR5 DogTag were compared using both GFP fluorescence and hexon immunostaining assays. Both assays were performed using the same wells on the same plate, n=4. Bars show mean + SD and dots represent spot counts from
30 individual wells. The results were not significantly different (ns) as calculated by a two-tailed t-test.

Example 6 - Reactivity of DogTag inserted into hexon loops with SnoopTagJr tagged peptides

Peptides were synthesized consisting of the SnoopTagJr sequence fused to T cell epitopes. These SnoopTagJr tagged peptides were coupled to Ad5(GFP) HVR5 DogTag using SnoopLigase. A gel shift assay with Coomassie staining was not suitable to assess the coupling efficiency due to the low molecular weight of these short peptides (~3 kDa). The efficiency of peptide coupling was instead assessed using a competition assay with DogCatcher (described in Figure 6A). SnoopTagJr-peptide (SnJr-peptide) and hexon-DogTag (hexon-DT) are coupled using SnoopLigase (SnL). After coupling, an excess of DogCatcher (DC) protein is added to the reaction. DC binds >90% of free (uncoupled) hexon-DT molecules on the surface of Ad5 (see Figure 3B), therefore the proportion of hexon-DT coupled to SnJr-peptide can be estimated to be the proportion of hexon that *does not* undergo a gel shift of ~20 kDa on SDS-PAGE after incubation with DC.

Coupling efficiency of SnoopTagJr-hTERT peptide (SnoopTagJr fused to a T cell epitope from human telomerase reverse transcriptase, EARPALTSRLRFIPK) to hexon-DT was assessed using the DogCatcher competition assay described above. Ad5(GFP) HVR5 DogTag (Ad5-DT, 1E+10 viral particles) was incubated with different combinations of SnL (70 µM) and SnJr-hTERT (80 µM), and in some samples DogCatcher (20 µM, excess) was added after the peptide-peptide coupling reaction to assess coupling efficiency (Figure 6B). All reactions were performed at 4 °C. Samples were run on SDS-PAGE with subsequent Coomassie staining (Figure 6B). The proportion of coupled hexon-DT:SnJr-hTERT compared to hexon-DT:DC (representing free hexon-DT after the initial SnL-catalysed reaction) was assessed by comparing band intensities as indicated. The optimum time interval for the hexon-DT:SnJr-hTERT reaction was determined to be 48 h.

Figure 6C shows an assessment of coupling efficiency of SnoopTagJr-SIINFEKL peptides (SIINFEKL is a mouse CD8⁺ T cell epitope derived from ovalbumin) to hexon-DT using the DogCatcher competition assay described above. PEP1 corresponds to the peptide sequence SnJr-GGSSIINFEKL and PEP2 corresponds to the peptide sequence SnJr-AAYSIINFEKL. Ad5-DT (1E+10 viral particles) was incubated with SnJr-SIINFEKL peptides (PEP1 or PEP2, 80 µM) and SnL (70 µM) for 48 h at 4 °C. DC (20 µM) was subsequently added. Samples were then incubated for a further 24 h at 4 °C. Samples were run on SDS-PAGE and peptide coupling efficiency was assessed as described above.

Alternatively, a direct gel shift assay using monovalent streptavidin (mSA) can be used to assess coupling efficiency of short peptides as described in Figure 6D. Biotinylated SnJr-peptide was

incubated with SnL and Ad5-DT as described previously. After 48 h, the coupling reaction was stopped by boiling in sample buffer including sodium dodecyl sulfate (SDS) and dithiothreitol (DTT) to denature all proteins and virion structures. Samples were briefly cooled on ice before incubation with an excess of monovalent streptavidin (mSA) for 30 min at 20 °C. Samples were run on SDS-PAGE, transferred to nitrocellulose, and Western blotting performed using an anti-hexon primary mouse monoclonal antibody (clone 65H6, ThermoFisher). A gel-shift (~50 kDa) is observed for hexon-DT protein coupled to SnJr-biotin by virtue of the strong interaction between mSA and biotin (hexon-DT:SnJr-biotin/mSA). Figure 6E shows the SDS-PAGE of the mSA direct gel shift assay as described above with additional controls. Bands corresponding to hexon-DT:SnJr-biotin/mSA and hexon-DT species are indicated. Figure 6F shows a vector infectivity assay (by GFP focus enumeration, as described in example 5) was performed on the same samples shown in Figure 6C. The results demonstrate that Ad5-DT infectivity is not affected by surface display of SnJr-peptides.

Example 7 - Coupling of Ad5 HVR DogTag to DogCatcher fusion proteins.

The circumsporozoite protein (CSP) of *Plasmodium falciparum* (Pf) has been extensively studied as a malaria vaccine candidate antigen. The protein contains a highly immunogenic repetitive region, primarily consisting of repeats of the sequence NANP. Repeat sequences of varying lengths from this region were fused to the C-terminus of DogCatcher and the resulting fusion proteins coupled to Ad5(GFP) HVR5 DogTag. Three DogCatcher fusion constructs; NANP9, NANP18, and NANPD (consisting of the entire NANP repetitive domain of PfCSP from the 3D7 strain) are shown in Figure 7A.

Reactivity of DogCatcher-NANPn with DogTag inserted into hexon HVR5 loop was assessed. Ad5(GFP) vectors (1E+9 viral particles) displaying DogTag at HVR5 were incubated with different DogCatcher-NANPn fusions (as indicated) at 15 µM. Reactions were performed for 16 h at 4 °C. Samples were run on SDS-PAGE and proteins visualised by Coomassie staining (Figure 7B). Coupling efficiency was assessed as described above. A vector infectivity assay (by GFP focus enumeration, as described above) was performed on the same samples shown in Figure 7B (Figure 7C).

Example 8 - Coupling of DogCatcher-NANPn to the surface of Ad5 via hexon reduces the potency of virus neutralising antibodies.

Ad5(GFP) HVR5 DogTag vectors (Ad5-DT, 1E+10 viral particles) were incubated with SnoopLigase (SnL) and SnJr-AffiHER2 (or SnJr-AffiHER2 alone) for 48 h at 4 °C. After 48 h, approximately 60-65% of the hexon was coupled to SnJr-AffiHER2 (a comparable coupling efficiency to the experiment shown

in Figure 4B). Coupled vector was incubated with serially diluted virus-neutralising mouse monoclonal anti-hexon antibody mAb 9C12 (Developmental Studies Hybridoma Bank, University of Iowa) for 1 h at 37 °C, before the vector-antibody mix was added to an 80% confluent monolayer of HEK293A cells in a 96-well plate format (cells were infected at a multiplicity of infection of 200 ifu/cell). Cells were incubated with the vector-antibody mix for 2 h at 37 °C with 5% CO₂, before the mix was replaced with fresh media and the plates returned to 37 °C with 5% CO₂ for a further 24 h. After 24 h, GFP expression within HEK293A cells was employed as a readout of infectivity - bulk fluorescence was measured on a fluorimeter using an excitation of 395 nm and emission of 509 nm. The data, shown in Figure 8A, demonstrated an increase in the IC₅₀ of a potent neutralising anti-hexon monoclonal antibody upon coupling of SnoopTagJr-AffiHER2 to Ad5 DogTag. IC₅₀ for mAb 9C12 neutralisation increased from 2.5 ng/ml (Ad5-DT alone, and Ad5-DT + SnJr-AffiHER2 only) to 7 ng/ml with coupled vector (Ad5-DT + SnL + SnJr-AffiHER2).

In Figure 8B, a similar experiment to that described above was performed using the DogCatcher-NANPn fusions described in Figure 7A. Ad5(GFP) HVR5 DogTag vectors (Ad5-DT, 1E+9 viral particles) were incubated with DogCatcher-NANPn constructs for 16 h at 4 °C, exactly as described in Figure 7. Coupling efficiency of each of the constructs to Ad5-DT was similar to that shown in Figure 7B. As described above, vector was incubated with mAb 9C12 for 1 h, the mix added to cells at a multiplicity of infection of 200 ifu/cell for 2 h, and vector replaced with fresh media prior to reading GFP fluorescence after a further 24 h. A substantial increase in IC₅₀ for mAb 9C12 was observed with the DogCatcher-NANPn coupled vectors compared to Ad5-DT alone, implying shielding of the hexon from the neutralising monoclonal antibody (Figure 8B). Ad5-DT:DC-NANP18 exhibited the greatest increase in IC₅₀, >10-fold compared to Ad5-DT alone.

In Figure 8C, a neutralisation assay with Ad5-positive mouse serum (instead of mAb 9C12) was performed on coupled Ad5-DT:DC-NANPn vectors. To generate Ad5-positive mouse serum, mice were immunised intramuscularly with 1E+8 ifu Ad5(Ovalbumin) (WT hexon) vector (Ad5 E1 and E3 deleted vector with an unmodified hexon expressing ovalbumin instead of GFP under the control of a constitutive CMV promoter encoded at E1 locus) and serum was harvested two-weeks post-immunisation. The results of the neutralization assay demonstrated that IC₅₀ of the neutralizing anti-serum is increased with Ad5-DT:NANP9 and Ad5-DT:NANP18 compared to Ad5-DT alone (Figure 8C).

Example 9 - Human coagulation Factor X-dependent vector transduction of SKOV3 cells

It has been demonstrated that, particularly after intravenous administration, some serotypes of adenovirus including Ad5 can transduce hepatocytes via an interaction between human coagulation Factor X (FX) and the hexon protein of the virus [Simon N. Waddington, John H. McVey, David Bhella, Menzo J.E. Havenga, Stuart A. Nicklin, Andrew H. Baker, Adenovirus Serotype 5 Hexon Mediates
 5 Liver Gene Transfer. *Cell*, 2008, Volume 132, Issue 3, P397-409]. *In vitro*, FX mediated infection can be assessed by measuring vector transduction of SKOV3 cells, a human ovarian cancer cell line, in the presence or absence of FX.

Ad5(GFP)-DogTag (Ad5) or Ad5(GFP)-DogTag:DogCatcher-NANP18 (Ad5-NANP18) vectors (2E+9 viral particles) were incubated in the presence or absence of human coagulation Factor X (8 µg/mL) on
 10 SKOV3 cells for 2 h at 37°C in serum-free media. Then media was replaced with fresh complete media and plates were incubated for a further 48 h. Infectious titres were then calculated by enumeration of GFP-positive foci by fluorescence microscopy.

The data indicate that coupling of DogCatcher-NANP18 to the Ad5 hexon reduces FX dependent infection of SKOV3 cells, presumably by shielding the viral capsid from interaction with FX.

15 **Example 10 - Mouse immunogenicity experiment to assess CD8⁺ T cell responses to Ad5 surface-displayed peptide antigens.**

C57BL/6 mice (4/group) were immunised intramuscularly with either surface-display vector Ad5(GFP) HVR5-DT:SnJr-GGSSIINFEKL (5E+9 viral particles, dialysed to remove excess peptide and Snoopigase) (Group 1), the same SIINFEKL surface display vector as in Group 1 but without dialysis
 20 to remove excess peptide and Snoopigase (5E+9 viral particles, excess SIINFEKL peptide 0.7 µg) (Group 2), Ad5(GFP) vector (5E+9 viral particles) co-administered with SnJr-GGSSIINFEKL peptide (0.7 µg, not coupled to the vector) (Group 3), or SnJr-GGSSIINFEKL peptide (5 µg, co-administered with 10 µg poly I:C) (group 4) (Figure 10A). The effective dose of SIINFEKL peptide displayed on the coupled vector from Group 1 was calculated to be approx. 10 ng, taking into account the molecular
 25 weight of SnJr-GGSSIINFEKL, a coupling efficiency of 80% hexon coverage (see Figure 6C, PEP1), 720 copies of hexon per virion, and 5E+9 virions per vaccine dose. The dose of peptide in Group 4 is 500-fold higher than in Group 1. After 14 days post-immunisation, mice were sacrificed and CD8⁺ T cell responses in the spleen were measured by overnight *ex vivo* IFNγ-ELISPOT.

Spleen *ex vivo* IFNγ-ELISPOT responses to SIINFEKL, a murine CD8⁺ T cell epitope are shown in Figure
 30 10B. SIINFEKL responses in Group 1 and Group 2 were higher than those in Group 3, demonstrating that attachment of SnJr-GGSSIINFEKL to the vector capsid is required to achieve potent SIINFEKL T

cell responses. Spleen *ex vivo* IFN γ -ELISPOT responses to DTLVNRIEL (EGFP₁₁₈₋₁₂₆), a murine CD8⁺ T cell epitope present in the encoded GFP transgene expressed by the vector upon cell transduction, are shown in Figure 10C. There were no significant differences in EGFP₁₁₈₋₁₂₆ responses between Groups 1-3, demonstrating that surface decoration of the vector capsid did not impair T cell responses to the encoded GFP transgene antigen.

Example 11 - Modular covalent decoration of the adenovirus capsid via fusion of SpyCatcher at the C-terminus of pIX.

An (EAAAK)₃ linker was inserted between the C-terminus of viral pIX and the N-terminus of SpyCatcher Δ N1 to facilitate successful rescue of the virus and efficient capsid display as shown in Figure 11A.

Ad5(GFP) pIX-SpyCatcher vectors (3E+9 viral particles) were incubated with SpyTag-Maltose binding protein (SpyTag-MBP, 5 μ M) or SpyTag-Human cytomegalovirus pentamer (SpyTag-Pentamer, 2.5 μ M) for 16 h at 4 °C (Figure 11B). Samples containing SpyTag-MBP or SpyTag-Pentamer alone were included as controls. After conjugation, samples were run on SDS-PAGE and transferred to nitrocellulose for Western blotting. pIX-SpyCatcher, pIX-SpyCatcher:SpyTag-MBP, and pIX-SpyCatcher:SpyTag-gH (from the HCMV Pentamer) species were detected using antisera from mice immunised with SpyCatcher protein (Figure 11B).

Ad5(GFP) pIX-SpyCatcher vectors (3E+9 viral particles) were incubated with biotinylated SpyTag peptide (5 μ M) for 16 h at 4 °C (Figure 11C). To assess peptide coupling efficiency to pIX-SpyCatcher by gel-shift assay, vector material was denatured and boiled in sample buffer including sodium dodecyl sulfate (SDS) and DTT, before cooling and incubating with monovalent streptavidin (mSA) as described in Figure 6D. pIX-SpyCatcher and pIX-SpyCatcher:SpyTag-biotin/mSA species were detected by SDS-PAGE and Western blotting with anti-SpyCatcher antisera as described in B.

A vector infectivity assay (by GFP focus enumeration, described previously) was performed on the same samples shown in Figures 11B and 11C (Figure 11D). The results demonstrated that Ad5(GFP) pIX-SpyCatcher infectivity is not affected by surface display of SpyTag-protein fusions or peptides.

Example 12 - Viability, genetic stability, and yield of different recombinant adenovirus vectors with SpyCatcher, SnoopCatcher or DogCatcher fused to the C-terminus of pIX

Further research demonstrated that the vector construct described in Example 11 (SpyCatcher fused to the C-terminus of pIX via an EAAAK3 linker) while reactive, was not genetically stable. A range of alternative constructs with alternative linker sequences (GSGGSGGSG (GSG3), GGSEAAAKEAAAKEAAAKGS (EAAAK3), or GGSPANLKALEAQKQKEQRQAAEELANAKKLKEQLEKGS (a helical sequence from ribosomal protein L9, Veggiani et al, Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1202-7. doi: 10.1073/pnas.1519214113) (HELIX)), GS hinge sequences either side of the linker, or alternative Catchers (SpyCatcher dN1, SpyCatcher dN1dC2, SnoopCatcher, DogCatcher) were constructed (Figure 12A). Each vector DNA construct was linearised by PacI restriction digest to release the viral inverted terminal repeats (ITRs) prior to transfection into HEK293A cells. Viability of each construct was assessed by inspecting cell monolayers for development of cytopathic effect (CPE) which would indicate successful rescue of the recombinant virus. Viable viral vector preparations were passaged to increase virus titer, with three passages typically required to obtain sufficient material for purification by CsCl gradient ultracentrifugation (from initial transfection). A forth passage was required to obtain a second batch of each viable vector, and genetic stability was assessed after the third and fourth passage by sequencing of the pIX locus. To assess vector yield, viable vectors were amplified from a total of 10 x T150 flasks (total surface area 1500cm² HEK293A cells), purified by CsCl ultracentrifugation, and infectious titer calculated by GFP infectivity assay as described previously (Figure 12B).

Example 13 - Reactivity of SnoopCatcher and DogCatcher fused to the C-terminus of pIX

To assess reactivity of Ad5(GFP) pIX-SnoopCatcher with SnoopTagJr-fused ligands, Ad5(GFP) pIX-SnoopCatcher vectors were incubated with tagged full-length SARS CoV2 Spike (Spike) or SARS CoV2 spike receptor binding domain (RBD) proteins. Both recombinant proteins were produced in mammalian suspension 293F cells, with SnoopTagJr fused at the C-terminus. After a 16h coupling reaction at 4°C, samples were run on SDS-PAGE and a western blot performed using mouse sera with reactivity against SnoopCatcher (sera from mice immunised with IMX313-DogTag:SnoopTag-CIDR:SnoopLigase, Andersson, A.C., Buldun, C.M., Pattinson, D.J. et al. SnoopLigase peptide-peptide conjugation enables modular vaccine assembly. Sci Rep 9, 4625 (2019)) (Figure 13A). Controls included vector alone (Vector), Spike alone (Spike) and RBD alone (RBD). Species including pIX-SnoopCatcher (pIX-SnC), and covalently coupled pIX-SnoopCatcher:SnoopTagJr-Spike (pIX-SnC:SnJr-Spike) and pIX-SnoopCatcher:SnoopTagJr-RBD (pIX-SnC:SnJr-RBD) are indicated. Immediately after the coupling reactions described in Figure 13A, a vector infectivity assay (GFP foci) was undertaken with the same samples (Figure 13B). The data indicate that SnoopCatcher is reactive when fused to

the C-terminus of pIX, and that coupling of ligands to pIX does not impair vector infectivity *in vitro* (despite the size of the SARS CoV2 Spike trimer exceeding 500kDa).

To assess reactivity of Ad5(GFP) pIX-DogCatcher with DogTag-fused ligands, Ad5(GFP) pIX-DogCatcher vectors were incubated with *E coli* expressed small ubiquitin modifier (SUMO) protein with DogTag fused at the C-terminus. After a 16h coupling reaction at 4°C, samples were run on SDS-PAGE and a western blot performed using mouse sera with reactivity against DogCatcher (Figure 13C). The same mouse sera used for the western blot described in Figure 13A was also used in Figure 13C, since DogCatcher shares a significant degree of sequence identity with SnoopCatcher. Controls included vector alone (Vector) and SUMO alone (SUMO). Species pIX-DogCatcher (pIX-DC) and pIX-DogCatcher:DogTag-SUMO (pIX-DC:DT-SUMO) are indicated.

Example 14 - Reactivity of SnoopTagJr and SpyTag fused to the C-terminus of pIX

Ad5(GFP) vectors were constructed with SnoopTagJr or SpyTag fused to the C-terminus of pIX, with an EAAAK3 linker between pIX and tag flanked by GGS and GS hinges, similar to the SnoopCatcher and DogCatcher fusion constructs shown in Figure 12A. Both Ad5 pIX-SnoopTagJr and Ad5 pIX-SpyTag vectors were transfected into HEK293A cells, passaged, and amplified into 10 x T150 cm² flasks. Infectious yield of both vectors was high, and comparable to Ad5(GFP) HVR5-DogTag (Figure 14A).

To assess reactivity of SnoopTagJr and SpyTag displayed as a pIX fusion, Ad5 pIX-SnoopTagJr (Ad5 pIX-SnJr) or Ad5 pIX-SpyTag (Ad5 pIX-ST) vectors were co-incubated with recombinant mammalian (Chinese Hamster Ovary, CHO) cell expressed SARS CoV2 RBD proteins fused to either SnoopCatcher (RBD-SnC or SnC-RBD, C- or N-terminal fusions to RBD respectively) or SpyCatcher (RBD-SC, C-terminal fusion). After a 16h coupling reaction at 4°C, samples were run on SDS-PAGE and a western blot performed using an anti-SARS CoV2 RBD polyclonal antibody (Sino Biological) (Figure 14B). Protein species representing coupling between Tag and Catcher modules are indicated (*). Immediately after the coupling reactions described in Figure 14B, a vector infectivity assay (GFP foci) was undertaken with the same samples (Figure 14C). Coupling of ligands did not impair infectivity of either Ad5 pIX-SnoopTagJr or Ad5 pIX-SpyTag.